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ABSTRACT OF DISSERTATION 
 
 
THE ROLE OF PXR AND IKKβ SIGNALING  
IN CARDIOMETABOLIC DISEASE 
  Cardiovascular disease (CVD) is the leading cause of death worldwide 
and is partially attributed to perturbations in lipid metabolism.  Xenobiotics, such 
as pharmaceutical drugs and environmental chemicals, have been associated 
with increased risk of CVD in multiple large-scale human population studies, but 
the underlying mechanisms remain poorly defined.  We and others have 
identified several xenobiotics as potent agonists for the pregnane X receptor 
(PXR), a nuclear receptor that can be activated by numerous drugs as well as 
environmental and dietary chemicals.  However, the role of PXR in mediating 
the pathophysiological effects of xenobiotic exposure in humans and animals 
remains elusive.   
 The work herein identified several widely used pharmaceutical agents and 
endocrine disrupting chemicals as PXR-selective agonists such as drugs 
involved in HIV therapy and phthalates/phthalate substitutes, respectively.  We 
investigated the role of amprenavir, an HIV protease inhibitor, and tributyl 
citrate, a phthalate substitute, on PXR-dependent alterations in lipoprotein 
metabolism.  Acute exposure with either xenobiotic in mice elicited increases in 
the proatherogenic LDL-cholesterol levels in a PXR-dependent manner.  PXR 
activation significantly induced expression of genes involved in intestinal lipid 
metabolism.  Further, we went on to identify the intestinal cholesterol 
transporter, Niemann-Pick C1-Like 1 (NPC1L1), as a direct PXR-target gene.  
PXR activation also stimulated cholesterol uptake in both murine and human 
intestinal cells.  Moreover, we provide evidence that the microsomal triglyceride 
transfer protein (MTP) may be a direct PXR-target gene.  Taken together, these 
findings provide critical mechanistic insight into the role of xenobiotic-mediated 
PXR activation on lipid homeostasis and demonstrate a potential role of PXR in 
mediating adverse effects of xenobiotics on CVD risk in humans. 
 In addition to PXR signaling, we investigated the role of IκB kinase β 
(IKKβ), a central coordinator of inflammation, in adipocyte progenitor cells.  
Targeting IKKβ in adipose progenitor cells resulted in decreased high fat diet 
(HFD)-elicited adipogenesis, while protecting mice from inflammation and 
 
associated insulin resistance.  Consistently, we discovered that IKKβ inhibition 
by antisense oligonucleotides ablated HFD-induced adiposity, while protecting 
mice against associated metabolic disorders.  In conclusion, targeting IKKβ with 
antisense therapy may present as a novel therapeutic approach to combat 
obesity and metabolic dysfunctions. 
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Adipogenesis, Insulin Resistance 
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Chapter 1: Introduction  
1.1 Cholesterol Metabolism – an Overview 
 Atherosclerotic cardiovascular disease (CVD; otherwise known as 
coronary artery disease, or CAD) is a leading cause of mortality and morbidity 
worldwide [1].  Atherosclerosis is a chronic inflammatory disease characterized 
by the accumulation of lipids and inflammatory molecules in the subendothelium 
of the artery, which can restrict blood flow and ultimately lead to myocardial 
infarction and stroke.  Although atherosclerosis occurs in the general 
population, some people are at greater risk for developing CAD and these risk 
factors can be classified into either modifiable or non-modifiable.  Non-
modifiable risk factors for developing CAD are age, gender, and genetic 
heritability [2].  Moreover, modifiable CAD risk factors include smoking, obesity, 
nutrition, hypertension, sedentary lifestyle, stress, and hyperlipidemia [2].  
Elevated plasma lipid levels, particularly low density lipoprotein (LDL)-
cholesterol, have been strongly associated with atherosclerosis development [3, 
4].  Lipid-lowering therapy has produced up to a 30% reduction in a major 
coronary event, validating the cholesterol hypothesis [3-5].  Mechanisms 
governing cholesterol homeostasis are still being evaluated and there is an 
urgent need to identify new targets for cholesterol-lowering therapy to alleviate 
the morbidity and mortality associated with CAD.  
 Cholesterol is a key structural component of cellular membranes to 
maintain integrity, permeability, and fluidity, but also serves as precursors for 
bile acid and steroid hormone production.  The conversion of cholesterol into 
bile acids is absolutely essential for solubilization of dietary fats into micelles.  
Although cholesterol can by synthesized by the body, it requires a substantial 
energy requirement; thus, intestinal cholesterol absorption has evolved to take 
up cholesterol from the gut lumen [6].  Cholesterol derived from de novo 
synthesis and absorption is carried in the circulation in the form of lipoproteins 
(lipid-protein complexes) which are delivered to cells for utilization (Fig. 1.1).   
 Efficient cholesterol transport relies heavily on the expression of specific 
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proteins and perturbation of these proteins may disturb whole-body cholesterol 
homeostasis resulting in diseases.  The principle plasma lipoproteins are 
chylomicrons, very low-density-lipoproteins (VLDL), LDL, and high-density 
lipoproteins (HDL).  It is well established that the proatherogenic lipoproteins are 
chylomicrons, VLDL, and LDL, and the antiatherogenic lipoproteins are HDL.  I 
will briefly discuss the basic pathway of lipoprotein formation, secretion, and 
uptake, as well as perturbations in these processes (see Fig. 1.1 for an 
overview).   
 Chylomicrons are secreted by enterocytes into the lacteals of the intestine 
and they ultimately reach the circulation via the thoracic duct.  Chylomicrons are 
comprised primarily of triglycerides and cholesterol esters.  Short chain fatty 
acids (less than 8-10 carbons) passively diffuse into the enterocyte and enter 
the portal blood directly without being packaged into chylomicrons.  Long-chain 
fatty acids are internalized by enterocytes via passive diffusion and protein-
facilitated fatty acid transfer.  One protein that has been reported to facilitate 
fatty acid uptake is the fatty acid translocase (FAT/CD36).  It is worth noting that 
many groups have investigated the role of CD36 in atherosclerosis   and the 
studies are currently controversial.  Once in the enterocyte, long chain fatty 
acids are incorporated into triglycerides via the acyl CoA:diacylglycerol 
acyltransferase (DGAT) enzymes.  These triglycerides are complexed with 
apolipoprotein B 48, a process involving the microsomal triglyceride transfer 
protein (MTP; a more thorough review below) to ultimately form chylomicrons.  
ApoB is a hydrophobic protein that is present in plasma as apoB-48 or apoB-
100.  In humans, apoB48 and apoB100 are primarily associated with 
chylomicrons and VLDL, respectively [7].  MTP expression is absolutely 
essential for generation of apoB-containing lipoproteins.  For example, intestinal 
MTP-deficiency impairs the ability to secrete chylomicrons and, as a result, 
there is a robust accumulation of neutral lipids in the enterocytes [8].   
 Free cholesterol is also absorbed from mixed micelles by the enterocytes 
from the gut lumen.  This process is mediated by Niemann-Pick C1-Like 1 
(NPC1L1; a more thorough review below).  Free cholesterol is then re-esterified 
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by the Acyl-CoA:cholesterol acyltransferase-2 (ACAT2) enzyme in the 
endoplasmic reticulum (ER).  The cholesterol ester is packaged along with 
triglycerides to form the core of chylomicrons.  Cholesterol ester packaging into 
chylomicrons is also regulated by MTP [9].  It is worth noting that remaining 
unesterified cholesterol may be effluxed back out of the enterocyte by the 
apically localized heterodimeric sterol transporters ATP-binding cassette (ABC) 
transporters G5 and G8 (ABCG5/8) (Fig. 1.1).  In addition, some unesterified 
cholesterol may be transported out of the enterocyte into HDL via ABCA1, which 
is located at the basolateral membrane of enterocytes.  In mice, approximately 
30% of the steady-state plasma HDL-cholesterol levels are derived from 
intestinal ABCA1 [10]. 
 Once the chylomicrons enter the circulation, they are lipolyzed by 
lipoprotein lipase, which is located on the vascular endothelium of tissues such 
as skeletal muscle and adipose tissue [11].  LPL hydrolyzes the triglycerides of 
chylomicrons and, as a result, produces cholesterol-rich chylomicron remnants 
[11].  The chylomicron remnants are then taken up by the liver via LDL receptor-
like protein (LRP) (Fig. 1.1). 
 Hepatic cholesterol can be derived de novo or can be taken up by 
hepatocytes from circulating lipoproteins such as LDL, HDL, and chylomicron 
remnants via LDL-receptor (LDLR), HDL receptor scavenger receptor class B 
type 1 (SR-B1), and LRP, all of which are localized at the basolateral membrane 
of hepatocytes [6].  Free cholesterol may be converted to bile acids by multi-
enzymatic reactions that convert hydrophobic cholesterol into more water-
soluble amphipathic compounds [12].  Analogous to intestinal cholesterol 
metabolism, free cholesterol may be esterified to fatty acids via ACAT2 and be 
packaged into VLDL particles with triglycerides in a MTP-dependent 
mechanism.  Free cholesterol may be transported to ABCA1 on the sinusoidal 
membrane for HDL biogenesis or to ABCG5/ABCG8 on the canalicular 
membrane for direct secretion into the bile.  Moreover, in humans and 
nonhuman primates, NPC1L1 can counterbalance the function of 
ABCG5/ABCG8 by reabsorbing biliary cholesterol into hepatocytes [6].   
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 Whether synthesized de novo or taken up from the circulation, intracellular 
cholesterol is very tightly controlled by a variety of mechanisms.  A major 
mechanism for sensing intracellular sterol levels involves the sterol-response 
element binding proteins (SREBPs).  SREBPs comprise a subclass of the helix-
loop-helix leucine zipper transcription factors [13].  In mammals, there are two 
SREBP genes that encode SREBP1 and SREBP2, which give rise to 3 proteins 
[14, 15].  SREBP1a and SREBP1c are encoded from alternative promoters that 
are expressed at varying levels in different tissues and cultured cells.  These 
transcripts are thought to primarily play a role in fatty acid metabolism [14, 15].  
SREBP2, however, is a major regulator of cholesterol metabolism [14, 15].   
 SREBPs are synthesized as ER transmembrane proteins and their 
activation depends on a polytopic ER membrane protein known as the SREBP 
cleavage-activating protein (Scap).  Scap acts as both an escort protein for 
SREBP ER-Golgi transport and as a sterol sensor.  The sterol-sensing property 
of Scap is mediated by the polytopic membrane domain, which possesses a 
motif that is shared with other proteins that are postulated to interact with sterols 
[16].  Mutations within this sterol sensing domain (SSD) of Scap prevent sterol 
repression of SREBP cleavage and lead to an excess cholesterol production 
[16-18].  When ER cholesterol falls less than 5% of total lipids, the cholesterol-
free Scap/SREBP complex translocate to the Golgi for processing by the Site-1 
and Site-2 proteases [16].  Transcriptionally active SREBP then enters the 
nucleus to regulate genes involved in lipid metabolism.  The SREBP2 isoform, 
for example, transcriptionally regulates LDLR, HMG CoA reductase, NPC1L1, 
and other genes required for cholesterol synthesis and uptake to maintain 
cellular cholesterol homeostasis [19].   
 Given the consequences of excess plasma cholesterol on CAD, there 
have been extensive efforts to understand the molecular mechanisms regulating 
cholesterol homeostasis.  The pregnane X receptor (PXR) is a xenobiotic 
receptor that has been implicated in modulating cholesterol homeostasis and 
atherosclerosis.  The primary focus of this dissertation was to identify specific 
mechanisms by which ligand activated PXR-mediates hypercholesterolemia.  In 
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Chapter 3, I provide conclusive evidence that PXR transcriptionally regulates 
NPC1L1 and promotes cholesterol uptake in mouse and human intestinal cells.  
Further, in Chapter 5, I demonstrate that PXR may transcriptionally regulate MTP 
and promote chylomicron/VLDL secretion.  Taken together, this work herein 
implicates PXR as a transcriptional regulator linking xenobiotic and cholesterol 
metabolism. 
1.1.1 Niemann-Pick C1-Like 1 (NPC1L1) 
 NPC1L1 was first identified by Altmann and colleagues utilizing a 
bioinformatics approach that identified genes based on the following criteria: 
presence of a SSD, extracellular signal peptide, and enriched expression in 
absorptive enterocytes [20, 21].  Mice deficient in NPC1L1 had a significant 
reduction in sterol absorption (approximately 70%), which is similar to the 
reduction produced in mice treated with the potent intestinal cholesterol 
absorption inhibitor Ezetimibe [20].  Moreover, NPC1L1-deficient mice were 
resistant to Ezetimibe treatment, indicating the inhibition of cholesterol absorption 
by Ezetimibe was mediated through NPC1L1 [20].  Shortly thereafter, it was 
discovered that the target of Ezetimibe is, indeed, NPC1L1 [22].  Ezetimibe 
lowers circulating plasma cholesterol levels in humans by 15-20%, and when co-
administered with statins can synergistically decrease plasma cholesterol levels 
[23-25].   
 NPC1L1 is a polytopic transmembrane protein comprised of 1332 amino 
acids.  It is a homolog of Niemann-Pick C1 (NPC1), a protein when mutated 
results in a genetic disorder characterized by lysosomal accumulation of 
cholesterol and other lipids.  NPC1L1 has a conserved N-terminal NPC1 domain, 
a signal peptide, 13 transmembrane domains, and extensive glycosylation sites.  
It has been demonstrated that the conserved NPC1 domain contains a sterol-
binding pocket, thus it is likely that this region also binds sterols.  Five of the 13 
transmembrane domains constitute the SSD.  The SSD is conserved in many 
transmembrane proteins involved in cholesterol metabolism, including NPC1, 
HMG-CoA reductase, SCAP, and 7-dehydrocholesterol reductase (7DHCR) [26].  
The functional significance of the SSD in NPC1L1 remains to be determined. 
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 In humans and nonhuman primates, NPC1L1 is predominantly expressed 
on the apical surface of absorptive enterocytes [20, 27, 28] and on the 
canalicular surface of hepatocytes [29].  In rodents, however, NPC1L1 is 
primarily expressed in the intestine, with little to no expression in the liver [20, 
21].  However, the underlying mechanism for this species-specific expression is 
still unclear.   
 Mechanisms governing NPC1L1 transcriptional regulation have not been 
well established.  Several nuclear receptors have been previously reported to 
regulate intestinal cholesterol absorption, including LXR, PPARα, and RXR; 
however, these effects may not be due to direct transcriptional regulation of 
NPC1L1.  SREBP-2, however, is a major transcriptional regulator of NPC1L1 [30, 
31] and overexpression of a constitutive nuclear form of SREBP2 enhanced 
NPC1L1 promoter activity quite dramatically (approximately 8 fold; R.N. Helsley 
unpublished).  Moreover, other groups have identified hepatocyte nuclear factor 
4α (HNF4α) and HNF1α as important regulators of SREBP-2 dependent 
regulation of NPC1L1 [31, 32].  More work is required to identify novel regulators 
of NPC1L1.  In Chapter 3 I identified PXR as a novel transcriptional regulator of 
NPC1L1, which links xenobiotic and cholesterol metabolism in mice and humans.  
1.1.2 Microsomal Triglyceride Transfer Protein (MTP) 
 MTP was first identified as a protein that associated with triglyceride and 
cholesterol ester transfer activity in liver microsomes [33, 34].  It was later 
identified that individuals with abetalipoproteinemia lack apoB-lipoproteins in 
their plasma and have mutations in the MTTP gene, which result in the loss of 
lipid transfer activity in the liver and intestine [35].  Abetalipoproteinemia is an 
autosomal recessive disease that is characterized by fat malabsorption, 
defective lipid transport, accumulation of fat-laden enterocytes, decreased 
plasma triglyceride and cholesterol levels, and fat-soluble vitamin deficiencies 
[7, 36].  MTP contains both an apoB binding domain and a lipid transfer domain.  
While the two domains are thought to act independent of one another, both are 
required for efficient secretion of apoB-containing lipoproteins [37-39].  
Consistently, independent groups identified a physical interaction between apoB 
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and MTP [40, 41].  MTP has been demonstrated to be pivotal for apoB-
containing lipoprotein assembly in two ways: (1) by acting as a chaperone 
mediating translocation of newly synthesized apoB across the ER membrane 
and (2) by facilitating the lipidation of apoB during its translocation into the ER 
[42]. 
 Expression of MTP is enriched in the intestine and liver; however, MTP 
expression has been detected in other tissues but to a much lesser extent.  
MTP expression decreases from the proximal to distal end of the intestine, with 
negligible expression in the colon [43].  Moreover, MTP expression also varies 
vertically within the crypt-villus axis, with the highest expression along the villi 
[7].  Isolated crypts are devoid of MTP mRNA and protein [7, 44].  In Caco2 
cells, MTP induction expression increases throughout differentiation into 
polarized enterocyte-like cells [44].  Hepatocytes also express high levels of 
MTP [7].  The consequence of altering MTP expression in these tissues will be 
discussed briefly. 
 Homozygous deficiency in mice results in embryonic lethality.  
Heterozygote deletion of MTP results in decreased LDL plasma cholesterol 
levels in mice fed chow, and decreased chylomicron/VLDL and LDL cholesterol 
levels under high-fat diet (HFD)-feeding conditions [45].  Homozygous deletion 
of MTP in the visceral endoderm of yolk sacs produces a marked accumulation 
of cytosolic fat droplets, indicative of impaired secretion of lipids [45].  To 
circumvent embryonic lethality in global MTP deficiency, Raabe and colleagues 
generated liver-specific MTP knockout mice and studied the effects on 
lipoprotein metabolism [46].  Suppression of hepatic MTP reduces VLDL 
triglycerides, as well as VLDL/LDL and HDL cholesterol levels [46].  In addition, 
apoB-100 is decreased in plasma by more than 95 % [46].  The liver-specific 
knockout mice possess profound hepatic steatosis, which is associated with 
elevated cytosolic lipid droplets in the hepatocytes [46].  Reduced MTP 
expression via antisense oligonucleotides (ASO) decreases hepatic VLDL 
triglycerides and cholesterol secretion in mice [47].  In contrast, hepatic 
overexpression of MTP results in elevated secretion of VLDL triglycerides [48].  
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Xie and colleagues set out to investigate the overall contribution of intestinal 
MTP expression on lipoprotein metabolism.  Intestinal-specific knockout mice 
exhibit increases in the number of lipid droplets in absorptive enterocytes and 
the mice display steatorrhea, growth arrest, and decreases in cholesterol 
absorption [49].  The decreases in cholesterol absorption most likely result from 
reduced expression of NPC1L1 in intestinal-specific MTP KO mice.  
Chylomicron secretion is impaired by 80% and plasma lipids, as well as hepatic 
triglyceride and cholesterol content, are reduced in mice with intestinal MTP-
deficiency [49].  Intestine-specific KO mice have an increase in both hepatic 
lipogenesis and VLDL secretion, which is attributed to the liver compensating for 
the lack of intestinally-derived lipid [49].  Collectively, alterations in MTP 
expression clearly alter apoB-lipoprotein secretion.  In Chapter 5, we provide 
evidence that PXR may transcriptionally regulate MTP expression, but whether 
PXR mediates apoB secretion remains to be determined. 
1.2 Highly Active Antiretroviral Therapy (HAART) – an Overview 
 The human immunodeficiency virus (HIV) is the cause of the acquired 
immune deficiency syndrome (AIDS) and is currently considered a pandemic, 
with approximately 37 million people globally living with HIV (UNAIDS 2014).  
Since the first class of antivirals were developed and used as a monotherapy in 
the early 1990’s, the standard of care has evolved to include a combination of 
antiretroviral drugs (ARVs) targeting different stages of the HIV life cycle [50].  
The combination of ARVs is defined as highly active antiretroviral therapy 
(HAART) and has significantly reduced the morbidity and mortality associated 
with HIV infection and AIDS [50].  HAART is a customized combination of 
different classes of ARVs, including: fusion inhibitors, CCR5 antagonists, 
reverse transcriptase inhibitors (comprised of nucleoside [NRTIs] and 
nonnucleoside [NNRTIs]), integrase inhibitors, and protease inhibitors (PIs).  
Approximately 37% of all people living with HIV are currently on ARV drug 
therapy (UNAIDS 2014).  Consequently, AIDS-related deaths have fallen by 
35% since 2005, which is partially attributed to the development of HAART 
(UNAIDS 2014).  As longevity increases in HIV-infected individuals, chronic 
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illnesses, such as accelerated atherosclerosis and cardiovascular disease, are 
emerging as leading health issues in this population [51]. 
1.2.1 Epidemiological Studies Linking HAART to CVD 
 Despite reductions in the morbidity and mortality associated with HIV 
infection, HAART has been associated with dyslipidemia and increased risk of 
CVD [52-62].  Findings from the Data Collection on Adverse Events of Anti-HIV 
Drugs study suggested that the incidence of CVD increased with longer 
exposure to HAART [63].  Another large-scale study including more than 23,000 
HIV patients also concluded that ARV drugs such as PIs are associated with an 
increased risk of CVD, which is partly explained by dyslipidemia [55]. A Swiss 
HIV Cohort Study found that PIs can cause dyslipidemia in patients [58] and 
several other studies have reached the same conclusion [64, 65]. For example, 
Lang et al. conducted a case-control study nested within a large HIV patient 
database and found that the risk of myocardial infarction was increased by 
cumulative exposure to almost all of the studied ARV drugs [66].  Many currently 
recommended first-line ARV drugs including several PIs and NNRTIs have been 
shown to cause hyperlipidemia [67].  Despite the strong evidence linking 
HAART with dyslipidemia and CVD, the underlying mechanisms responsible for 
the adverse effects of ARV drugs remain elusive.   
1.2.2 Mechanisms of HAART-Elicited Hyperlipidemia 
and CVD 
 Mounting evidence has linked HAART to alterations in plasma lipid levels 
in humans.  Many of these studies are conducted in HIV-positive individuals; 
however, other studies confirmed a direct association between HAART 
exposure and hyperlipidemia in normal healthy subjects [68].  Liang and 
colleagues first identified a possible mechanism linking PI therapy to 
hyperlipidemia [69].  HIV PI treatment inhibited the proteasomal degradation of 
nascent apoB [69].  ApoB secretion was also impaired with HIV PI treatment, 
which associated with decreased MTP activity [69].  In the presence of oleic 
acid, PI treatment increased secretion of apoB-containing lipoproteins above 
controls [69].  The authors concluded that the PI-mediated hindrance to apoB 
secretion can be overwhelmed by the excess supply of core lipids [69].   
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 Independent groups also demonstrated the ability of certain PIs to induce 
hyperlipidemia in animal models [70, 71].  Treatment of ritonavir for 10 days in 
WT mice on either a low fat or high fat diet produced pronounced increases in 
plasma cholesterol and triglyceride levels [70].  Ritonavir treatment also resulted 
in significant hepatic steatosis and hepatomegaly, which were attributable to the 
accumulation of transcriptionally active SREBP1 and SREBP2 [70].  In an 
independent study, the same group went on to demonstrate that ritonavir 
treatment enhanced VLDL secretion without altering lipoprotein clearance [71].  
Collectively, these adverse effects with HIV PI treatment associated with 
increased expression of genes involved in lipid synthesis and enhanced VLDL 
secretion [70, 71].   
 The activation of the SREBP signaling pathway with HIV PI treatment 
stimulated the work by other groups.  PI treatment in murine macrophages 
enhanced transcriptionally active nuclear SREBP expression, which resulted in 
an accumulation of free cholesterol in intracellular membranes and elevated 
apoptosis [72].  The authors also observed that PI treatment induced 
endoplasmic reticulum stress and activated the unfolded protein response 
(UPR) in these cells [72].  Since intracellular cholesterol can activate ER stress 
and the UPR [73], it is likely the adverse effects associated with PI treatment 
may be linked to the initial nuclear SREBP accumulation; however, this warrants 
further investigation.  The same group went on to demonstrate that treatment 
with various PIs resulted in a variety of responses in mouse primary 
hepatocytes [74].  For example, atazanavir and ritonavir increased nuclear 
SREBP levels and activated the unfolded protein response, while amprenavir 
had no effect [74].  Further, atazanavir and ritonavir treatment suppressed 
CYP7A1 protein levels and bile acid synthesis, while amprenavir had no 
significant effect [74]. 
 These results clearly demonstrate that individual HIV PIs may have 
different effects on lipid metabolism in mice, which is what is observed in 
humans [75].  There is an urgent need to identify new HAART-elicited off-target 
effects that influence lipid metabolism.  In Chapter 2, I provide evidence that HIV 
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PIs activate PXR and induce hyperlipidemia in mice.  This new signaling 
pathway linking HAART to xenobiotic and lipid metabolism may partially explain 
the adverse side effects associated with HAART.  
1.3 Endocrine Disrupting Chemicals (EDCs) – an Overview 
 There is growing concern about the possible health threat posed by 
endocrine-disrupting chemicals (EDCs), substances found in our food, 
environment, and consumer products that ultimately disrupt normal homeostatic 
processes and have the capability to cause diseases [76].  The U.S. 
Environmental Protection Agency define an EDC as, “an exogenous agent that 
interferes with synthesis, secretion, transport, metabolism, binding action, or 
elimination of natural blood-borne hormones that are present in the body and 
are responsible for homeostasis, reproduction, and developmental process” 
[76].  A few examples of compounds that have been identified as EDCs are 
polychlorinated biphenyls (PCBs), plasticizers (phthalates and phthalate 
substitutes), and certain pesticides [76].  It was originally thought that EDCs act 
primarily through nuclear hormone receptors; however, it is now widely 
accepted that EDCs act through a variety of signaling mechanisms, which 
include but are not limited to, nonnuclear steroid receptors, nonsteroid 
receptors, orphan receptors, and enzymatic pathways ultimately responsible for 
maintaining endocrine homeostasis [76].  EDCs have been linked to obesity and 
CAD; however, the mechanisms governing this phenomenon remain poorly 
understood.   
1.3.1 Epidemiological Studies Linking EDCs to CVD 
 Bisphenol A (BPA) is a base compound widely used in the production of 
foods and plastics, and has been recently studied in humans to correlate 
exposure to disease risk.  Using a cross-sectional analysis to measure urinary 
BPA and health status, Lang and colleagues recently demonstrated that higher 
urinary BPA concentrations were associated with cardiovascular disease, 
including CAD [77].  This finding was further supported by an independent 
group [78, 79].  Further, high BPA exposure in adolescents and young adults 
has been associated with significantly increased carotid intima media thickness, 
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a measure of atherosclerosis progression [80].   
 Aside from BPA, other phthalates and phthalate metabolites have been 
associated with atherosclerosis.  Phthalate metabolites are associated with 
increased atherosclerosis in the elderly [81].  Interestingly, Sergeev and 
colleagues demonstrated that people living within close proximity to sites 
contaminated with organic pollutants compared to sites not containing any 
identified hazardous waste had a 20% increase in acute myocardial infarction 
hospital discharge rates [82].  Overall, there have been many studies 
associating environmental chemicals with disease; however, whether these 
compounds are causative and the mechanisms involved remain elusive.   
1.3.2 Mechanisms of EDC-Elicited Hyperlipidemia and 
CVD 
 Mechanisms linking EDC exposure to cholesterol metabolism are largely 
unknown; however, a few groups have examined exposure to atherosclerosis 
and obesity, which will briefly be discussed.  For example, various EDCs were 
screened for their ability to activate the glucocorticoid receptor (GR), and four 
were identified to induce GR-promoter activity [83].  This activity was correlated 
with enhanced adipogenesis in 3T3-L1 murine preadipocytes [83].  Surprisingly, 
the effect of EDCs on promoting lipid accumulation during adipogenesis was not 
contributed to changes in PPARγ expression [83].  
 Consistent with the notion that EDCs play a role in adipocyte stem cell 
differentiation, an independent group demonstrated that PCBs, specifically PCB-
77, increased adipocyte differentiation in low doses [84].  This effect on 3T3L1 
differentiation was ablated by an aryl hydrocarbon receptor (AhR) antagonist 
[84].  Furthermore, administration of PCB-77 increased body weight gain in WT 
mice, but not in AhR-deficient mice [84].  PCB-77 treatment also enhanced the 
obesity phenotype, as well as augmenting dyslipidemia and atherosclerosis in 
ApoE-deficient mice [84].  The effect on dyslipidemia with PCB-77 treatment 
was pronounced with approximately a 133% increase in plasma cholesterol 
levels [84].  The specific mechanism linking PCB exposure to 
hypercholesterolemia was not investigated.  Our group, as well as others, 
discovered that BPA is proatherogenic in animal models [85, 86] (see section 
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1.5.1); however, the precise mechanisms linking EDC-exposure to alterations in 
lipid metabolism and atherogenesis are not well characterized and need to be 
investigated further.  One important area of research in our laboratory is to 
understand the mechanisms linking EDC-exposure and sterol metabolism.  In 
Chapter 3, I identified a phthalate substitute known as tributyl citrate (TBC), as 
an intestinal-specific PXR agonist.  Further, acute TBC exposure stimulated 
hypercholesterolemia which may be mediated through PXR transcriptional 
regulation of NPC1L1. 
1.4 Identification of the Pregnane X Receptor (PXR) 
 Pharmaceutical drugs and environmental chemicals are metabolized 
through a series of enzymatic reactions to generate more polar derivatives that 
are ultimately excreted by the body.  Many of these compounds are first 
metabolized by a member of the cytochrome (CYP) P450 monooxygenase gene 
family. The CYP enzymes are comprised of four gene families (CYP1, CYP2, 
CYP3, and CYP4) and are referred to as phase 1 enzymes because they 
catalyze the first step in the detoxification process.  The CYP enzymes are 
highly expressed in the liver and intestine.  Among the family of CYP enzymes, 
the CYP3A family is recognized to metabolize up to 50% of clinically used drugs 
as well as other xenobiotics [87, 88].  Additionally, the CYP2B enzymes 
metabolize another 25-30% of these compounds [88].  The ability of organisms 
to adapt to their surroundings and possess a host defense mechanism against 
toxic chemicals is essential to maintain life. 
 The pregnane X receptor (PXR; otherwise termed the steroid and 
xenobiotic sensor, or SXR) was initially discovered in 1998 by multiple groups.  
PXR was designated NR1I2 (nuclear receptor subfamily 1, group I, member 2) 
using standard nomenclature and was named based on the observation that 
pregnanes (21-carbon steroids) activate the receptor [89].  Like other nuclear 
receptors, PXR contains both an N’-terminal DNA binding domain (DBD) and a 
C’-terminal ligand-binding domain (LBD), which are responsible for DNA binding 
and ligand binding as well as interaction with co-regulators, respectively.  PXR 
is activated by numerous endogenous hormones, dietary steroids, 
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pharmaceutical agents, and xenobiotic chemicals [90, 91]. It functions as a 
heterodimer with the retinoid X receptor (RXR) to modulate gene transcription 
[92, 93].  PXR was initially characterized based on the observation that ligands 
activating the receptor induced CYP3A4 expression.  Consequently, it was 
further identified that PXR transcriptionally regulates CYP3A4 [89, 94-96]. 
Similar to the CYP enzymes, PXR is highly expressed in the liver and intestine 
[89, 94-96], two sites of first line defense against toxic xenobiotics. The 
discovery of PXR led to identification of many novel target genes involved in 
detoxification and transport of lipophilic compounds, such as genes that encode 
phase I (e.g., CYP450s) and phase II (e.g., glutathione transferase) 
detoxification enzymes, as well as the ABC family transporters (e.g., multidrug 
resistance 1 [MDR1]).  Since its initial discovery, PXR has been shown to be a 
critical regulator for other processes, such as modulating lipid levels, 
atherogenesis, bone homeostasis, and inflammation.   
1.4.1 PXR Gene Structure 
 The human PXR (hPXR) gene consists of nine exons on chromosome 3. 
Despite only one PXR gene discovered in the human genome, three PXR 
variants resulting from alternative splicing have been characterized [97-100]. 
PXR variant 1 encodes two products (isoforms hPXR.1 and hPXR.2), through 
the use of alternative translational codons. PXR variant 3 (hPXR.3) has a 
unique 5’ untranslated region and start codon, which encodes the longest 
isoform with the addition of 39 amino acids on its N’ terminus relative to hPXR.1 
[97-100]. PXR variant 4 (hPXR.4) is similar to hPXR.1 but is lacking 111 base 
pairs due to an in-frame deletion in the LBD at exon 5 [97-100] (Fig. 1.2). 
Particularly, hPXR.4 lacks ligand binding pocket resides 206Leu, 208Ser, and 
209Leu and has been demonstrated to lack the ability to undergo ligand-elicited 
transactivation in reporter assays [100] (Fig. 1.2). Interestingly, however, 
hPXR.4 has been demonstrated to act as a dominant-negative protein 
interfering with hPXR.1 transactivation [100].  This is most likely due to 
competing occupation for DNA binding, thus alleviating maximal ligand 
activation of PXR.  Further, ligands can bind to the LBD of hPXR.4, however 
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with weak associations and thereby corepressors remain tightly bound and 
coactivators are not recruited for PXR transactivation [100]. Likewise, UGT1A1, 
1A3, and 1A4 gene expression were all induced by hPXR.1 and hPXR.3 but not 
by hPXR.4 [98]. All four variants were found in human liver and intestinal tissue; 
however, a great deal of interindividual variation was found [98].  This may 
partially explain the great deal of interindividual variation in drug metabolism 
associated with CYP expression.  
 The mouse PXR (mPXR) gene is located on chromosome 16. The mPXR 
gene generates two variants that are quite similar with hPXR.1 and hPXR.4 [89]. 
Mouse PXR variant 1 (mPXR.1) is 431 amino acids in length and mouse PXR 
variant 2 (mPXR.2) is a splicing variant that lacks 41 amino acids within the LBD 
[89] (Fig. 1.2). Similar to the hPXR.4, mPXR.2 lacks the ability to be activated by 
numerous ligands, such as the synthetic steroids dexamethasone and 
pregnenolone 16α-carbonitrile (PCN) [89]. Although mPXR.2 was expressed in 
a similar tissue-specific pattern as mPXR.1, it was expressed at a much lesser 
extent indicating mPXR.1 is the major isoform in mice [89]. Although other 
transcript variants may exist through the use of alternative promoters, 
alternative splicing, and/or alternative polyadenylation, they have not been 
completely characterized [91, 97, 99].  
1.4.2 Species-Specific PXR Activity and Animal Models 
 Since the initial discovery of PXR in 1998, many orthologues have been 
cloned from a wide variety of organisms, including mammals [89, 94-96, 101-
104], Drosophila [105], and C. elegans [101]. In Drosophila, the PXR orthologue 
was termed DHR96 [105]. Furthermore, three orthologues of PXR are 
represented in C. elegans as DAF12, NHR-8, and NHR-48 [101]. Despite acting 
as orthologous receptors, the pharmacology of PXR differs substantially 
between species. Mouse and human PXR only exhibit approximately 70-80% 
homology within the LBD but share approximately 95% homology in their DNA 
binding domains (DBD) [106, 107]. The observation for species differences in 
CYP3A induction observed in vivo appears to be partially reliant on sequence 
differences in the LBD of PXR. For example, PCN, a known CYP3A inducer in 
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rodents, acts as a potent agonist of mouse and rat PXR, but does not activate 
human PXR [106]. Further, rifampicin, a known inducer of CYP3A in humans 
and rabbits, does not activate mouse PXR. Thus, by binding to wide array of 
structurally diverse compounds, it has been suggested that PXR exhibits 
directed promiscuity [106, 107].  
 Since the homology of PXR differs quite substantially between species, 
mouse models were generated to understand human xenobiotic metabolism in 
vivo. Xie et al. generated transgenic mice expressing wild-type (WT) human 
PXR driven by the albumin promoter on a PXR-null background [108]. These 
mice express hPXR specifically in the liver, while maintaining mouse PXR-
deficiency [108]. Later in the 2000s, Ma and colleagues generated another 
‘humanized’ mouse model utilizing a bacterial artificial chromosome clone 
containing the complete hPXR gene and the corresponding 5’ and 3 flanking 
sequences [109]. This humanized model displays the same tissue-specific 
patterns as human PXR and responds to human-specific PXR agonists, such as 
rifampicin, but not mouse-specific PXR agonists, such as PCN [109]. Although 
these models are essential to understand the PXR-mediated effects on 
metabolic homeostasis, it raises the question about the ability of human PXR to 
drive expression of mouse PXR target genes. For example, the human PXR 
response element within the CYP3A4 promoter is not found in mouse CYP3A11 
[110]. To address this issue, CYP3A4/hPXR double transgenic mice were 
generated [111]. Consequently, rifampicin is a robust inducer of CYP3A4 in the 
double transgenic model [111], compared with only slight induction of CYP3A11 
[112]. Since many CYP3A4 substrates are also PXR ligands, it is essential to 
utilize the double transgenic model to assess the pharmacokinetics of 
pharmaceuticals and other xenobiotics in vivo. Two more models were 
generated to investigate constitutive activation of human PXR in the mouse liver 
and intestine. The first constitutively active mouse model was generated by 
utilizing the albumin promoter to drive human PXR, which was fused at the 5’ 
end to the herpes simplex virus activation domain (VP16) [108]. Subsequently, 
another model was generated utilizing the fatty acid binding protein promoter to 
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drive VP16-hPXR to overexpress PXR in both the liver and gastrointestinal tract 
[113]. Collectively, all the hPXR mouse models show a normal phenotype, 
except for the albumin-driven VP16hPXR mouse model, which displays growth 
retardation, hepatomegaly, and histological liver toxicity [108, 114].  
1.4.3 Post-Transcriptional Regulation of PXR 
 Micro-RNAs (miRNAs) are short noncoding regulatory RNAs that bind to 
complementary regions in the 3’ UTR of mRNA target sequences and suppress 
their translation and/or facilitate degradation [115, 116]. Aside from alternative 
splicing, PXR has been demonstrated to undergo another level of gene 
regulation from microRNAs. PXR mRNA and protein levels were measured in 
25 human livers and their relative expression was compared [117]. Interestingly, 
the transcript and protein levels were not associated, suggesting post-
transcriptional regulation of PXR [117]. In an independent study, 19 single 
nucleotide polymorphisms (SNPs) correlated with plasma cholesterol in humans 
and many of these SNPs were found in the 3’ UTR [118].  Further, 16 
microRNAs were predicted to bind PXR mRNA in human liver samples [117].  
MiR-148a was later identified as a critical regulator of human PXR expression 
[117].  Overexpression of miR-148a suppressed PXR protein levels and, in 
contrast, inhibition of miR-148a elicited increases in PXR protein expression 
[117].  A similar binding site was discovered in CYP3A4; however, CYP3A4 was 
unresponsive to mir-148a overexpression [117].  Although the 3’UTR of PXR is 
not well conserved between species, the miR-148a element has been 
discovered in both mice and rat, indicating that this specific miRNA may control 
PXR gene expression in other mammals [117].  
 In another human cohort, genetic variants in the 3’ UTR were identified in 
specific genes involved in xenobiotic metabolism [116].  For example, 
bioinformatics analysis revealed 1,025 unique microRNA’s that were predicted 
to bind to the hPXR 3’ UTR [116].  The CYP3A4 gene was also predicted to be 
regulated by 889 unique microRNAs [116].  The variant rs1054190C in hPXR 
was predicted to result in the presence of a binding site for miR1250-5p [116].  
In contrast, the variant rs1054191G was predicted to result in the loss of a 
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binding site predicted to bind miR-371b-3p, miR-4258, and miR-4707 [116].  
Although there has been evidence of other regulatory miRNAs targeting PXR 
[116], the physiological consequence on PXR stability and xenobiotic and/or 
lipid metabolism has not been characterized. 
1.4.4 Post-Translational Regulation of PXR 
 It is well known that transcriptional regulation of PXR target genes is 
governed by ligand-activation; however, PXR has been established to undergo 
a host of post-translational modifications including phosphorylation, 
SUMOylation, ubiquitination, and acetylation [119].  This section will provide a 
brief overview of post-translational modifiers in altering PXR subcellular 
localization, dimerization, DNA binding, coregulator activity, and transcriptional 
regulation.  
 
Phosphorylation 
 Recently, there has been a host of evidence demonstrating site-specific 
phosphorylation of PXR, which provides a mechanism for PXR-mediated 
regulation of CYP expression.  It should be noted that phosphorylation of PXR is 
mostly correlated with an inhibitory response in its transcriptional activity.  Many 
kinases have been demonstrated to phosphorylate PXR including p70 S6K 
[119-122], protein kinase A (PKA) [122-124], protein kinase C (PKC) [122, 125], 
cyclin-dependent kinase (Cdk2) 2 [126-128] and 5 [129], thereby regulating the 
activity of PXR.  Metabolic labeling studies indicated that immunopurified hPXR 
is phosphorylated by numerous kinases such as glycogen synthase kinase 3 
(GSK3), casein kinase II (CK2), and Cdk1 [119, 120, 123].   
 It was been well documented that CYP expression is greatly reduced 
during hepatocyte proliferation.  For example, hepatocyte exposure to human 
growth factors such as hepatocyte growth factor potently induces hepatocyte 
proliferation, yet significantly suppresses the CYP isoenzymes [119, 130, 131].  
In recent work led by Lin and colleagues, it was initially hypothesized that hPXR 
changes expression throughout various phases of the cell cycle.  This study 
provided compelling evidence that hPXR is phosphorylated by Cdk2, a key 
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regulator of the cell cycle, and suppresses its transcriptional activity [128].  This 
group went on to identify two small molecule inhibitors that were Cdk2 inhibitors, 
which ultimately increased hPXR activity.  This increase in hPXR activity was 
thought to be ligand-independent, as these two molecules bound to hPXR with 
low affinity.  The serine 350 (Ser350) was discovered to be the site at which 
Cdk2 phosphorylates PXR.  Consistently, a phosphomimetic mutation (S350D) 
of the putative Cdk2 phosphorylation site on PXR mimicked the inhibitor effect 
of Cdk2.  In contrast, a phosphorylation-deficient mutation (S350A) conferred 
resistance to Cdk2 suppression.  Furthermore, PXR transcriptional activity was 
significantly reduced in the S-phase of the cell cycle, which is when Cdk2 
activity increases, and this was not due to simply reduced hPXR expression.  
Since neither the phosphomimetic mutation nor the phosphorylation-deficient 
mutation rendered 100% resistance to the inhibitor effect of Cdk2, it is likely that 
Cdk2 phosphorylates multiple sites on hPXR [128].  This work is the first to 
identify a possible mechanism linking Cdk2 to CYP3A4 expression in 
hepatocytes, and implicates the importance of considering cell cycle status 
when investigating PXR activity and CYP expression [128]. 
 Consistent with the notion that PXR phosphorylation suppresses 
transcriptional activity, another kinase downstream of the PI3K-Akt signaling 
pathway was demonstrated to phosphorylate PXR and suppress its activity.  A 
study by Pondugula and colleagues demonstrated that p70 S6K acts as an 
upstream kinase of PXR and phosphorylates threonine 57 (Thr57), which 
suppresses PXR transactivation.  This Thr57 residue is a highly conserved 
phosphorylation site within the DBD of human nuclear receptors, including 
numerous PXR orthologous, indicative of its importance in PXR physiology 
[119].  In this study, a phosphorylation-deficient (T57A) and a phosphomimetic 
(T57D) were generated to assess PXR activity and subcellular localization.  As 
expected, the T57D but not the T57A mutation abolished its PXR transcriptional 
activity.  Interestingly, however, neither mutation altered hPXRs interaction with 
the coactivator SRC-1.  Both WT and the T57A mutant exhibited a homogenous 
distribution in the nuclei of cells whereas the T57D phosphomimetic mutant 
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exhibited a punctate pattern, suggesting that phosphorylation at T57 could alter 
subcellular localization.  However, it is still unclear how the punctate nuclear 
localization pattern affects PXR signaling.  Since this T57 residue is highly 
conserved, it raises the possibility that this amino acid is pivotal for DNA binding 
across many nuclear receptors.  In conjunction with this notion, the T57D 
mutation, but not the T57A mutation, impaired hPXR’s ability to bind to the 
CYP3A4 promoter.  The p70 S6K was later described to phosphorylate T57 on 
PXR and suppress its transcriptional activation through loss of binding at the 
CYP3A4 promoter [121].   
 A further study was conducted to investigate the mechanism by which 
phosphomimetic mutations at various sites within PXR result in changes in 
subcellular localization and activity.  Phosphomimetic mutations at threonine-
290 and threonine-408 demonstrated similar subcellular localization properties, 
with suppressed translocation of hPXR into the nucleus [132].  In another study, 
the same group demonstrated the ability of Ca2+/calmodulin-dependent protein 
kinase II (CaMKII) to phosphorylate hPXR at threonine-290, leading to its 
retention in the cytoplasm [133].  They went on to further illustrate that both WT 
and the T408D mutant immunoprecipitated with chaperone proteins to a similar 
extent in the cytoplasm [132].  When they treated cells with autophagy 
inhibitors, the T408D mutant led to higher cytoplasmic accumulation than WT 
and co-localized with the autophagic cargo [132].  Collectively, these data 
support the notion that PXR is phosphorylated at threonine 408 and undergoes 
autophagy regulated degradation.   
 There has been mounting evidence in support of additional amino acid 
residues on PXR that have been predicted to be phosphorylated by numerous 
kinases [119, 134].  Although more work is required to functionally validate the 
importance of each one of these kinases, PXR clearly has other levels of 
regulation aside from ligand-dependent transcriptional activation that modulate 
PXR transcriptional activity, stability and subcellular localization [119, 134]. 
 
Ubiquitination 
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 Ubiquitination is a multi-step process that occurs at several levels of signal 
transduction.  Ubiquitin attaches to the substrate by an isopeptide bond 
between the C’ terminus of ubiquitin and a lysine residue on the substrate [135].  
The placement of ubiquitin on the substrate is governed by three enzymes: E1 
(ubiquitin activating), E2 (ubiquitin conjugating), and E3 (ubiquitin ligases) [135].  
The degradation of proteins by the proteasome relies on ubiquitin tagged 
substrates.  The mechanisms governing degradation of PXR by ubiquitination 
have not been well investigated; however, there are a few studies suggesting 
PXR stability being altered by ubiquitination.  In 2000, Masuyama and 
colleagues demonstrated that ubiquitin may regulate PXR stability.  This group 
revealed that the suppressor for gal-1 (SUG1) interacted with PXR [136].  SUG1 
is a known subunit of the 26S proteasome [137] and was first demonstrated to 
bind to a host of other nuclear receptors [138], but PXR was not initially 
described in this data.  This interaction, however, only occurred in the presence 
of progesterone, but not with other PXR activators, such as phthalic acid or 
nonylphenol [136], which highlights the fact that various PXR activators may 
alter PXR degradation differently [119]. Subsequently, the same group went on 
to illustrate that PXR protein levels were increased in the presence of 
proteasome inhibitors [139].  Overexpression of SUG1 elicited increases in PXR 
degradation, as evident by enhanced proteolytic PXR fragments, which was 
blocked by proteasomal inhibition.  Interestingly, the interaction between PXR 
and SUG1 depended on the presence of progesterone because proteolytic 
fragments were not generated in the absence of this steroid.  Overexpression of 
SUG1 suppressed progesterone-mediated PXR transactivation on the CYP3A1 
promoter in vitro [119, 136, 139].  It has been noted that the interaction with 
SUG1 may result from conformational changes of the receptor upon distinct 
ligand binding [119], such as progesterone, however more work will be required 
to elucidate the precise mechanism by which this occurs.   
 More recently, another group identified an E3 ubiquitin ligase as an hPXR-
interacting protein.  The ring-B-box-coiled protein interacting with protein kinase 
C-1 (RBCK1) was discovered by utilizing a yeast-two hybrid screening approach.  
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Overexpression of RBCK1 in AD-293 cells decreased PXR levels, which was 
inhibited by the proteasomal inhibitor MG-132.  Most importantly, overexpression 
and silencing of RBCK1 resulted in inhibition and induction of endogenous PXR, 
respectively, in human primary hepatocytes.  Silencing RBCK1 enhanced 
rifampicin-elicited induction of human PXR target genes [140].   
 Collectively, these results provide compelling evidence that PXR stability 
can be directly linked to conformational changes elicited by a specific ligand 
(e.g., progesterone), in part by disrupting the association between PXR and 
SUG1 [136, 139].  Furthermore, other groups have demonstrated that PXR is 
directly ubiquitinated by protein kinase A and RBCK1, both of which regulate 
PXR stability and ultimately, PXR transcriptional activity.  However, the 
interaction between PXR and the ubiquitin-signaling pathway warrants further 
investigation [119].  
 
SUMOylation 
 Another post-translation mechanism altering PXR protein-protein 
interactions and stability, ultimately fine-tuning gene transcription is 
SUMOylation.  SUMOylation is characterized by the addition of a small 
ubiquitin-related modifier (SUMO) to its substrate.  SUMOylation shares many 
common characteristics with ubiquitination [141, 142].  For instance, SUMO-
specific enzymes attach SUMO proteins in an enzymatic cascade completely 
reliant on ATP and some SUMO proteins can serve as direct substrates for 
SUMOylation, thereby generating a protein that is polysumoylated [141, 142].  
To date, four SUMO proteins (SUMO1, SUMO2/3, and SUMO4) have been 
identified in mammalian cells [141, 143, 144].  The attachment of a SUMO 
moiety to a target lysine residue on a specific substrate is governed by three 
enzymes: E1 (SUMO activating), E2 (SUMO conjugating), and E3 (SUMO 
ligases) [141].  SUMO modification to a specific substrate is reversible due to 
SUMO-specific proteases that cleave the isopeptide bond between the SUMO 
protein and its substrate, thereby releasing SUMO for further cycles [141].  
 The signaling consequences of SUMOylation are substrate-specific.  
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Interestingly, SUMOylation of a number of nuclear receptors have been linked to 
inflammation [145-147].  For example, ligand-dependent SUMOylation of 
PPARγ results in recruitment to inflammatory gene promoters where it inhibits 
transcription by suppressing clearance of corepressor complexes in mouse 
macrophages [147].  Moreover, ligand-dependent SUMOylation of LXR 
represses inflammatory gene expression in brain astrocytes [146].  Consistently, 
inflammatory signaling in hepatocytes increased SUMOylation of liganded hPXR 
[145].  The SUMOylated form of PXR represses NF-κB target gene expression 
but had little effect on CYP3A4 gene expression, indicating a promoter-specific 
response upon exposure to RIF [145].  Utilizing a bioinformatics approach, Hu 
and colleagues were the first to identify four potential sites of SUMOylation 
within hPXR; however, the contribution of each predicted lysine in global PXR 
SUMOylation was not investigated and warrants further investigation [145].   
 The same group recently confirmed their previous work demonstrating that 
TNFα and the hPXR ligand RIF increased both global SUMOylation and 
ubiquitination in primary murine hepatocytes [148].  Interestingly, however, they 
discovered that PXR SUMOylation driven by two different E3 ligases actually 
elicited different responses in PXR activity [148].  For example, the protein 
inhibitor of activated signal transducer and activator of transcription-1 (PIAS1), a 
SUMO-E3 ligase, increased SUMOylation, as well as PXR-mediated induction 
of the xenobiotic response [148].  In contrast, the protein inhibitor of activated 
STAT Y (PIASy), another SUMO-E3 ligase, increased SUMOylation and 
alleviated interaction of PXR with the coactivator peroxisome proliferator-
activated receptor gamma coactivator-1-alpha (PGC-1α) [148].  Further, PIASy-
mediated SUMOylation of PXR suppressed ubiquitin-mediated degradation by 
the 26S proteasome [148].  Their latest work identified a possible mechanism by 
which SUMOylation can alter the xenobiotic response versus the inflammatory 
response in hepatocytes; however, how the cell senses the environment to 
regulate these two processes by differential expression of different SUMO-E3 
ligases and how this specifically alters the PXR response warrants further 
investigation. 
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 More recently, an independent group confirmed the four predicted 
SUMOylation sites and identified a Negative charge amino acid Dependent 
SUMOylation Motif (NDSM) in hPXR [149].  Further, they demonstrated that 
PXR SUMOylation in the presence of ligand induces target gene expression 
and this was due to enhanced interaction between PXR and its coactivator, 
steroid receptor coactivator-1 (SRC-1) [149].  SUMOylation did not, however, 
alter PXRs ability to bind to the PXR response element within CYP3A4 [149].  
They went on to demonstrate that site-directed mutagenesis of all four putative 
lysine residues along with the NDSM abolished SUMO-1 mediated 
transactivation [149].  Also, they identified a protein-protein interaction with an 
E2 conjugating enzyme known as UbCh9, and this interaction was slightly 
reduced with a NDSM mutant [149].  Collectively, these studies identified novel 
putative lysine residues involved in hPXR SUMOylation and this may contribute 
to ligand-elicited promoter-specific transsuppression and/or transactivation 
connecting inflammation to xenobiotic metabolism, respectively (For more 
information, see PXR in inflammation, section 1.5.4). 
 
Acetylation 
 The last post-translational modifier that will be discussed in regards to 
PXR function is acetylation.  As discussed in the sections of ubiquitination and 
SUMOylation, acetylation also targets the lysine side chain, which generates a 
great potential for crossregulation between the post-translational modifiers [150].  
Lysine acetylation was first identified in histones and is now known to occur in 
more than 80 transcription factors and various cytoplasmic proteins [150, 151].  
The acetylation pattern and impact vary from one protein to another, and the 
effects can be multifaceted for one protein [150, 151].  Two independent groups 
first described the physiological consequence of PXR acetylation and both will be 
discussed below. 
 Biswas and colleagues first demonstrated that endogenous PXR, as well 
as exogenous PXR, was acetylated in human cells [152].  Moreover, treatment 
with a PXR or RXR agonist drove deacetylation (and/or suppressed acetylation) 
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of PXR.  Since the deacetylase sirtuin-1 (SIRT1) has been demonstrated to 
deacetylate other nuclear receptors [153-155], they investigated the potential 
involvement of SIRT1 on PXR acetylation [152].  Overexpressing SIRT1 had a 
modest effect on PXR deacetylation but the effect was much more pronounced 
with the combination of RXR/PXR ligands [152].  They did go on to determine 
that SIRT1 could interact with PXR both in the presence and absence of 
RXR/PXR ligands, suggesting a ligand-independent interaction [152].  Further, 
resveratrol treatment (a SIRT1 activator) in WT murine primary hepatocytes 
promoted lipogenesis and phenocopied the effect of PCN treatment (mouse-
specific PXR agonist) and this effect was alleviated with treatment of a HDAC 
inhibitor (nicotinaminde), suggesting deacetylation of PXR may promote 
lipogenesis independent of ligands [152].  Neither resveratrol nor nicotinamide 
are PXR agonists.  The effect of resveratrol treatment in lipogenesis was 
alleviated in primary hepatocytes from PXR KO mice, suggestive of a PXR-
dependent effect.  This work provides evidence that HDACs play a role in PXR 
acetylation; however, SIRT1 seems to only act as a modest regulator thus more 
work is required to elucidate which specific HDACs are involved in PXR 
deacetylation.  Moreover, it would be of interest to investigate possible 
crossregulation at specific lysine residues with SUMOylation and ubiquitination 
and assess the impact on PXR function.  It is well known that PXR activation 
promotes lipogenesis; more studies are required to investigate the possible 
involvement of HDAC regulation on PXR activity in the context of lipogenesis.   
 An independent group examined the impact of energy sensing factors 
PGC-1α and SIRT1 on PXR expression and function.  Results from a mammalian 
two hybrid assay indicated that SIRT1 interfered with the PXR and PGC-1α 
interaction.  Moreover, SIRT1 interacted directly with PXR.  SIRT1 may disrupt 
the PXR/PGC-1α interaction by two possible mechanisms that are not mutually 
exclusive: the well-known deacetylation of PGC-1α [156] or the deacetylation of 
PXR (summarized above).  Collectively, both of these studies implicate 
acetylation as a post-translational mechanism that modulates PXR function.  
More work is required to elucidate the specific enzymes mediating 
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acetylation/deacetylation and the global effect this has on PXR activity. 
1.5 The Role of PXR in Sterol Metabolism 
 The role of PXR in xenobiotic metabolism has been thoroughly 
investigated; however, its involvement in cardiometabolic diseases remains 
elusive.  The primary focus of this dissertation is to investigate the role of PXR 
in cardiometabolic diseases, specifically hyperlipidemia.  Accordingly, this 
section will provide a comprehensive review of the current literature linking PXR 
to lipid metabolism, atherosclerosis, diet-induced obesity, and inflammation. 
1.5.1 PXR, Cholesterol Metabolism, and Atherogenesis 
 PXR has been implicated as a mediator of alterations in cholesterol 
homeostasis in mice and humans. It has been well documented that PXR 
transcriptionally regulates many genes involved in cholesterol catabolism, 
specifically in the bile acid pathway (see below). However, the role of PXR in 
sterol biosynthesis and secretion has been less defined. The first evidence of 
PXR regulating sterol metabolism was demonstrated by Bachmann and 
colleagues, who discovered that PXR agonist treatment in WT mice elicited 
increases in serum HDL-C and hepatic apoA-1 levels [157]. This effect was 
alleviated in PXR-deficient mice, indicating PXR is mediating this response 
[157].   
 In contrast, an independent group demonstrated that hPXR activation with 
rifampicin and lithocholic acid (LCA) treatment inhibited expression of ABCA1 
and SR-B1 in human hepatic cells.  This was further confirmed in rat primary 
hepatocytes treated with rPXR agonists PCN and LCA [158].  Although cellular 
cholesterol was unchanged with PXR agonists, cholesterol uptake or secretion 
into apoA1-containing lipoproteins was not investigated.  The effect of PXR 
activation on ABCA1 and apoA1 gene expression and ultimately HDL-
cholesterol levels warrants further investigation.   
 The role of PXR in response to bile acids was investigated in the context 
of altering lipoprotein metabolism.  ApoA1 gene expression is negatively 
regulated by FXR [159, 160]; however, other nuclear receptors have been 
reported to positively regulate apoA1, such as HNF4α [160, 161].  Moreover, 
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several PXR ligands were reported to increase HDL cholesterol and ApoA1 
gene expression; thus, Masson and colleagues set out to investigate the role of 
PXR in lipoprotein metabolism in response to dietary cholic acid (CA) [160].  
The authors concluded that the expression of PXR antagonizes the CA-
mediated downregulation of plasma HDL cholesterol and apoA1 gene 
expression [160].  The expression of a human PXR transgene in PXR-null mice 
completely reversed the deleterious effects of CA on plasma HDL [160].  
Collectively, these data support previous claims that PXR activation increases 
hepatic apoA1, circulating apoA1, and HDL cholesterol in rats, mice, and 
humans [96, 157, 162-167].   
 Recently, a more thorough investigation of intestinal PXR activation on 
ABCA1 and HDL metabolism was published.  Treatment with the human PXR 
ligand rifampicin significantly increased CYP27A1 expression in human 
intestinal Caco2 cells but not in human hepatic cells (both primary cells and the 
immortal HepG2 cells); however, rifampicin treatment did stimulate expression 
of CYP3A4 in both cell types, indicative of tissue-specific differences in gene 
expression [168].  This was further confirmed utilizing a CYP27A1 promoter 
luciferase construct overexpressed with hPXR.  hPXR overexpression only 
stimulated CYP27A1 promoter activity in human intestinal Caco2 cells but not 
human hepatic HepG2 cells [168].  Further, 3-PXR binding sites were identified 
in the CYP27A1 promoter and gel-shift analysis revealed PXR was competent 
at binding to each element [168].  ChIP analysis revealed rifampicin treatment 
promoted SRC-1 coactivator association at each PXR-response element.  It 
would have been interesting to utilize HepG2 nuclear extracts to repeat the 
ChIP experiments to determine if the recruitment of SRC-1 with rifampicin 
treatment is specific to human intestinal cells [168].  The authors went on to 
demonstrate that the direct-repeat-5 (DR-5) element approximately 1 kB 
upstream from the transcriptional start site is the most important by 
transactivation assays [168].  CYP27A1 catalyzes the oxidation of cholesterol to 
generate 27-hydroxycholesterol, a potent LXRα ligand [169-173].  The 
consequence of PXR-mediated CYP27A1 induction was elevated intracellular 
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27-hydroxycholesterol levels, which ultimately drove ABCA1 levels and 
increased cholesterol efflux from intestinal cells to ApoA1 and HDL, most likely 
through increased LXRα activity [168].   
 According to the work by Masson and colleagues, PXR antagonizes the 
CA-mediated decrease in plasma HDL levels.  So Hoekstra and colleagues 
hypothesized that PXR activation may decrease atherosclerosis by promoting 
reverse cholesterol transport via enhancing HDL-cholesterol.  They utilized both 
atherosclerosis mouse models (LDLR and ApoE-deficient mice) to assess the 
role of PXR activation on plasma lipid levels [174].  LDLR- knockout mice fed 
PCN for 3 days had a significant reduction in LDL-cholesterol levels, which was 
not attributed to decreases in VLDL-secretion [174].  The authors went on to 
demonstrate that lipolysis decreased with PCN treatment and this effect was 
primarily due to a decrease in hepatic lipase activity [174].  Hepatic lipase and 
its cofactor apolipoprotein A4 were both downregulated in the liver of PCN-
treated mice [174].  Consistent with a decrease in lipolysis, VLDL triglycerides 
were increased with PCN treatment.  The authors concluded that the change in 
the plasma lipoprotein profile was primarily due to impaired metabolism of VLDL 
[174].  Lastly, they examined the role of PXR in ApoE-deficient mice fed chow 
with and without PCN.  In both hyperlipidemic models, hepatic steatosis was 
enhanced with PCN treatment [174].  These data support the notion that PXR 
activation promotes hepatic steatosis by a variety of mechanisms (Fig. 1.3); 
however, the effect on plasma lipid levels needs to be further investigated.   
 A recent study revealed that PXR transcriptionally regulates Lipin-1, an 
enzyme involved in triglyceride production [182].  Further, PXR-deficient mice 
exhibit impaired VLDL secretion compared to WT mice; however, VLDL 
secretion was not measured in mice treated with PXR agonists.  Taken 
together, the current data suggest that PXR may play some role in altering 
VLDL secretion. 
 To further assess the role of PXR in lipid metabolism, Zhou and 
colleagues fed WT and PXR-deficient mice a low-cholesterol diet with and 
without PCN and examined the lipoprotein profiles [177].  After 2 weeks of 
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feeding, WT but not PXR KO mice fed PCN had significantly elevated 
proatherogenic VLDL and LDL cholesterol levels [177].  Moreover, PCN 
treatment for 8 weeks in ApoE-deficient mice accelerated atherosclerosis 
defined by neutral lipid staining in the brachiocephalic artery (+54%) and the 
aortic root (+116%) [177].  Plasma lipids were similar in ApoE-deficient mice fed 
control and PCN, however there was a slight reduction in HDL-cholesterol with 
PCN treatment [177].  These data suggest that the atherosclerosis phenotype is 
most likely independent of lipid levels in these ApoE-deficient mice.  
Accordingly, PXR activation increased CD36 expression and lipid accumulation 
in peritoneal macrophages [177].  This data implicates macrophage PXR as a 
modulator of atherosclerosis.  Furthermore, this was the first study identifying 
PXR activation elicits proatherogenic hypercholesterolemia.  The precise 
mechanisms regulating cholesterol metabolism is still unclear. 
 Consistent with the notion that PXR plays a role in macrophage function in 
atherosclerosis, our group demonstrated that PXR-deficiency on an ApoE-
deficient background decreased atherosclerosis [178].  Our laboratory 
generated PXR and ApoE double knockout mice (PXR-/-ApoE-/-) and deficiency 
of PXR did not alter plasma triglycerides or cholesterol levels compared to 
ApoE-/- mice [178].  However, PXR-/-ApoE-/- mice had decreased atherosclerosis 
quantified by Oil-Red O staining in the aortic root (-40%) and brachiocephalic 
artery (-60%) [178].  Consistent with the previous study [177], deficiency of PXR 
reduced expression of CD36, lipid accumulation, and oxidized LDL uptake in 
peritoneal macrophages [178].  CD36 expression was also decreased in the 
atherosclerotic lesions of PXR-/-ApoE-/- mice [178].  Collectively, this data 
demonstrates that basal PXR is essential for foam cell formation and 
atherosclerosis.   
 More recently, our group demonstrated that chronic exposure to BPA 
enhanced atherosclerosis in PXR-humanized ApoE-deficient mice 
(huPXRApoE-/-) [86].  We previously reported that BPA and its analogs activate 
PXR [179].  Interestingly, we found that BPA is a potent agonist for human PXR 
but not for mouse or rat PXR [179].  Since BPA is a human PXR-specific ligand, 
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we set out to generate a model to study the effects of BPA-mediated PXR 
activation on atherosclerosis in mice.  Thus, we utilized the previously 
characterized huPXR mice [109, 180], which express the human PXR gene in 
place of the mouse PXR gene, and crossed these mice with atherosclerosis-
prone ApoE-/- mice to generate huPXRApoE-/- and PXR-/-ApoE-/- mice [86].  The 
huPXRApoE-/- and PXR-/-ApoE-/- mice have the same genetic background 
(mPXR and ApoE null alleles) except for one allele of huPXRApoE-/- carrying 
the human PXR transgene [86].  Chronic 12-week BPA treatment did not alter 
body weight or plasma lipid levels in either huPXRApoE-/- or PXR-/-ApoE-/- mice; 
however, BPA exposure significantly enhanced atherosclerotic lesion area in 
both the aortic root and the brachiocephalic artery from huPXRApoE-/- mice, but 
not from PXR-/-ApoE-/- mice [86].  Furthermore, BPA increased foam cell 
formation and CD36 expression in macrophages and atherosclerotic lesions of 
huPXRApoE-/-, but not in PXR-/-ApoE-/- mice [86].  These findings demonstrate 
that BPA exposure increases atherosclerosis development in an animal model 
expressing only human PXR.   
 Consistent with the notion that PXR agonists have been reported to alter 
cholesterol levels in humans, 13 SNPs were identified in PXR that correlated 
with aberrant LDL-cholesterol levels [181].  Interestingly, many of these SNPs 
were located in the 3’ UTR of PXR [181], indicating possible post-transcriptional 
modifications in PXR.  Although the data did not demonstrate whether these 
SNPs correlated with elevated or decreased LDL-cholesterol levels, it would be 
worth investigating. 
 The main emphasis of the work in this dissertation was to identify new 
PXR ligands, as well as novel PXR transcriptional targets involved in cholesterol 
metabolism.  We identified NPC1L1 as a direct PXR target gene in Chapter 3; 
however the in vivo physiological consequence of PXR activation on intestinal 
cholesterol absorption remains to be determined.   
1.5.2 PXR in Cholesterol Catabolism – Emphasis on Bile 
Acids 
 Bile acids act as signaling molecules through a variety of mechanisms, 
including acting as ligands for the nuclear receptors FXR and PXR. For example, 
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utilizing a mammalian two-hybrid system, Xie and colleagues revealed that LCA, 
chenodeoxycholic acid, and deoxycholic acid are PXR agonists [183].  The major 
mouse metabolite of LCA, 3-keto-LCA, is a more potent PXR agonist than its 
parent [183, 184].  The hierarchy of potency is as follows: 3-keto-
LCA>LCA>DCA=CA [88, 184, 185].  They confirmed that both these primary and 
secondary bile acids could activate both mouse and human PXR and induce 
downstream CYP3A4 expression [183].  LCA has been shown to cause 
cholestasis and associated hepatotoxicity [183].  When WT, PXR-null, or Alb-
VPSXR transgenic animals were treated with control or LCA for 4 d, 58% of WT 
and 100% of PXR-null exhibited clear hepatic necrosis when treated with LCA 
[183].  In response to LCA treatment, compared with WT mice, PXR-null mice 
exhibited more hepatic inflammatory infiltration [183].  In comparison, the Alb-
VPSXR transgenic mice showed no histological changes with LCA treatment 
[183].  These data demonstrate that constitutive activation of hepatic PXR 
protects against LCA-induced liver damage.  To further investigate whether the 
induction of the CYP enzymes such as CYP3A provide a protective effect against 
LCA-induced hepatotoxicity, WT and PXR-null mice were pretreated with PCN 
prior to LCA treatment.  As anticipated, the incidence of LCA-induced histological 
liver damage after PCN treatment was decreased approximately 60%; however, 
PXR-null mice remained sensitive to LCA after PCN treatment [183].  This is 
consistent with data demonstrating that transgenic overexpression of PXR and 
the sustained induction of CYP3A enhanced protection against xenobiotic 
compounds [108, 183].  Further, PXR-null mice exhibit loss of protection to a 
wide range of xenobiotics, not just LCA [183].  The authors went on to 
demonstrate that the CYP3A enzymes in human liver microsomes primarily 
catalyze LCA hydroxylation [183].   
 Is PXR simply a sensor that is activated by bile acids to induce expression 
of CYP enzymes to promote hydroxylation and excretion of bile-acid derivatives?  
Although that is a major function of PXR in cholesterol catabolism, independent 
groups have observed and identified a feedback mechanism, much like FXR, 
where PXR also inhibits bile-acid synthesis by suppressing the rate-limiting 
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enzyme, CYP7A1.  Interestingly, rifampicin, a potent human PXR activator, has 
been used to treat cholestasis [186].  It was later identified that rifampicin is 
required for PXR and HNF4α binding, which blocked PGC-1α binding to HNF4α 
ultimately suppressing CYP7A1 gene transcription [187].  Thus, rifampicin 
inhibition of bile acid synthesis may be a protective mechanism against 
xenobiotic and bile-acid induced cholestasis [187].   
 Aside from transcriptionally repressing CYP7A1 to inhibit subsequent bile 
acid synthesis, PXR also transcriptionally activates genes involved in bile acid 
uptake, as well as bile acid elimination.  For instance, rat PXR was identified to 
transcriptionally regulate the organic anion transporting polypeptide 2 (OATP2), a 
liver transporter that mediates uptake of a variety of compounds, including 
conjugated steroids, thyroid hormones, and bile salts [188].  PXR has also been 
demonstrated to transcriptionally activate the multi-drug resistance associated 
proteins 2 (MRP2) [189], MRP3 [190], and the bile salt export pump (BSEP) [191] 
facilitating bile acid elimination [192].  Interestingly, PXR itself is a direct 
transcriptional target of ligand-activated FXR [185, 193].  Taken together, PXR 
acts as a bile acid sensor that can mitigate the harmful effects of toxic bile acids 
by driving expression of genes involved in hepatic detoxification [185].   
1.5.3 PXR and Energy Metabolism  
 Perturbations in lipid homeostasis are an underlying cause of many 
disease states, such as obesity and diabetes.  Hepatic lipid homeostasis is 
tightly controlled by a variety of mechanisms including lipogenesis, β-oxidation, 
lipid uptake, and secretion.  Many clinical observations led to the hypothesis that 
PXR may play a role in regulating lipid metabolism.  Notably, patients treated 
with rifampicin develop hepatic steatosis [194], which is also observed in many 
animal models [114, 194-197].  This section will provide insight into the role of 
PXR in modulating lipid homeostasis, with an emphasis on fatty acid and 
triglyceride metabolism.   
 Recent work by independent groups reported that PXR activation causes 
hepatic steatosis characterized by accumulation of hepatic triglycerides [114, 
194-197].  Mice expressing constitutively active hPXR in the liver [108] had 
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severe steatosis characterized by significant accumulation of triglycerides [114].  
Further analysis revealed the lipogenic gene expression signature was vastly 
altered.  Interestingly, however, expression of SREBP-1c, a major regulator of 
de novo hepatic lipid biosynthesis, was unaltered, as well as its major target 
genes fatty acid synthase (FAS) and acetyl CoA carboxylase (ACC) [114].  
These results suggest that the effect of PXR on hepatic steatosis was SREBP-
independent.  Further, CD36 was induced in a PXR-dependent manner [114].  
Mice lacking CD36 exhibit increased plasma free fatty acids and triglyceride 
levels, indicative of its role in fatty acid uptake [198].  PXR activation resulted in 
a decrease in plasma free fatty acids [114]; however, it is still unclear whether 
this is a CD36-dependent mechanism.  The authors went on to identify a 
functional PXR DR3-type response element within the CD36 promoter.  These 
results confirm that CD36 is indeed a PXR-target gene and may partially 
contribute to the hepatic steatosis phenotype observed in mice expressing 
constitutively active PXR [114].   
 PXR activation was also associated with upregulation of many genes 
involved in lipogenesis, such as PPARγ, stearyl CoA desaturase 1 (SCD1), and 
fatty acid elongase (FAE) [114, 195].  It was later confirmed that PPARγ is a 
PXR target gene [199, 200].  Interestingly, PPARγ is also a positive regulator of 
CD36 [201], indicating PXR activation may drive CD36 expression directly or 
through crosstalk with PPARγ (Fig. 1.3).  The consequence of PXR 
transcriptionally regulating PPARγ in the context of hepatic steatosis remains to 
be determined; however, two reports have demonstrated that overexpression of 
PPARγ in mice induced hepatic steatosis [194, 202, 203].  The marked steatosis 
associated with increased levels of lipogenesis-related genes, including CD36 
and SCD1, as well as others [202, 203].   
 Aside from PPARγ, other genes involved in lipogenesis were discovered 
as direct PXR targets.  The thyroid hormone-responsive SPOT14 homolog 
(S14) plays a critical role in inducing lipogenic enzyme gene expression, notably 
FAS and ATP citrate lyase (ACLY) [194].  It was later identified that S14 is a 
PXR target gene in human hepatocytes and mouse liver [204].  S14 
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overexpression in human HepaRG cells provoked increases in fatty acid 
accumulation and lipogenesis [204].  It was previously reported that PXR 
activation did not alter mRNA levels of FAS and ACLY [114].  Thus, more work 
is required to completely understand the complex mechanisms associated with 
PXR and its target genes in the context of hepatic steatosis.  
 Several observations made by independent groups suggest that PXR 
activation suppresses expression of genes involved in β-oxidation.  The 
constitutively active hPXR mice displayed a significant reduction in mRNA levels 
of several genes involved in fatty acid β-oxidation, such as PPARα and thiolase 
[114, 199].  Furthermore, an independent group revealed murine PXR activation 
down-regulates the mRNA level of mitochondrial carnitine palmitoyltransferase 1 
(Cpt1) and mitochondrial 3-hydroxy-3-methyl-glutarate CoA synthase 2 
(Hmgcs2) [195].  Cpt1α and Hmgcs2 are the rate-limiting enzymes of β-
oxidation and ketogenesis, respectively.  CPT1α expression is tightly controlled 
by a variety of transcription factors, such as the insulin-responsive forkhead 
factor A2 (FoxA2).  FoxA2 has been shown to positively regulate genes 
controlling β-oxidation [205].  Interestingly, it was demonstrated that PXR 
physically interacts with FoxA2 through their ligand and DNA binding domains, 
respectively [194, 195, 199].  This interaction prevents the binding of FoxA2 to 
its DNA response elements and represses its activation of Cpt1α and Hmgcs2 
gene promoters [194, 195, 199].  Consistent with the hypothesis that PXR 
affects both fatty acid β-oxidation and ketogenesis, PXR-deficient mice display 
elevated levels of oxygen consumption, liver mitochondrial β-oxidation, and are 
completely protected against HFD-induced obesity [182].  In contrast, transgenic 
expression of PXR suppressed hepatic β-oxidation and exacerbated hepatic 
steatosis [182].  Moreover, PXR activation decreased ketone body (3-
hydroxybutylate) levels in mice [182].  Collectively, PXR regulates hepatic lipid 
metabolism by driving expression of genes controlling hepatic lipid uptake and 
formation, while suppressing fatty acid catabolism by turning off genes involved 
in β-oxidation and ketogenesis (Fig. 1.3). 
  Hepatic gluconeogenesis is essential for survival during fasting or 
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starving because glucose is necessary as a fuel source in central and peripheral 
tissues.  Pyruvate is a precursor for gluconeogenesis, which undergoes several 
enzymatic steps to ultimately generate glucose.  Hepatic gluconeogenesis is 
positively regulated by glucocorticoids, cAMP, and glucagon, and negatively 
regulated by insulin and glucose [194].  Major enzymes involved in this process 
include notably phosphoenolypyruvate carboxykinase (PEPCK) and glucose-6-
phosphatase (G6Pase) [194].  These genes are significantly repressed in mice 
expressing a constitutively active form of PXR [114].  Consistently, murine PXR 
activation with PCN decreased fasting blood glucose levels in WT but not PXR-
deficient mice [195].  Other groups have demonstrated that PXR can bind to 
transcription factors and inhibit their ability to drive expression of target genes 
involved in gluconeogenesis.  For example, PXR represses glucagon-activated 
transcription of both G6Pase and PEPCK by directly binding to the cAMP-
response element binding protein (CREB) and inhibiting its DNA-binding ability 
[206].  Moreover, ligand-activated PXR can bind to the forkhead box protein O1 
(FoxO1), another positive regulator of gluconeogenesis, subsequently 
suppressing FoxO1-mediated activation of gluconeogenic gene expression 
[207].  However, this mechanism does seem to be gene-specific because 
FoxO1 acts as a positive regulator involved in PXR transactivation of its 
xenobiotic target genes [207].   
 Although reports have demonstrated that PXR activation suppresses 
gluconeogenesis in mice, studies in humans have suggested that PXR agonists 
increase blood glucose levels [208-213].  For example, rifampicin treatment 
increases blood glucose levels during oral glucose tolerance tests in 
tuberculosis patients and healthy subjects [210, 213].  Statins, which are weak 
PXR agonists, increase fasting blood glucose levels in patients with and without 
diabetes [209, 211, 212].  Recent studies by Gotoh and Negishi have elucidated 
the mechanism responsible for the species-specific differences in PXR-
regulated gluconeogenesis [208, 209].  They discovered that rifampicin 
treatment increased G6Pase and PEPCK mRNA levels in HepG2 cells stably 
expressing human PXR [208].  Further, they identified the serum- and 
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glucocorticoid-regulated kinsase 2 (SGK2) as a direct PXR target gene that is 
essential for PXR-induced gluconeogenic gene expression and increased 
glucose production [208].  This pathway is insulin-independent, as siRNA 
targeting FoxO1 did not affect rifampicin induction of G6Pase [208].  In human 
primary hepatocytes, PXR induced G6Pase in the presence of high levels of 
SGK2, whereas PXR repressed G6Pase in its absence [208].  These results 
suggest that differential expression of SGK2 may be responsible for the 
species-specific differences in PXR-mediated regulation of gluconeogenesis. 
 Gotoh and Negishi went on to demonstrate that PXR activation with 
statins increases binding between PXR, SGK2, and the protein phosphatase 2C 
(PP2C).  This increase in binding stimulates PP2C dephosphorylation of SGK2 
at Thr193 [209].  Nonphosphorylated SGK2 co-activates PXR transcription of 
gluconeogenic genes in human liver cells, thereby enhancing gluconeogenesis 
[209].  Interestingly, statin treatment increased SGK2 phosphorylation and 
decreased PEPCK1 levels in mice [209].  Thus, elevated SGK2 phosphorylation 
might be the underlying basis for the attenuated hepatic gluconeogenesis in 
mice after statin treatment [209]. 
 Taken together, these results clearly demonstrate that PXR has a complex 
role in energy metabolism by promoting lipogenesis and suppressing fatty acid 
β-oxidation and ketogenesis (Fig. 1.3).  Murine and human PXR, however, have 
opposing effects on gluconeogenesis possibly due to alterations in SGK2 
phosphorylation and its ability to act as a PXR coactivator. 
1.5.4 PXR and Inflammation 
 Inflammation is a biological response that recruits immune cells and tissue 
repair processes to sites of infection and injury [214].  Nuclear receptor ligands 
have been used extensively to treat inflammatory diseases [214].  Work 
pioneered by Hench and colleagues identified the use of cortisone for the 
treatment of rheumatoid arthritis [215].  It was later identified that cortisone is a 
ligand for the glucocorticoid receptor (GR) [214].  Constitutive activation of 
LXRα, for example, has been shown to suppress LPS-induced inflammatory 
gene expression in macrophages [216].  Moreover, ligand-activated LXR also 
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inhibits the induction of inflammatory genes [217-219].  The GR, as well as the 
PPARs and LXRs, have been shown to suppress inflammation by a 
transrepression mechanism, where the nuclear receptor tethers to the 
transcription factors nuclear factor-kappa B (NF-κB) or activator protein-1, 
preventing coactivator association necessary for gene activation [214].  Aside 
from directly interacting with pro-inflammatory transcription factors, nuclear 
receptors may also modulate inflammation by functions of their target genes.  
For example, LXR activation inhibits signaling from the toll-like receptors (TLRs) 
through ABCA1-dependent changes in membrane lipid composition, which 
disrupt the recruitment of adaptor proteins involved in the inflammatory 
response [220].  The involvement of nuclear receptors and their target genes in 
inflammation is complex and warrants further investigation.  Herein, I will 
describe some mechanisms by which PXR undergoes reciprocal crosstalk with 
NF-κB signaling. 
 Rifampicin, a macrocylic antibiotic and potent PXR ligand, was first used 
as an antituberculus agent and now is used for a wide variety of bacterial and 
fungal diseases [221, 222].  Aside from rifampicin, other PXR ligands have been 
shown to exert immunosuppressive side-effects [222, 223].  For this reason, 
PXR has recently been shown to be an attractive therapeutic target for the 
treatment of inflammatory bowel disease (IBD) [224, 225].  IBD is a chronic 
inflammatory disease of the gastrointestinal tract.  IBD primarily includes 
Crohn’s disease (CD) and ulcerative colitis (UC) [224, 225].  UC is an 
inflammatory disease that affects the lining of the intestine, whereas CD can 
affect any part of the digestive tract [224, 225].  While the etiology of IBD 
remains to be determined, it is thought to involve increased intestinal 
permeability and dysregulation of the mucosal immune system [226].  Both UC 
and CD result in abdominal pain, diarrhea, rectal bleeding, and malnutrition 
[224, 225].  Patients with either UC or CD exhibit a much higher incidence of 
colon cancer compared to the general population [225].   
 The role of PXR in IBD has recently been investigated experimentally in 
mouse models.  Dextran sulfate sodium (DSS) is used experimentally to induce 
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IBD in animal models.  WT mice treated with the mouse PXR ligand PCN were 
protected from DSS-induced IBD compared with vehicle control-treated mice 
[226].  However, this phenotype was not observed in PXR-null mice [226].  PCN 
treatment in WT mice did not enhance intestinal barrier function, but did 
significantly decrease NF-κB target gene expression in a PXR-dependent 
manner [226].  A similar phenotype was observed in human colon epithelial cells 
[227], as well as in PXR-humanized mice with treatment of rifaximin [228], a 
FDA-approved intestine-specific human PXR agonist used for the treatment of 
traveler’s diarrhea [224].  It was then confirmed that PXR activation inhibits LPS-
induced NF-κB DNA-binding activity [227].  Interestingly, treatment with PXR 
ligands increases the physical association between PXR and the NF-κB subunit 
p65 [227].  These results demonstrate that the suppressive effect of PXR may 
be due to the physical association between PXR and p65, thereby decreasing 
the overall promoter occupancy of NF-κB on its target genes [227].   
 Independent groups have reached a similar conclusion.  It was further 
confirmed that PXR agonists inhibit the expression of multiple NF-κB target 
genes in human liver samples [222].  PXR inhibited NF-κB activity in the 
absence of exogenous ligand and treatment with RIF further enhanced this 
repression mediated by PXR [222].  Consistently, PXR activation in mice inhibits 
NF-κB signaling in vivo and NF-κB target gene expression is upregulated in 
PXR-deficient mice, which associated with enhanced small bowel inflammation 
[222].   
 Targeting PXR for inflammatory diseases display some therapeutic 
promise.  The underlying mechanism how PXR disrupts NF-κB signaling and 
ultimately inflammation needs to be dissected further.  It should be noted that 
activation of NF-κB has also been shown to suppress PXR target gene 
expression [91], therefore implicating reciprocal regulation between PXR/NF-κB 
signaling.  Since others groups demonstrated that p65 and RXR physically 
interact [229], the binding between p65 and RXR may interfere with the 
formation of the p65-p50 complex, as well as the PXR/RXR complex upon an 
inflammatory stimulus; however, this needs to be investigated further [224, 229]. 
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1.5.5 IKKβ and NF-κB Signaling – an Overview 
 Pattern recognition receptors (PRRs) are essential to sense and respond 
to stimuli for early detection of invading pathogens and initiating an immune 
response.  PRRs are activated by a host of pathogen-associated molecular 
patterns which are present in microbes or nucleic acids of viruses or bacteria.  
Chronic activation of these receptors, such as the Toll-like receptors (TLRs), 
has been linked to a variety of disease states, including: cancer, obesity, type-2 
diabetes, and atherosclerosis.  There are 10 recognized TLR genes in humans 
and 12 in mice [230].  TLRs are activated by a variety of pathogen-associated 
molecules and endogenous signals, such as proatherogenic forms of LDL [231], 
saturated fatty acids [232, 233], and cleavage products of amyloid precursor 
protein [234], which can activate TLR4 and/or TLR2 [214].  After recognition of 
their ligands, TLRs recruit a set of adaptor proteins, such as MyD88, which 
result in triggering downstream signaling cascades that culminates in the 
activation of the transcription factor NF-κB [235].   
 NF-κB belongs to the Rel-homology domain-containing protein family, 
which includes p65/RelA, p50/NF-κB1, p52/NF-κB2, Relb, and c-Rel [236, 237].  
The prototypical NF-κB is thought to be a heterodimer consisting of the p65 and 
p50 subunits [236, 237].  In unstimulated cells, the heterodimer is sequestered 
in the cytoplasm by interacting with the inhibitor of NF-κB (IκB) proteins.  Upon 
stimulation of TLR signaling, IκBs are phosphorylated by the IKK complex 
consisting of the IKKα and IKKβ protein kinases and a regulator subunit, 
IKKγ/Nemo.  IKKβ is the predominant catalytic subunit involved in NF-κB 
activation [238, 239].  The phosphorylation targets IκBs for ubiquitination and 
degradation, allowing NF-κB to translocate to the nucleus to modulate gene 
transcription [237].   
 NF-κB signaling has been extensively studied in a variety of cell-types and 
disease states.  The work provided within Chapter 4 of this dissertation 
investigates the role of IKKβ in adipose stem cell differentiation in HFD-induced 
obesity.  The next section will provide an overview of some recent advances 
made in the field of inflammation and obesity, with an emphasis on IKKβ and 
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NF-κB. 
1.5.6 The Role of IKKβ Signaling in Diet-Induced Obesity 
and Insulin Resistance 
 Diet-induced obesity and associated insulin resistance is becoming 
increasingly prevalent, with approximately 35% of U.S. adults being obese 
[240].  Thus, there is an urgent need to identify therapeutic targets to treat 
obesity and its related conditions, including heart disease, stroke, type 2 
diabetes, and cancer.   
 High doses of salicylates (4-10 g/day), which include sodium salicylate 
and aspirin, have been used to treat inflammatory conditions such as 
rheumatoid arthritis, but they have also been demonstrated to lower blood 
glucose levels [241].  It was later demonstrated that salicylates can inhibit IKKβ 
[242], as opposed to working through the cyclooxygenases [241].  Treatment of 
genetically engineered obese animal models with high doses of salicylates 
reversed hyperglycemia, hyperinsulinemia, and dyslipidemia by sensitizing 
insulin action [241].  Further, heterozygote deletion of IKKβ protected mice 
against insulin resistance associated with HFD-feeding [241].  It should be noted 
that mice with homozygous deletion of IKKβ die in utero due to enhanced liver 
apoptosis [243].  To further understand the tissue-specific role of IKKβ in 
obesity-induced insulin resistance, Arkan and colleagues generated hepatocyte 
and myeloid-specific IKKβ knockout mice and assessed the contribution of each 
tissue in insulin tolerance and glucose disposal [244].  Interestingly, hepatocyte-
specific KO mice retained insulin sensitivity in the liver, but developed insulin 
resistance in muscle and fat [244].  Myeloid-specific KO mice, however, retained 
global insulin sensitivity and were protected from insulin resistance [244].  Acute 
LPS injection induced acute inflammation and hyperglycemia, however both 
hepatocyte and myeloid-specific KO mice were more glucose tolerant.  
Conclusions from this data suggest that IKKβ activation is deleterious to insulin 
signaling and inhibition in specific cell types may be beneficial against type-2 
diabetes [242].   
 A follow-up study by an independent group tested the hypothesis that 
acutely elevated FFA (as opposed to chronically elevated FFA as seen above) 
41 
 
would stimulate hepatic insulin resistance, which would be completely reversed 
by sodium salicylate [245].  Seven hour infusion of intralipid suppressed insulin-
induced stimulation of peripheral glucose utilization and endogenous glucose 
production; however, salicylate co-infusion completely prevented this phenotype 
[245].  The authors demonstrated that salicylate treatment reversed lipid-
induced phosphorylation of insulin-receptor substrate (IRS) and protein kinase B 
(Akt) [245].  Years later, salicylates were also identified to activate adenosine 
monophosphate-activated protein kinase (AMPK) [246].  Aspirin also activates 
AMPK, but at high doses, so the results seen in both of these studies, as well as 
humans, may partially be due to AMPK activation [246].   
 IKKβ and NF-κB activity are enhanced in response to excess FFA in a 
variety of tissues, including liver, adipose tissue, and the hypothalamus [241, 
244, 247-249].  Many other inducers of insulin resistance activate IKKβ, 
including sphingomyelinase and ceramide [250].  IKKβ has been demonstrated 
to phosphorylate IRS-1 promoting its degradation and thereby contributing to 
insulin resistance [250].  Further, mutations at these specific sites enable the 
mutated IRS proteins to better propagate insulin signaling [250].  Thus, IKKβ 
may contribute to insulin resistance by directly suppressing the insulin signaling 
pathway. 
 We and others have recently published reports investigating the role of 
IKKβ in adipocyte hyperplasia.  Ligands that activate the IKKβ signaling 
pathway, such as FFA and LPS, stimulate adipocyte hyperplasia from 
surrounding progenitor cells [251-254].  Likewise, we demonstrated that deletion 
of IKKβ in smooth-muscle cells impaired adipocyte differentiation [255].  These 
mice had elevated energy expenditure, decreased inflammation, and were 
completely protected against HFD-induced obesity [255].  The main focus of the 
work within Chapter 4 of this dissertation was to identify the mechanism of HFD-
elicited adipocyte hyperplasia by investigating the role of IKKβ specifically in the 
adipose progenitor population in vivo. 
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1.6 Scope of Dissertation 
1.6.1 The Role of PXR in Xenobiotic-Induced 
Dyslipidemia 
 The general hypothesis of the research herein is that xenobiotic-elicited 
PXR activation promotes cardiovascular disease by modulating plasma lipid 
levels.  We also hypothesized that intestinal PXR contributes to xenobiotic-
elicited hyperlipidemia by enhancing cholesterol absorption and chylomicron 
secretion.  To test these hypotheses, the following specific aims were proposed: 
 
Specific Aim 1:  To test the hypothesis that specific xenobiotics, such as HIV 
drugs and phthalates/phthalate substitutes, are PXR-specific agonists and that 
acute exposure to these xenobiotics induces hyperlipidemia in a PXR-
dependent manner. 
 
Specific Aim 2:  To test the hypothesis that intestinal PXR is necessary for 
xenobiotic-induced hyperlipidemia through transcriptional regulation of NPC1L1 
and MTP, which facilitates cholesterol absorption and chylomicron secretion, 
respectively. 
 
1.6.2 Targeting IKKβ in Adipocyte Lineage Cells for 
Treatment of Obesity and Metabolic Dysfunctions 
 The general hypothesis of the research herein is that IKKβ signaling in 
adipose progenitor cells promotes adipocyte hyperplasia thereby contributing to 
HFD-induced obesity and insulin resistance.  To test this hypothesis, the 
following specific aims were proposed: 
 
Specific Aim 1:  To test the hypothesis that IKKβ is essential for adipose stem 
cell differentiation in vitro and targeting adipose progenitor IKKβ in vivo will 
alleviate diet-induced obesity, adipose tissue inflammation, and insulin 
resistance. 
 
Specific Aim 2:  To test the hypothesis that pharmacological inhibition of IKKβ 
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with antisense oligonucleotides (ASOs) will protect mice from diet-induced 
obesity and associated metabolic disorders. 
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Figure 1.1 Schematic illustration of lipoprotein metabolism. 
This figure depicting lipoprotein metabolism was reprinted by permission from 
Macmillan Publishers Ltd: Nature Reviews: Genetics [256], 2009. This 
illustration coincides with Chapter 1.1 (Cholesterol Metabolism- an Overview). 
Abbreviations: cholesterol (C), triglyceride (TG), fatty acid (FA), Niemann-
Pick C1-like 1 (NPC1L1), heterodimeric ATP-binding cassette transporter 
G5/G8 (ABCG5/G8), microsomal triglyceride transfer protein (MTTP), 
chylomicron (CM), apolipoprotein B (APOB) isoform 48 and 100 (B48/B100), 
apolipoprotein A5 (A5), apolipoprotein C2 and C3 (C2/C3), chylomicron 
remnant (CMR), low-density lipoprotein (LDL), low-density lipoprotein 
receptor (LDLR), LDLR-related protein-1 (LRP1), very low-density lipoprotein 
(VLDL), VLDL remnant (IDL), hepatic lipase (HL), 3-hydroxy-3-methylglutaryl 
coenzyme A reductase (HMGCR), adaptor protein (AP), proprotein 
convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein A1 (A1), ATP-
binding cassette A1 and G1 (ABCA1/ABCG1), lecithin cholesterol 
acyltransferase (LCAT), cholesterol ester transfer protein (CETP), endothelial 
lipase (LIPG), and scavenger receptor class B type 1 (SRB1).  
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Figure 1.2 Structure of human and mouse PXR. 
Cartoon depiction of human and mouse PXR variants, as previously 
illustrated [89, 98].  In humans, variant 1 (V1) corresponds to PXR wild type.  
Variant 2 differs from V1 by the use of alternative translational start codons.  
Variant 3 differs from V1 at the N-terminus, resulting in an open reading 
frame 39 amino acids longer (denoted in red).  Variant 4 contains an in-frame 
deletion of 111 nucleotides (denoted in grey).  In mice, V1 is analogous to 
human V1.  Mouse V2 contains an in-frame deletion of 123 nucleotides in a 
similar region of the LBD and is analogous to human V4. 
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Figure 1.3 Schematic representation of the role of PXR in energy 
metabolism, xenobiotic metabolism, sterol metabolism, and 
inflammation. 
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Figure 1.3 Schematic representation of the role of PXR in energy 
metabolism, xenobiotic metabolism, sterol metabolism, and 
inflammation. 
The information within this cartoon was compiled from previous review 
articles [194, 199].  (A) PXR activation induces fatty acid uptake, lipogenesis, 
and may promote VLDL secretion through induction of CD36, PPARγ, Lipin1, 
Spot14, SCD-1, and possibly MTP.  PXR may directly induce CD36 
expression or indirectly through PPARγ.  (B) PXR inhibits NF-κB-mediated 
inflammation.  It should be noted that mutual repression exists between these 
two pathways.  (C) Activation of PXR results in induction of Phase 1 and 
Phase II drug-metabolizing enzymes and drug transporters.  (D) PXR inhibits 
fatty acid β-oxidation and ketogenesis through its suppression of PPARα 
gene expression and by disrupting FoxA2-mediated activation of Cpt1α and 
Hmgcs2.  (E) In mice, PXR inhibits PEPCK and G6Pase gene expression by 
interacting with the positive regulators of gluconeogenesis, CREB and 
FoxO1, and disrupting their ability to activate these genes in mice.  In 
addition, mouse SGK2 remains phosphorylated at Thr193, thus it can no 
longer act as a PXR coactivator on gluconeogenic promoters.  In humans, 
ligand-activated PXR promotes PP2C dephosphorylation of SGK2 at Thr193 
leading to SGK2s ability to act as a coactivator for PXR on gluconeogenic 
promoters, thus inducing gluconeogenesis.  (F)  PXR activation promotes 
hypercholesterolemia through regulation of NPC1L1 and CYP27A1, while 
suppressing CYP7A1, the rate-limiting enzyme involved in bile acid synthesis.  
It has also been proposed that PXR may regulate ABCA1 gene expression, 
but these studies are currently controversial.  The focus of this dissertation is 
to identify novel PXR target genes involved in lipid metabolism.  Regulation of 
NPC1L1 and MTP have been described herein, thus they have larger font 
size in the current figure. 
 
 
 
 
 
 
 
 
 
Copyright © Robert Nathaniel Helsley, 2016 
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Chapter 2: HIV Protease Inhibitors Activate PXR and Induce Hyperlipidemia 
in WT Mice 
2.1 Introduction 
 The introduction of highly active anti-retroviral therapy (HAART) has led to 
a marked increase in survival for people infected with human immunodeficiency 
virus (HIV) [257]. However, HAART has also been associated with dyslipidemia 
and an increased risk of cardiovascular disease [52, 53, 55, 58, 63, 64, 66]. For 
example, findings from the Data Collection on Adverse Events of Anti-HIV Drugs 
(DAD) study suggested that the incidence of cardiovascular disease increased 
with longer exposure to HAART [63].  Another large-scale study including more 
than 23,000 HIV patients analyzed the combination of drugs used in HAART 
and concluded that protease inhibitors (PIs) are associated with an increased 
risk of cardiovascular disease, which is partly explained by dyslipidemia [55]. A 
Swiss HIV Cohort Study found that PIs are the cause of dyslipidemia in patients 
[58], and several other studies have reached the same conclusion [64, 66].  
Despite the strong evidence linking PIs with dyslipidemia and cardiovascular 
disease, the underlying mechanisms responsible for the adverse effects of PIs 
remain elusive. 
 Several PIs such as ritonavir have been implicated to activate the 
pregnane X receptor (PXR, also known as steroid and xenobiotic receptor) [91, 
258]. PXR is a nuclear receptor activated by numerous endogenous hormones, 
dietary steroids, pharmaceutical agents, and xenobiotic chemicals [89, 91, 95].  
PXR functions as a xenobiotic sensor that induces expression of genes required 
for xenobiotic metabolism in the liver and intestine, including cytochrome P450s,  
 
Reprinted with permission of the American Society for Pharmacology and 
Experimental Therapeutics. All rights reserved. 
Copyright © 2013 by The American Society for Pharmacology and Experimental 
Therapeutics 
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conjugating enzymes (e.g., glutathione transferase), and ABC family 
transporters (e.g., multidrug resistance 1 [MDR1]) [90, 91]. In the past decade, 
the role of PXR as a xenobiotic sensor has been well established [91]. 
 Recent evidence indicates that PXR may also play an important role in the 
regulation of lipid homeostasis [114, 177, 259, 260]. It is well known that many 
clinically relevant PXR ligands can elevate plasma lipid levels in patients and 
may increase their risk of cardiovascular disease [177, 261-264].  A recent 
meta-analysis of seven genome-wide association studies indicated that 
common genetic variants in PXR can affect plasma low-density lipoprotein 
(LDL) cholesterol levels in humans [118]. Modulation of PXR activity has been 
found to alter lipid homeostasis and affect plasma lipid levels in several animal 
models.  We recently reported that chronic activation of PXR led to increased 
levels of plasma total cholesterol and atherogenic LDL and very-low-density 
lipoprotein (VLDL) in wild-type (WT) mice, but not in PXR-deficient (PXR-/-) mice 
[177].  Activation of PXR also increased plasma total cholesterol and VLDL 
levels in apolipoprotein E (ApoE)*3-Leiden mice which exhibit a human-like 
lipoprotein distribution on a cholesterol-rich diet [260]. Another report showed 
that acute activation of PXR increased plasma triglyceride levels in both LDL 
receptor-deficient (LDLR-/-) and ApoE- deficient (ApoE-/-) mice but decreased 
LDL cholesterol levels in LDLR-/- mice [174].  Activation of PXR can regulate 
many genes involved in lipid homeostasis including CD36, Stearoyl-CoA 
desaturase-1, 7-dehydrocholesterol reductase, S14, and lipin-1 in the liver, 
intestine, or macrophages of several animal models [91, 114, 174, 182, 204, 
260, 265]. These studies indicate that PXR can mediate cholesterol and lipid 
homeostasis at multiple levels. 
 We report that amprenavir, a widely used HIV PI, is a potent PXR-
selective agonist. Computational docking studies together with site-directed 
mutagenesis identified several key residues within PXR’s ligand-binding pocket 
that constitute points of interaction with amprenavir. Amprenavir efficiently 
activated PXR and induced PXR target gene expression in vitro and in vivo. 
Short-term exposure to amprenavir significantly increased plasma total 
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cholesterol and atherogenic lipoprotein LDL cholesterol levels in WT mice, but 
not in PXR−/− mice. Amprenavir-mediated PXR activation significantly regulated 
several key intestinal genes involved in lipid homeostasis. These findings 
provide critical mechanistic insight for understanding the impact of PIs on 
cardiovascular disease and demonstrate a potential role of PXR in mediating 
the adverse effects of PIs in humans. 
 
2.2 Materials and Methods 
2.2.1 Reagents and Plasmids 
 Pregnenolone 16α-carbonitrile (PCN) and rifampicin (RIF) were purchased 
from Sigma- Aldrich (St. Louis, MO). Amprenavir, ritonavir, nelfinavir, saquinavir, 
and indinavir sulfate were obtained from NIH AIDS Research and Reference 
Reagent Program. All chemicals were dissolved in dimethyl sulfoxide (DMSO).  
Human (h) and mouse (m) PXR expression vectors; GAL4 DNA-binding domain 
(DBD)-linked nuclear receptor ligand-binding domain (LBD) vectors (GAL4-
hPXR, GAL4-mPXR, GAL4-rPXR, GAL4-RARα, GAL4-RXR, GAL4-FXR, GAL4-
LXR, GAL4-PPARα, GAL4-PPARγ and GAL4-VDR); and CMX-β-gal expression 
vectors have been described before [179, 222, 266].  VP16-PXR, GAL4-nuclear 
receptor corepressor (NCoR), GAL4-silencing mediator of retinoid and thyroid 
hormone (SMRT), GAL4-steroid receptor coactivator (SRC1), GAL4-PPAR 
binding protein (PBP), PXR-dependent CYP3A4 promoter reporter 
(CYP3A4XREM-Luciferase); CYP3A2 promoter reporter [(CYP3A2)3-luciferase]; 
and GAL4 reporter (MH100-Luciferase) have also been described previously 
elsewhere [179, 222, 266, 267]. 
2.2.2 Cell Culture and Transfections 
 The human hepatic cell line HepG2 and intestine epithelial cell line LS180 
were obtained from the American Type Culture Collection (Manassas, VA).  The 
human hepatoma HepaRG cells were purchased from Life Technologies 
(Carlsbad, CA).  Transfection assays were performed as described previously 
[179, 266].  The cells were transfected with various expression plasmids or 
hPXR mutants as well as the corresponding luciferase reporter plasmids, 
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together with cytomegalovirus X-β-galactosidase control plasmids using 
FuGENE6 (Roche Diagnostics, Indianapolis, IN).  The cells were then incubated 
with the corresponding ligands as indicated in the figure legends for 24 h, and β-
gal and luciferase assays were performed as described elsewhere [179, 266].  
Fold activation was calculated relative to solvent controls.  
 Each data point represents the average of triplicate experiments ± SD and 
was replicated in 3-5 independent experiments.  EC50 values were calculated 
by curve fitting of data, using Prism software (GraphPad Software, San Diego, 
CA).  For the mammalian two-hybrid assays, HepG2 cells were transfected with 
GAL4 reporter, VP16-hPXR, and GAL-SRC1, GAL-PBP, GAL-NCoR, and GAL-
SMRT [179, 266].  The cells were then treated with compounds at the indicated 
concentrations. 
2.2.3 Computational Docking Studies 
 Preparation of the protein structure for subsequent ligand-receptor 
docking studies was conducted as previously described [179].  Briefly, the 
structural coordinates of the tethered hPXR linker PXR/SRC-1 were retrieved 
from the RSCB Protein Data Bank entry 3HVL [268].  The larger PXR fragment 
of chain A, Gly142-Glu458, was extracted for molecular modeling using MOE 
2010 software (Chemical Computing Group, Montreal, Quebec, Canada), and 
for ligand-receptor docking studies using GOLD software (version 5.0) [269].  
Water molecules, salt ions, ligand [SR12813, tetraethyl 2-(3,5-di-tert-butyl-4-
hydroxyphenyl)ethenyl-1,1-bisphosphonate], and co-receptor fragments were 
deleted.  After the addition of hydrogen atoms and assigning of the AMBER99 
force-field charges to the protein, the hydrogen atomic positions were allowed to 
relax [268].  The resulting protein structural coordinates were saved in Tripos 
mol2 format and used later for GOLD docking.  
 The ligands were docked to the 3HVL [268] chain A using semiflexible 
docking whereby the ligand has full conformational flexibility and the hydroxyl 
groups of designated protein side chains in the binding pocket can rotate to 
optimize hydrogen bond contacts. Each ligand was docked 50 independent 
times. The binding pocket was defined as all atoms within an 8-Å radius around 
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the bound ligand, SR12813. 
2.2.4 Site-Directed Mutagenesis 
 The hPXR full-length plasmid was used as a wild-type template to 
generate a series of mutant plasmids using the QuikChange II Site-Directed 
Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) according to the 
manufacturer-supplied protocol as described before [179]. The primers used for 
mutant generation are listed in Table 2.1. 
2.2.5 RNA Isolation and Quantitative Real-Time 
Polymerase Chain Reaction Analysis 
 Total RNA was isolated from mouse tissues, intestinal LS180, and 
HepaRG cells using TRIzol Reagent (Life Technologies) per the manufacturer-
supplied protocol. Quantitative real-time polymerase chain reaction (QPCR) was 
performed using gene-specific primers and the SYBR green PCR kit (Life 
Technologies) as described previously [179, 266]. The primer sets used in this 
study are listed in Table 2.2. 
2.2.6 Animals 
 C57BL/6 WT mice were purchased from The Jackson Laboratory (Bar 
Harbor, ME).  PXR- deficient mice (PXR-/-) on C57BL/6 background were 
employed as described previously elsewhere [177]. All the animals were housed 
in a specific pathogen-free environment with a light-dark cycle maintained by the 
Division of Laboratory Animal Resources, University of Kentucky, and the 
protocol was approved by the Institutional Animal Care and Use Committee. We 
fed 8-week-old male WT or PXR-/- mice a semisynthetic low-fat AIN76 diet 
containing 0.02% cholesterol (Research Diet; New Brunswick, NJ) [177, 178, 
270] and treated them by oral gavage with vehicle (corn oil) or 10 mg/kg body 
weight amprenavir daily for 7 days.  On the day of euthanization, mice were 
anesthetized by intraperitoneal injection with Ketamine (Fort Dodge Animal 
Health, Fort Dodge, Iowa). The mice were exsanguinated by left ventricular 
puncture, and the blood was collected into EDTA-containing syringes.  Plasma 
was prepared by spinning at 16,000 g for 10 min.  The circulation was flushed 
with phosphate-buffered saline, and the intestinal and liver tissues were 
collected and stored in RNAlater solution (Life Technologies). 
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2.2.7 Plasma Analysis 
 Plasma total cholesterol and triglyceride concentrations were determined 
enzymatically by colorimetric methods as described previously (Roche 
Diagnostics) [177, 271]. Plasma from multiple mice (n=4-7) was pooled, and the 
plasma lipoprotein cholesterol distributions were determined by fast-
performance liquid chromatography (FPLC) [178].  The lipoprotein fractions 
were isolated by spinning 60 μl of plasma in a TL-100 ultracentrifuge (Beckman 
Coulter, Brea, CA) at its own density (1.006 g/ml) at 70,000g for 3 hours to 
harvest the supernatant, and then after adjusting the infranatant with solid KBr 
to a density of 1.063 g/ml spinning it for 70,000g for 18 hours to harvest the 
supernatant [272]. The cholesterol content of each supernatant and the final 
infranatant were measured and taken to be very-low-density lipoprotein (VLDL) 
(<1.006 g/ml), low-density lipoprotein (LDL) (1.006 ≤ d ≤ 1.063 g/ml), and high-
density lipoprotein (HDL) (d >1.063 g/ml) cholesterol, respectively. Cholesterol 
concentrations in all three fractions were then determined enzymatically by a 
colorimetric method (Roche Diagnostics).  Plasma triglyceride levels were 
determined enzymatically in the original plasma sample.  
2.2.8 Statistical Analysis 
 All data are expressed as means ± SD unless otherwise noted.  Statistical 
analysis was performed using a two-sample, two-tailed Student t-test unless 
otherwise noted, with P<0.05 regarded as significant.  One-way analysis of 
variance was used when multiple comparisons were made, followed by 
Dunnett’s t-test for multiple comparisons to a control.  Statistical analysis was 
performed using SigmaPlot 13.0. 
 
2.3 Results 
2.3.1 Amprenavir Is a Potent PXR-Selective Agonist 
 We tested several widely used HIV PIs, including amprenavir, ritonavir, 
nelfinavir, saquinavir, and indinavir sulfate, for PXR activation by use of 
transfection assays.  Because PXR exhibits considerable differences in its 
pharmacology across species (namely, mouse versus human) [91, 95], the 
potent PXR ligands RIF and PCN were used as the positive control for human 
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(h) and mouse (m) PXR, respectively.  Consistent with a previous report [258], 
ritonavir activated PXR and induced PXR-mediated reporter activity (Fig. 2.1, A 
and B).  Interestingly, amprenavir was a more potent PXR agonist than any of 
the other tested PIs (Fig. 2.1, A and B). Amprenavir can activate both human 
and mouse PXR and induced reporter gene activity in a dose-dependent 
manner (Fig. 2.1, A and B). Dose-response analysis indicated that amprenavir 
was able to activate PXR at concentrations as low as 1 μM, reaching peak 
activation at 30 μM (Fig. 2.1, C). The EC50 for amprenavir activation of PXR-
mediated CYP3A4 promoter activity was 8.6 μM (Fig. 2.1, C).  We next tested 
the ability of amprenavir to activate a panel of other nuclear receptors, including 
human retinoid acid receptor, retinoid X receptor, farnesoid X receptor, liver X 
receptor α, PPARα, PPARγ, vitamin D receptor, estrogen receptor α, and 
estrogen receptor β (Fig. 2.1, D).  Amprenavir was unable to activate any of 
these other nuclear receptors.  Results from this panel emphasize the 
importance of studying the effects of amprenavir-mediated PXR agonism. 
2.3.2 Amprenavir Promotes PXR Coactivator 
Recruitment and Corepressor Disassociation 
 Nuclear receptor co-regulators play critical roles in nuclear receptor 
signaling [90].  We used a mammalian two-hybrid assay [179, 266] to evaluate 
the effects of amprenavir on PXR coregulator interaction.  Similar to the potent 
PXR ligand RIF, amprenavir promoted the specific interactions between PXR 
and the coactivators SRC-1 and PBP (Fig. 2.2, A).  Consistent with our previous 
reports [179, 266], unliganded PXR interacted with corepressors, NCoR and 
SMRT.  Amprenavir disrupted this interaction, as did RIF (Fig. 2.2, B).  Binding 
of amprenavir to PXR inhibits PXR/corepressor interaction and promotes 
PXR/coactivator recruitment, thereby inducing PXR transcriptional activation in 
a concentration-dependent manner. 
2.3.3 Computational Docking and Modeling Studies 
 To investigate the potential interaction pattern between amprenavir and 
PXR, a structure-based approach was employed.  Amprenavir was docked into 
the high-resolution crystal structure of human PXR in complex with SR12813 
[268]. The results from GOLD docking are shown in Figure 2.3A.  The binding 
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pose of amprenavir in the PXR ligand-binding domain (LBD) is similar to 
SR12813.  The PXR LBD appears to possess four hydrophobic subpockets and 
a connection region in the middle. Amprenavir occupies all four subpockets, and 
its hydroxyl group forms a hydrogen bond with Ser247, which is located in the 
connection region of PXR, to help to position the drug in the optimal orientation 
inside the receptor.  Another two hydrogen bonds were formed between 
amprenavir and PXR (Gln285 and His407) that provide additional electrostatic 
interactions.   
 Nonpolar contacts also play a key role in stabilizing amprenavir within the 
ligand binding pocket of PXR. As displayed in Fig. 2.3B, the interaction map of 
amprenavir and PXR revealed an important π-π stacking between ring A of 
amprenavir and Phe288 in subpocket 1 of PXR. Tyr306 forms a 3.5-Å edge-to-
face contact to the same phenol ring of the drug that also engages in 
hydrophobic interactions with Trp299, the other hydrophobic residue in 
subpocket 1.  In subpocket 2, amprenavir forms direct contacts with one residue 
on αAF of the PXR activation function-2 (AF-2) surface, Phe429, which may 
stabilize the active AF-2 conformation of the receptor and contribute to the 
agonist activity of amprenavir on PXR. Subpockets 3 and 4 of PXR are located 
on the bottom of the cavity, which corresponds to the most structurally flexible 
region of the PXR LBD.  This region is dominated by hydrophobic residues (e.g., 
Met323 and Leu209) that form van der Waals contacts with amprenavir. 
2.3.4 Key LBD Residues of PXR Are Required for 
Amprenavir’s Agonistic Activity 
 To validate the results of the docking analysis, we mutated the key amino 
acids responsible for amprenavir’s agonist activity including Ser247, Gln285, 
Phe288, and Tyr306.  We also included Thr248, a key amino acid known to be 
important for PXR/coactivator interaction [179, 273], and Leu411, an amino acid 
predicted by the docking analysis not to interact with amprenavir, as the putative 
positive and negative controls for our mutagenesis study, respectively.  As 
shown in Fig. 2.3C, Ser247Leu and Tyr306Leu mutations completely blocked 
amprenavir’s agonist activity at all tested drug concentrations.  Gln285Leu and 
His407Ala exerted little or no effects on the drug at low concentration (5 μM). At 
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higher concentrations (10 and 20 μM), these mutations showed inhibitory effects 
on amprenavir’s activity. Phe288Ala showed some inhibitory effects on 
amprenavir’s activity.  As expected, the Thr248Leu mutation abolished the 
activity of amprenavir; Leu411Phe did not inhibit but rather slightly promoted 
amprenavir as an agonist.  In summary, our site-directed mutagenesis analysis 
confirmed the docking model and revealed the key residues within PXR’s 
binding pocket responsible for amprenavir’s agonist effects. 
2.3.5 Amprenavir Induces PXR Target Gene Expression 
in Human Cells 
 We next used human hepatoma HepaRG cells [274] and intestinal LS180 
cells [222, 266] to test the effects of amprenavir exposure on PXR activity and 
target gene expression.  Similar to the known human PXR ligand RIF, 
amprenavir induced the expression of bona fide PXR target genes involved in 
phase I (CYP3A4), phase II (UGT1A1), and phase III (MDR1) metabolism in 
both HepaRG cells (Fig. 2.4, A) and LS180 cells (Fig. 2.4, B). These results 
suggest that amprenavir can activate PXR and induce PXR target gene 
expression in human cells. 
2.3.6 Amprenavir Elevates Plasma Lipid Levels in WT 
Mice, but Not in PXR-/- Mice 
 To further investigate the effects of amprenavir on PXR activity in vivo, WT 
and PXR-/- mice were treated with vehicle (corn oil) or 10 mg/kg body weight of 
amprenavir daily by oral gavage for 1 week.  Amprenavir-treated WT mice had 
significantly increased total cholesterol levels compared with control WT mice 
(Fig. 2.5, A).  By contrast, amprenavir did not affect plasma cholesterol levels in 
PXR-/- mice (Fig. 2.5, B).  The FPLC analysis of the cholesterol distribution 
pattern revealed that amprenavir increased atherogenic LDL cholesterol 
fractions in WT mice, but not in PXR-/- mice (Fig. 2.5, C and D). The lipoprotein 
fractions (VLDL, LDL, and HDL) were isolated by ultracentrifugation [272], and 
the cholesterol concentrations in all three fractions were then measured. 
Consistent with the FPLC results (Fig. 2.5, C and D), amprenavir treatment did 
not affect HDL or VLDL cholesterol levels but significantly increased LDL 
cholesterol levels in WT mice (Fig. 2.6, A).  By contrast, amprenavir did not 
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affect any of the lipoprotein levels in PXR-/- mice (Fig. 2.6, B).  These results 
suggest that the adverse effects of amprenavir on plasma cholesterol levels are 
mediated, at least in part, through PXR in mice. 
2.3.7 Amprenavir Affects Genes Involved in Lipid 
Homeostasis 
 To determine whether amprenavir can activate PXR in these mice, the 
expression levels of known PXR target genes were measured in the intestine 
and liver.  Amprenavir stimulated expression of known PXR target genes, 
including CYP3A11, glutathione transferase A1, and MDR1a, in the intestine 
(Fig. 2.7, A) of WT mice but not in PXR-/- mice.  Interestingly, amprenavir did not 
affect the expression of hepatic PXR target genes (Fig. 2.7, B), which might be 
due to the insufficient accumulation of amprenavir in the liver.  To elucidate the 
possible molecular mechanisms through which amprenavir-mediated intestinal 
PXR activation might induce dyslipidemia, the expression levels of genes 
involved in lipid homeostasis were measured (Fig. 2.7, C). Of the genes 
surveyed, CD36 showed significant change, with its expression levels increased 
more than 10-fold.  CD36, a class B scavenger receptor, plays an important role 
in intestinal lipid absorption [275].  
 Consistent with a recent report [265], the expression levels of 
diacylglycerol acyltransferase 1 and 2 (DGAT1 and 2), two enzymes involved in 
intestinal lipid transportation and chylomicron secretion [276], were also induced 
by amprenavir-mediated PXR activation in WT mice.  It was recently reported 
that a Drosophila PXR ortholog DHR96 regulates expression of the intestine 
lipase Magro (CG5932) which mediates cholesterol and triglyceride 
homeostasis in Drosophila.  Magro protein is most similar to mammalian gastric 
lipase (LipF) (56% similarity) and lysosomal lipase (LipA) (50% similarity) [277].  
Interestingly, amprenavir-mediated PXR activation stimulated the expression of 
both LipF and LipA in the intestine of WT mice, but not in PXR-/- mice (Fig. 2.7, 
C), indicating a possible role of intestinal PXR in mediating dietary lipid 
breakdown and absorption in mammals.  Taken together, upregulation of those 
genes by PXR activation may contribute to amprenavir-elicited hyperlipidemia. 
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2.4 Discussion   
 PIs have been associated with dyslipidemia and an increased risk of 
cardiovascular disease [55, 58, 66], but the underlying mechanisms are still 
unknown.  Several PIs have been shown to activate PXR which functions as a 
xenobiotic sensor to regulate genes required for xenobiotic metabolism in the 
liver and intestine [90, 91].  We identified a widely used PI amprenavir as a 
potent and selective PXR agonist.  Amprenavir is usually taken by patients with 
or without ritonavir. Interestingly, a case-control study suggested that the risk of 
cardiovascular disease was increased by exposure to all PIs and, in particular, 
to amprenavir with or without ritonavir [66].  We found that amprenavir activated 
both human and mouse PXR but did not affect the activity of other nuclear 
receptors.  Short-term exposure to amprenavir significantly increased plasma 
total cholesterol and LDL cholesterol levels in WT mice, but not in PXR-/- mice.  
Amprenavir-mediated PXR activation regulated several key intestinal genes 
involved in lipid homeostasis. These findings provide critical mechanistic insight 
for understanding the impact of PIs on cardiovascular disease and demonstrate 
a potential role of PXR in mediating adverse effects of HIV PIs in humans. 
 Using in silico ligand-PXR docking studies combined with site-directed 
mutagenesis, we identified Tyr306, Ser247, His407, and Phe288 as 
participating in the amprenavir-PXR interaction (Fig. 2.3).  A critical polar 
interaction with Ser247 helps to orient amprenavir in the ligand-binding cavity 
that enables formation of nonpolar interactions with a highly hydrophobic region 
of PXR’s ligand binding pocket lined by Phe288, Trp299 and Tyr306.  These 
three residues are highly conserved among different species and interact with 
structurally diverse PXR agonists as shown in multiple published PXR X-ray 
crystal structures.  This Ser247-directed orientation of amprenavir also guided 
the selection of the most plausible binding alignment among the multiple poses 
generated by our docking simulations.  Based on our previous modeling results 
on diverse ligands with PXR, we conclude that two essential features need to be 
satisfied for ligand binding to PXR, namely, (1) one key hydrogen bond with 
Ser247 or His407 and (2) van der Waals contacts with subpocket 1.  Besides 
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the interactions formed by these two essential features, numerous hydrophobic 
contacts between amprenavir and PXR further stabilize the ligand binding and 
indirectly promote contact with the AF-2 region, thus forming the optimal 
orientation of αAF helix to interact with coactivators.  Our observations 
regarding the key pharmacophoric features for PXR binding will hopefully 
provide guidance useful for PXR ligand screening in the future. 
 The role of PXR in xenobiotic metabolism has been well established; 
however, recent studies have revealed the role of PXR in dyslipidemia and 
atherosclerosis.  We recently demonstrated the pro-atherogenic effects of PXR 
in animals [177, 178].  We previously reported that chronic activation of PXR 
elicited by feeding mice the mouse PXR ligand PCN led to increased levels of 
plasma total cholesterol and VLDL and LDL in WT mice, but not in PXR-/- mice 
[177].  In our present study, mice were treated with 10 mg/kg per day 
amprenavir to investigate its potential effects on lipid levels.  Patients usually 
take a daily dose of 1,400 mg or 2,800 mg of the amprenavir prodrug 
fosamprenavir, which is rapidly and extensively converted to amprenavir after 
oral administration [278].  Pharmacokinetic studies have demonstrated that the 
mean peak plasma concentration of amprenavir is approximately 18 μM after a 
1,200-mg single dose [279, 280], which is sufficient to activate PXR based on 
our results (Fig. 2.1). Therefore, we believe that amprenavir can activate PXR 
and regulate PXR target genes in patients taking this drug routinely.   
 The dose of 10 mg/kg per day amprenavir used in the present study to 
treat animals is considered low or modest.  Nevertheless, after 1 week of 
treatment, amprenavir significantly increased plasma total cholesterol and LDL 
cholesterol levels in WT mice, but not in PXR-/- mice, indicating the significant 
role of PXR in mediating the adverse effects of amprenavir (Figs. 2.5 and 2.6).  
Interestingly, amprenavir regulated the PXR target genes in the intestine but not 
in the liver (Fig. 2.7).  This could be explained by the relative low dose of 
amprenavir and short-term treatment in this study.  In addition, amprenavir is 
metabolized by CYP3A4 enzyme in the liver [281]. Therefore, the relative low 
dose of amprenavir used in the present study may be insufficient for amprenavir 
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to reach the high concentrations required to activate PXR in the liver. 
 Intestinal lipid transportation plays a central role in lipid homeostasis.  In 
addition to prototypic PXR target genes (e.g., CYP3A11, MDR1a), amprenavir 
significantly stimulated expression of several key genes involved in intestinal 
lipid homeostasis in WT mice, including CD36, DGAT1, and DGAT2.  We and 
others have previously reported that activation of PXR induces CD36 
expression and increases lipid accumulation in the liver [114], intestine [265], 
and macrophages [177].  The role of CD36 in mediating intestinal fatty acid 
uptake has been well established [275, 282, 283]; several studies have also 
indicated that CD36 mediates cholesterol uptake in the intestine [282, 283]. For 
example, cholesterol uptake was significantly decreased in the enterocytes 
isolated from CD36-deficient (CD36-/-) mice [283].  In a lipid infusion study, 
CD36-/- mice exhibited accumulation of dietary cholesterol in the intestinal lumen 
and reduction of cholesterol transport into the lymph [282].  Therefore, the PXR-
mediated CD36 upregulation may contribute to amprenavir-stimulated elevation 
of cholesterol levels.   
 In addition, Liang et al. [284] previously reported that PIs such as ritonavir 
inhibit degradation and secretion of apolipoprotein B (ApoB), the primary 
apolipoprotein of chylomicrons and LDL. Interestingly, the inhibitory effects of PI 
on ApoB secretion were reversed by oleic acid, a fatty acid that stimulates 
neutral-lipid biosynthesis [284].  In the presence of oleic acid, PI treatment even 
increased ApoB secretion above controls [284].  Because CD36 plays an 
important role in the absorption of oleic acid [283], it is plausible that PXR-
mediated CD36 expression increases oleic acid absorption and contributes to 
PI-induced ApoB secretion and hyperlipidemia. 
 The precise mechanisms through which PXR modulates lipid homeostasis 
and cholesterol levels in various animal models as well as in humans remain to 
be determined. By contrast, the Drosophila PXR ortholog DHR96 has been 
established to be a key regulator in mediating cholesterol and triglyceride 
homeostasis [277, 285, 286]. Recent studies have shown that DHR96 regulates 
expression of the intestine lipase Magro, which is most similar to mammalian 
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LipA and LipF [277]. Both LipA and LipF were upregulated by amprenavir-
mediated PXR activation in the intestine of WT mice but not in PXR-/- mice (Fig. 
2.7, C).   
 LipA is an enzyme responsible for hydrolysis of cholesterol esters and 
triglycerides within lipoprotein particles internalized by receptor-mediated 
endocytosis [287, 288]. Previous studies have demonstrated an important role 
of LipA in maintaining cholesterol levels in mice [289], and mutations in LipA 
result in cholesterol ester storage disease, which is associated with 
hyperlipidemia in humans [290].  LipF also contributes to lipid catabolism by 
hydrolysis of dietary triglycerides in the stomach and intestine, sequentially 
producing free fatty acids and diacylglycerol [291, 292]. It would be interesting 
to further investigate the detailed mechanisms by which PXR transcriptionally 
regulates LipA and LipF expression and mediates intestinal lipid homeostasis. 
Upregulation of those key genes by PXR activation contribute to amprenavir-
elicited hyperlipidemia. 
 In summary, we demonstrated that amprenavir as a selectively potent 
PXR agonist. Amprenavir efficiently activated PXR and stimulated PXR target 
gene expression in vitro and in vivo. Computational docking studies and site-
directed mutagenesis analysis identified key residues within PXR’s ligand 
binding pocket that interact with amprenavir. Our study provides critical insight 
for understanding the mechanism by which clinically relevant PXR ligands 
interact and activate PXR. We also showed, for the first time, that amprenavir-
mediated activation of PXR elevated lipid levels in an animal model, which has 
direct clinical consequence for patients under long-term treatment with 
amprenavir and other PIs.  Activation of PXR may present a key mechanism for 
adverse effects of PIs in humans. 
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Table 2.1 Primer sequences for site-directed mutagenesis. 
 
Mutant Primer sequences 
PXR-S247L 
5’-CTGCTGCCCCACATGGCTGACATGTTAACCTACATGTTCAAAGGC-3’ 
5’-GCCTTTGAACATGTAGGTTAACATGTCAGCCATGTGGGGCAGCAG-3’ 
PXR-Q285L 
5’-GGGCCGCTTTCGAGCTGTGTCTACTGAGATTCAACACAGTG-3’ 
5’-CACTGTGTTGAATCTCAGTAGACACAGCTCGAAAGCGGCCC-3’ 
PXR-F288A 
5’-CGAGCTGTGTCAACTGAGAGCCAACACAGTGTTCAACGCGG-3’ 
5’-CCGCGTTGAACACTGTGTTGGCTCTCAGTTGACACAGCTCG-3’ 
PXR-Y306L 
5’-GGGAGTGTGGCCGGCTGTCCCTCTGCTTGGAAGACACTGCAGG-3’ 
5’-CCTGCAGTGTCTTCCAAGCAGAGGGACAGCCGGCCACACTCCC-3’ 
PXR-H407A 
5’-CCGCAGCATCAATGCTCAGGCCACCCAGCGGCTGCTGCGCATCC-3’ 
5’-GGATGCGCAGCAGCCGCTGGGTGGCCTGAGCATTGATGCTGCGG-3’ 
PXR-L411F 
5’-GCTCAGCACACCCAGCGGTTCCTGCGCATCCAGGACATAC-3’ 
5’-GTATGTCCTGGATGCGCAGGAACCGCTGGGTGTGCTGAGC-3’ 
 
63 
 
 
Table 2.2 Primer sequences for QPCR. 
Genes Primer sequences Genes Primer sequences 
mCYP3A11 
5’-CAGCTTGGTGCTCCTCTACC-3’ 
5’-TCAAACAACCCCCATGTTTT-3’ 
mDGAT2 
 
5’-ACTCTGGAGGTTGGCACCAT-3’ 
5’-GGGTGTGGCTCAGGAGGAT-3’ 
mGSTA1 
5’-CAGCCTGGCAGCCAGAGA-3’ 
5’-TCTGTGGCTCCATCAATGCA-3’ 
mGAPDH 
 
5’-AACTTTGGCATTGTGGAAGG-3’ 
5’-GGATGCAGGGATGATGTTCT-3’ 
mMDR1a 
5’-CCCCCGAGATTGACAGCTAC-3’ 
5’-ACTCCACTAAATTGCACATTTCCTTC-3’ 
hCYP3A4 
 
5’-GGCTTCATCCAATGGACTGCATAAAT-3’ 
5’-TCCCAAGTATAACACTCTACACAGACAA-3’ 
mCD36 
5’-CAGTCGGAGACATGCT-3’ 
5’-CTCGGGGTCCTGAGTT-3’ 
hUGT1A1 
5’-TGCTCATTGCCTTTTCACAG-3’ 
5’-GGGCCTAGGGTAATCCTTCA-3’ 
mLipF 
5’-ATGGTTTGATTGCATCAGCCA-3’ 
5’-TTCCCCAGCCACACATCATAG-3’ 
hMDR1a 
5’-CCCATCATTGCAATAGCAGG-3’ 
5’-GAGCATACATATGTTCAAACTTC-3’ 
mLipA 
5’-TGTTCGTTTTCACCATTGGGA-3’ 
5’-CGCATGATTATCTCGGTCACA-3’ 
hGAPDH 
5’-ACAGTGGGGGTGTACGAGTC-3’ 
5’-AGGGGAGATTCAGTGTGGTG-3’ 
mDGAT1 
5’-GTGCCATCGTCTGCAAGATTC-3’ 
5’-GCATCACCACACACCAATTCAG-3’ 
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Figure 2.1 Amprenavir is a potent PXR-selective agonist. 
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Figure 2.1 Amprenavir is a potent PXR-selective agonist. 
(A and B) HepG2 cells were transfected with (A) full-length hPXR together with a 
hPXR reporter (CYP3A4-luc) or (B) full-length mPXR together with a mPXR 
reporter ((CYP3A2)3-luc) and CMX-β-galactosidase control plasmid.  Cells were 
then treated with DMSO control, amprenavir, ritonavir, nelfinavir, saquinavir, 
indinavir sulfate, RIF (a hPXR ligand) or PCN (a mPXR ligand) at the indicated 
concentrations for 24 h.  (C) HepG2 cells were co-transfected with hPXR together 
with CYP3A4-luc reporter and CMX-β-galactosidase plasmid.  Cells were then 
treated with amprenavir or RIF at the indicated concentrations for 24 h.  (D) HepG2 
cells were co-transfected with a GAL4 reporter and a series of GAL4 constructs in 
which the GAL4 DBD is linked to the indicated nuclear receptor LBD.  Cells were 
treated with DMSO control or 10 μM amprenavir for 24 h.  Data are shown as fold 
induction of normalized luciferase activity compared with DMSO treatment and 
represent the mean of triplicate experiments.  Results are presented as mean ± 
SEM. 
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Figure 2.2 Amprenavir promotes PXR co-activator recruitment and 
co-repressor disassociation. 
(A and B) HepG2 cells were transfected with a GAL4 reporter and VP16-
hPXR as well as expression vector for GAL4 DBD or GAL4 DBD linked to the 
receptor interaction domains of the indicated PXR co-activators (GAL-SRC1 
and GAL-PBP) (A) or co-repressor (GAL-SMRT and GAL- NCoR) (B). Cells 
were then treated with DMSO control, amprenavir, or RIF at the indicated 
concentrations for 24 h.  Results are presented as mean ± SEM. 
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Figure 2.3 Key residues of PXR LBD are required for amprenavir’s 
agonistic activity.  
(A)  Overlay of docked amprenavir and SR12813 (green) inside the LBD of 
PXR.  Atoms in amprenavir were colored by atom type (oxygen in red, 
phosphor in yellow, nitrogen in blue and carbon in grey), while all the atoms 
in SR12813 were colored in green for clear comparison.  Four subpockets 
were presented by black circles.  (B)  Interaction map between amprenavir 
and PXR.  Amprenavir was computationally docked in the ligand binding 
pocket of the hPXR X-ray crystal structure (3hvl.pdb).  The amprenavir-PXR 
complex was stabilized by three hydrogen bonds with residues Ser247, 
Gln285 and His407, respectively.  The noncovalent contacts with the 
aromatic side chains Phe288, Trp299, and Tyr306 lining in the subpocket 1 
contributed significantly to amprenavir binding.  Phe288 was well positioned 
to engage in π-stacking interactions with the phenyl ring of amprenavir.  The 
interaction diagram reveals that amprenavir occupied the major portion of the 
large, flexible PXR ligand binding pocket.  (C)  HepG2 cells were co-
transfected with a full-length PXR WT plasmid or mutant PXR plasmids as 
indicated, together with CYP3A4-luciferase reporter and CMX-β-galactosides 
plasmid.  After transfection, cells were treated with control medium or 
medium containing amprenavir at indicated concentrations for 24 h.  Results 
are presented as mean ± SEM. 
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Figure 2.4 Amprenavir induces PXR target gene expression in 
human cells. 
(A and B)  Human HepaRG hepatoma cells (A) and LS180 intestinal cells (B) 
were treated with control medium or medium containing 10 μM amprenavir 
for 24 h.  Total RNA was isolated and gene expression levels were analyzed 
by QPCR with primers for human CYP3A4, UGT1A1 or MDR1 (n=3, 
**P<0.01, ***P<0.001; assessed by one-way ANOVA).  Results are presented 
as mean ± SEM. 
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Figure 2.5 Amprenavir elicits hyperlipidemia in WT, but not in 
PXR-/- mice. 
(A and B) 8-week-old WT (A) and PXR-/-(B) mice were treated with vehicle 
(corn oil) or 10 mg/kg of amprenavir by oral gavage for 1 week.  Plasma 
total cholesterol levels were measured by a standard method (n= 4-7; 
*P<0.05; assessed by student’s t-test). (C and D)  Plasma cholesterol 
distribution of WT (C) and PXR-/- mice (D) was analyzed by FPLC.  Results 
are presented as mean ± SEM. 
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Figure 2.6 Amprenavir elevates atherogenic LDL cholesterol levels 
in WT mice.  
(A and B)  Eight-week-old WT (A) and PXR-/-(B) mice were treated with 
vehicle or 10 mg/kg of amprenavir by oral gavage for 1 week.  Lipoprotein 
fractions (VLDL, LDL, and HDL) were isolated and the cholesterol levels of 
each fraction were measured by a standard method (n=4-7; *P<0.05; 
assessed by student’s t-test).  Results are presented as mean ± SEM. 
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Figure 2.7 Activation of PXR by amprenavir stimulates the 
expression of intestinal genes involved in lipid homeostasis.  
Eight-week-old WT and PXR-/- mice were treated with vehicle (corn oil) or 10 
mg/kg of amprenavir by oral gavage for 1 week. Total RNA was isolated from 
the small intestine (duodenum) and liver.  (A and B)  The mRNA levels of 
known PXR target genes, CYP3A11, GSTA1, and MDR1a, in the intestine 
(A) and liver (B) were measured by QPCR. (C)  Expression levels of intestinal 
genes involved in lipid homeostasis were measured by QPCR. (n=4-5; 
*P<0.05, **P<0.01; assessed by student’s t-test).  Results are presented as 
mean ± SEM. 
Copyright © Robert Nathaniel Helsley, 2016 
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Chapter 3: Intestinal PXR Links Xenobiotic Exposure and 
Hypercholesterolemia 
3.1 Introduction 
 Influences of the chemical environment on human health have recently 
become the subject of intense interest.  Mounting evidence shows that 
endocrine disrupting chemicals (EDCs) can interfere with complex endocrine 
signaling mechanisms and result in adverse consequences in humans and 
wildlife [76, 293].  Recent findings have implicated exposure to EDCs in the 
etiology of cardiovascular disease (CVD) and metabolic disorders [76-78, 293-
295].  For instance, higher bisphenol A (BPA) exposure has been consistently 
associated with CVD in multiple large-scale human population studies [77-79].  
Exposure to certain polychlorinated biphenyls (PCBs) induces 
hypercholesterolemia and promotes atherosclerosis in animals [84, 296].  
Circulating PCB levels have been associated with atherosclerotic plaques in 
elderly individuals [297].  High circulating levels of phthalates are also 
associated with carotid atherosclerosis [81].  However, the underlying 
mechanisms responsible for these associations remain largely unknown, which 
continues to hamper rational assessment of the health risks of EDC exposure. 
 Many EDCs such as phthalates, PCBs, and BPA and its analogs have 
been implicated in the activation of the pregnane X receptor (PXR) (also known 
as steroid and xenobiotic receptor, or SXR) [91, 136, 179, 298].  PXR is a 
nuclear receptor activated by numerous endogenous hormones, dietary 
steroids, pharmaceutical agents, and xenobiotic chemicals [89, 91, 95].  PXR 
functions as a xenobiotic sensor that induces expression of genes required for 
xenobiotic metabolism in the liver and intestine, including cytochromes P450s 
(CYP), conjugating enzymes (e.g., glutathione transferase), and ABC family 
transporters (e.g., multidrug resistance 1 [MDR1]) [90, 91].  In the past decade, 
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the role of PXR as a xenobiotic sensor has been well established [91].  
However, the role of PXR in mediating the pathophysiological effects of EDCs in 
humans and animals remains elusive. 
 The identification of PXR as a xenobiotic sensor provided an important 
tool for the study of new mechanisms through which xenobiotic exposure 
impacts diseases.  Recent evidence indicates that PXR may also play an 
important role in the regulation of lipid homeostasis [114, 177, 260, 265, 299, 
300].  For instance, it is well-known that many clinically relevant PXR ligands 
(e.g. rifampicin, ritonavir) can elevate plasma lipid levels in patients and 
increase their CVD risk [52, 261, 263, 264].  A meta-analysis of 7 genome-wide 
association studies indicated that common genetic variants in PXR can affect 
plasma lipid levels in humans and 19 PXR SNPs were identified to significantly 
affect plasma low-density lipoprotein (LDL) cholesterol levels [118].  We recently 
demonstrated the pro-atherogenic effects of PXR in animals.  Chronic activation 
of PXR elicited by feeding mice the mouse PXR ligand pregnane 16α-
carbonitrile (PCN) led to increased levels of plasma total cholesterol and 
atherogenic lipoproteins LDL and very-low-density lipoprotein (VLDL) in wild-
type (WT) mice, but not in PXR-deficient (PXR-/-) mice [177].  Activation of PXR 
also increased plasma total cholesterol and VLDL levels in apolipoprotein E*3-
Leiden mice, which exhibit a human like lipoprotein distribution on a cholesterol-
rich diet [260].  In Chapter 2, we identified amprenavir, a widely used anti-
retroviral drug, as a potent PXR-selective agonist [299].  Exposure to 
amprenavir significantly increased plasma total cholesterol and LDL cholesterol 
levels in WT mice, but not in PXR-/- mice [299].  
 Despite emerging evidence consistent with the hypothesis that modulation 
of PXR activity alters lipid homeostasis, the mechanisms underlying PXR ligand-
elicited hyperlipidemia remain largely unknown.  PXR is expressed at high 
levels in the liver and intestine, two organs that play a central role in whole-body 
lipid homeostasis.  PXR has been reported to regulate several key hepatic 
lipogenic genes that promotes dyslipidemia and hepatic steatosis, including 
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CD36, SCD-1, lipin-1, Insig-1, and S14 [114, 182, 204, 301]; however, the role 
of intestinal PXR in the regulation of lipid homeostasis remains elusive.  Here 
we report that intestinal PXR plays an important role in linking EDC exposure 
and hypercholesterolemia.  We identified several widely used phthalate 
substitute plasticizers widely used in food packaging materials, medical devices, 
cosmetics, and pharmaceutical drugs as agonists of PXR.  Tributyl citrate 
(TBC), one of a large group of Food and Drug Administration (FDA)-approved 
pharmaceutical plasticizers, is a potent and selective PXR agonist but does not 
activate other nuclear receptors. Interestingly, TBC is an intestine-specific PXR 
ligand but does not affect hepatic PXR activity.  Short-term TBC exposure 
increased plasma total cholesterol and atherogenic LDL cholesterol levels in WT 
mice, but not in PXR-/- mice.  We found that TBC-mediated PXR activation 
stimulated the expression of the intestinal cholesterol transporter Niemann-Pick 
C1-Like 1 (NPC1L1) and significantly increased lipid uptake by human and 
murine intestinal cells.  We also identified a PXR-binding site in the NPC1L1 
promoter, indicating NPC1L1 is a bona fide PXR target gene.  These findings 
provide critical mechanistic insight for understanding the impact of EDC-
mediated PXR activation on lipid homeostasis and demonstrate a potential role 
of PX R in mediating adverse effects of EDCs on CVD risk in humans. 
 
3.2 Materials and Methods 
3.2.1 Reagents and Plasmids 
 TBC, acetyl tributyl citrate (ATBC), di (2-ethylhexyl) phthalate (DEHP), 
acetyltriethyl citrate (ATEC), diisononyl phthalate (DiNP), triethyl citrate (TEC), 
di-n-butyl phthalate (DnBP), di-isobutyl phthalate (DiBP), diethyl phthalate 
(DEP), pregnenolone 16α-carbonitrile (PCN) and rifampicin (RIF) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA).  All the chemicals were 
dissolved in dimethyl sulfoxide (DMSO). Human (h) and mouse (m) PXR 
expression vectors; GAL4 DNA-binding domain (DBD)-linked nuclear receptor 
ligand-binding domain (LBD) vectors (GAL4-hPXR, GAL4-mPXR, GAL4-rat 
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PXR, GAL4-retinoid acid receptor [RARα], GAL4-retinoid X receptor [RXR], 
GAL4-farnesoid X receptor [FXR], GAL4-liver X receptor [LXR], GAL4-
peroxisome proliferator-activated receptor [PPAR]α, GAL4-PPARγ and GAL4-
vitamin D receptor [VDR]); and CMX-β-gal expression vectors were been 
described before [179, 222, 266].  VP16-PXR, GAL4-nuclear receptor 
corepressor (NCoR), GAL4-silencing mediator of retinoid and thyroid hormone 
(SMRT), GAL4-steroid receptor coactivator (SRC1), GAL4-PPAR binding 
protein (PBP), PXR-dependent CYP3A4 promoter reporter (CYP3A4XREM-
Luciferase), CYP3A2 promoter reporter [(CYP3A2)3-luciferase], and GAL4 
reporter (MH100-Luciferase) were described previously[179, 266, 267].  For the 
human NPC1L1/DR-4 reporter, 4 copies of the DR-4 element were synthesized 
and inserted into a pGL3 promoter vector (Promega) by annealing 
complementary oligonucleotides 5’-GCAGATCACTTGAGGTCAGG-3’ 
containing cohesive ends of the restriction enzyme sites, KpnI and MluI.  
3.2.2 Cell Culture and Transfections 
 The human intestine epithelial cell line LS180 and hepatic cell line HepG2 
were obtained from the American Type Culture Collection.  The human 
hepatoma HepaRG cells were purchased from Life Technologies.  Transfection 
assays were performed as described previously [179, 299].  The cells were 
transfected with various expression plasmids as well as the corresponding 
luciferase reporter plasmids, together with CMX-β-galactosidase control 
plasmids using FuGENE 6 (Roche Diagnostics).  The cells were then incubated 
with the corresponding ligands as indicated in the figure legends for 24 hours, 
and β-galactosidase and luciferase assays were performed as described [179, 
301].  Fold activation was calculated relative to solvent controls.  Each data 
point represents the average of triplicate experiments ± SEM and was replicated 
in 3-5 independent experiments.  For the mammalian 2-hybrid assays, LS180 
cells were transfected with GAL4 reporter, VP16-hPXR, and GAL-SRC1, GAL-
PBP, GAL-NCoR, and GAL-SMRT [179, 301].  The cells were then treated with 
compounds at the indicated concentrations.  
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3.2.3 Animals 
 C57BL/6 WT mice were purchased from The Jackson Laboratory. PXR-
deficient mice (PXR-/-) on C57BL/6 background were employed as described 
previously [177]. All the animals were housed in the Division of Laboratory 
Animal Resources, University of Kentucky, as approved by the Institutional 
Animal Care and Use Committee in the specific pathogen-free environment with 
a light-dark cycle.  Eight-week-old male WT or PXR-/- mice were fed a 
semisynthetic low-fat AIN76 diet containing 0.02% cholesterol (Research Diets) 
[177, 178, 270, 299] and treated by oral gavage with vehicle (corn oil) or 10 
mg/kg body weight (BW) TBC daily for 7 days.  In addition, WT mice were also 
treated with vehicle control or 10 mg/kg/BW TBC daily by ip injection.  On the 
day of euthanization, mice were fasted for 6 hours after the dark phase (feeding 
cycle) [177, 178].  Mice were then anesthetized by intraperitoneal injection with 
Ketamine (Fort Dodge Animal Health).  Mice were exsanguinated by left 
ventricular puncture, and blood was collected into EDTA-containing syringes.  
Plasma was prepared by spinning at 16,000 g for 10 min.  The circulation was 
flushed with PBS; intestinal and liver tissues were collected and stored in 
RNAlater solution (Life Technologies).  Mouse primary hepatocytes and 
enterocytes were isolated as previously described [302, 303].  Primary cells 
were cultured in multiwell plates and treated with the indicated compounds 
before being harvested for quantitative real-time PCR (qPCR) and Western blot 
analysis or cholesterol uptake assays. 
3.2.4 Plasma Analysis 
 Plasma total cholesterol and triglyceride concentrations were determined 
enzymatically by colorimetric methods as described previously (Roche) [299, 
304].  Lipoproteins fractions were isolated by spinning 60 μl of plasma in a TL-
100 ultracentrifuge (Beckman Coulter) at its own density (1.006 g/ml) at 70,000 
RPM for 3 hours to harvest the supernatant, and then after adjustment of the 
infranatant with solid KBr to a density of 1.063 g/ml spinning it for 70,000 RPM 
for 18 hours to harvest the supernatant [304].  The cholesterol content of each 
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supernatant and the final infranatant were measured and taken to be very-low-
density lipoprotein (VLDL) (<1.006 g/ml), low-density lipoprotein (LDL) (1.006 ≤ 
d ≤ 1.063 g/ml), and high-density lipoprotein (HDL) (d >1.063 g/ml) cholesterol, 
respectively. Cholesterol concentrations in all three fractions were then 
determined enzymatically by a colorimetric method (Roche).  Total plasma 
cholesterol levels were determined enzymatically in the original plasma sample.   
3.2.5 Cholesterol Uptake Assay 
 Cholesterol uptake assay was performed as previously described [305]. In 
brief, micelles were prepared by mixing 9.7 mM of Taurocholate (Sigma-
Aldrich), 6.47 mM of egg yolk L-α-Phosphatidylcholine (Sigma-Aldrich), and 1.5 
mM of Cholesterol (Sigma-Aldrich), together with 1 µCi of [1,2-3H(N)]-
Cholesterol (PerkinElmer)/µmol of Cholesterol and evaporated under a mild 
stream of argon.  The lipid film was hydrated in serum-free MEM containing 
0.5% fatty acid-free BSA (Sigma-Aldrich) and incubated at 37 ºC in a rotating 
incubator.  Solutions were filtered through a 0.45 μm surfactant-free cellulose 
acetate filter (Corning) and used to incubate the LS180 cells or primary 
enterocytes.  After extensive PBS washing, cellular [3H]-cholesterol was 
counted by a β-counter.  
3.2.6 Electrophoretic Mobility Shift Assay (EMSA) 
 EMSA was performed as described previously [255, 303].  In brief, 
NPC1L1/DR-4 and CYP3A4/ER-6 probes were created by annealing the 
oligonucleotides 5’-GGGCAGATCACTTGAGGTCAGGAG-3’ (NPC1L1/DR-4), 
5’-GGGCAGAACACTTGAGAACAGGAG-3’ (NPC1L1/DR-4m1), 5’-
GGGCAGATCTCTTGAGATCTGAG-3’(NPC1L1/DR-4m2), or 5’-
ATATGAACTCAAAGGAGGTCAGTG-3’ (CYP3A4/ER6) to the complementary 
strand.  Double-stranded oligonucleotides were end labeled using T4 
polynucleotide kinase (New England Biosciences) and γ-[32P]-ATP 
(PerkinElmer).  Then 5 μl of in vitro-translated PXR or RXR protein was 
incubated with 2 µg poly d(I-C) (Promega), 2 µl bandshift buffer (50 mM MgCl2 
and 340 mM KCl), and 6 µl delta buffer (0.1 mM EDTA, 40 mM KCl, 25 mM 
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HEPES (pH 7.6), 8% Ficoll 400, and 1 mM dithiothreitol) on ice for 10 minutes.  
32P-labeled double-stranded oligonucleotide probe (100,000 cpm) was then 
added, and the reaction was incubated for another 30 minutes on ice.  For the 
supershift assays, proteins were incubated with 2 μg of goat anti-PXR (sc-7739; 
Santa Cruz Biotechnology) or rabbit anti-PXR (sc-25381; Santa Cruz 
Biotechnology) antibodies for 1 hour before the addition of 32P-labeled probe.  
The binding complexes were subjected to electrophoresis in a 6% 
nondenaturing polyacrylamide gel containing 0.5× Tris-borate- 
EDTA (TBE).  The gels were dried and visualized by exposure to X-ray film.  
3.2.7 Chromatin Immunoprecipitation 
 ChIP analysis was performed by using an antibody against PXR (sc-
25381; Santa Cruz Biotechnology) and SimpleChIP Enzymatic Chromatin IP Kit 
(Cell Signaling).  The precipitated genomic DNA relative to inputs was analyzed 
by semi-quantitative PCR using specific primers and DNA polymerase (Takara).  
The sequences of primer sets used for PCR are listed in Table 3.1. 
3.2.8 RNA Isolation and QPCR Analysis 
 Total RNA was isolated from mouse tissues and intestinal LS180, 
HepaRG, and primary cells using TRIzol Reagent (Life Technologies) per the 
manufacturer-supplied protocol.  QPCR was performed using gene-specific 
primers and the SYBR green PCR kit (Life Technologies) as described 
previously [179, 299].  The primer sets used in this study are listed in Table 3.1. 
3.2.9 Western Blot Analysis 
 Western blot analysis was performed as previously described [255]. 
Proteins were isolated from cells or mouse tissues by homogenization in 
radioimmunoprecipitation assay buffer with complete mini protease inhibitor 
cocktail (Roche).  Protein concentrations were determined by the Pierce BCA 
protein assay kit (Thermo scientific).  Anti-PXR antibodies were purchased from 
Santa Cruz Biotechnology (sc-7739); anti-NPC1L1 antibodies were purchased 
from Novus Biologicals (NB400-128); and anti-β-actin antibodies were 
purchased from Sigma-Aldrich (A2066).  
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3.2.10 Statistical Analysis 
 Data are expressed as means ± SEM unless otherwise noted.  Statistical 
analysis was performed using a two-sample, two-tailed Student t-test unless 
otherwise noted, with P < 0.05 regarded as significant.  One-way analysis of 
variance was used when multiple comparisons were made, followed by 
Dunnett’s t test for multiple comparisons to a control.  Two-way analysis of 
variance was used when multiple comparisons were made, followed by a 
Bonferroni’s post-hoc test.  Analysis was performed using SigmaPlot 13.0.   
 
3.3 Results 
3.3.1 FDA-Approved Phthalate Substitute Plasticizers 
can Activate PXR 
 Based on previous findings that several plastic-associated chemicals 
including BPA and phthalates can activate PXR [179, 306], we examined 
several widely used phthalates and phthalate substitute plasticizers for PXR 
activation in transient transfection assays.  Consistent with previous reports 
[307, 308], DEHP, DiNP, and ATBC can activate PXR and induce PXR-
mediated CYP3A4-luciferase reporter activities (Fig. 3.1, A).  TBC, an FDA-
approved phthalate substitute plasticizer used in food contact substances and 
as a pharmaceutical excipient, was a more potent PXR agonist than any of the 
other tested plasticizers and induced reporter gene activity in a dose-dependent 
manner (Fig. 3.1, A).  We tested the ability of TBC to activate a panel of other 
nuclear receptors, including mouse PXR, human RARα, RXR, FXR, LXRα, 
PPARα, PPARγ, VDR, constitutive adrostane receptor, and estrogen receptor α 
(Fig. 3.1, B).  TBC can activate both human and mouse PXR but was unable to 
activate any of other nuclear receptors.  Thus, TBC is a PXR-selective agonist.  
 Nuclear receptor co-regulators play critical roles in nuclear receptor 
signaling.  We then used a mammalian 2-hybrid assay to evaluate the effects of 
TBC on PXR co-regulator interaction. TBC promoted the specific interactions 
between PXR and the coactivators SRC-1 and PBP (Fig. 3.1, C).  Consistent 
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with our previous report [179, 266], unliganded PXR interacted with co-
repressors, NCoR and SMRT (Fig. 3.1, D), and TBC disrupted this interaction 
as did the potent human PXR ligand RIF (Fig. 3.1, D). Thus, binding of TBC to 
PXR inhibits PXR-corepressor interaction and promotes PXR-coactivator 
recruitment, thereby inducing PXR transcriptional activation in a concentration-
dependent manner.  
3.3.2 TBC is an Intestine-Specific Ligand 
 We next used human hepatoma HepaRG cells [274] and intestinal LS180 
cells [266, 299] to test the effects of TBC exposure on PXR activity and target 
gene expression.  The known human PXR ligand RIF induced the expression of 
bona fide PXR target genes involved in phase I (CYP3A4), phase II (UGT1A1), 
and phase III (MDR1) metabolism in both cell lines.  Interestingly, TBC 
stimulated PXR target gene expression in intestinal LS180 cells but not in 
HepaRG cells (Fig. 3.2, A).  We then isolated mouse primary hepatocytes and 
enterocytes to confirm these findings.  As expected, the mouse PXR ligand PCN 
induced PXR target gene expression in both hepatocytes and enterocytes (Fig. 
3.2, B).  However, TBC was only able to induce PXR target gene expression in 
enterocytes but not in hepatocytes (Fig. 3.2, B).  We also performed transfection 
assays in LS180 and HepG2 cell lines. Consistently, TBC did not activate PXR 
in HepG2 cells but was able to induce PXR reporter activity in LS180 cells after 
being treated for as few as 3 hours (Fig. 3.3, A and B).  
 To further investigate the effects of TBC on PXR activity in vivo, WT mice 
were treated with vehicle (corn oil), 10 mg/kg BW TBC, or PCN daily by oral 
gavage for 1 week.  Consistent with our previous report [303], PCN activated 
PXR and induced target gene expression in both liver and intestine (Fig. 3.2, C).  
However, TBC only stimulated expression of known PXR target genes in 
intestine but not in liver (Fig. 3.2, C). To examine whether lower TBC doses can 
activate intestinal PXR in vivo, we also treated mice with 2.5 or 5 mg/kg/d TBC 
by oral gavage for 1 week.  Neither 2.5 nor 5 mg/kg/d TBC activated PXR or 
induced PXR target gene expression in the intestine (Fig. 3.4).  Next, to 
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determine whether the tissue-specific effect of TBC on intestinal PXR is related 
to poor absorption into the circulation, WT mice were also treated with 10 
mg/kg/d TBC by ip deliver. Interestingly, TBC was still unable to induce PXR 
target gene expression in liver even by ip delivery (Fig. 3.5).  Therefore, it is 
unlikely that the inability of TBC to activate hepatic PXR is due to poor 
absorption by the intestine.  Taken together, these results suggest that 
exposure to TBC at a relevant dose via oral delivery activates intestinal PXR but 
does not affect hepatic PXR signaling.  
3.3.3 TBC Exposure Elevates Plasma Lipid Levels in WT 
Mice, but not in PXR-/- Mice 
 We previously reported that activation of PXR by feeding PCN at a high 
dose (200 mg/kg in diet) for 2 weeks significantly increased plasma total 
cholesterol levels and atherogenic LDL and VLDL levels in WT mice [177].  
Consistent with our previous report, WT mice treated with a relatively low dose 
of PCN (10 mg/kg/BW/d via oral deliver) for 1 week also had significantly 
increased plasma total, LDL, and VLDL cholesterol levels (Fig. 3.6, A).  
Although TBC only activates intestinal PXR, TBC treatment significantly 
increased total cholesterol levels compared with those in control WT mice (Fig. 
3.6, A).  TBC treatment did not affect HDL or VLDL cholesterol levels but 
significantly increased LDL cholesterol levels in WT mice (Fig. 3.6, A).  The 
relatively stronger effects of PCN on plasma lipid levels could be due to its 
effects on hepatic PXR signaling.  In contrast, TBC did not affect any of the 
lipoprotein levels in PXR-/- mice (Fig. 3.6, B), indicating that TBC-elicited 
hypercholesterolemia effects are mediated by PXR signaling.  Taken together, 
these results suggest that activation of intestinal PXR by TBC is sufficient to 
increase plasma cholesterol levels.  
3.3.4 TBC Stimulates the Expression of Intestinal 
Cholesterol Transporter NPC1L1 and Drives 
Cholesterol Uptake by Intestinal Cells 
 Small intestine lipid absorption is the key step for lipid accumulation in the 
body.  Interestingly, we found that TBC stimulated expression of the 
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transporters responsible for intestinal lipid absorption including CD36 and 
NPC1L1 in the intestines of WT mice, but not in intestines of PXR-/- mice (Fig. 
3.7, A).  The known PXR target gene, CD36 [114], encodes a fatty acid 
transporter that plays an important role in intestinal fatty acid absorption and 
chylomicron production [282, 309].  NPC1L1 is an essential transporter 
mediating intestinal cholesterol absorption [6, 20, 27].  Western blot analysis 
also confirmed that TBC induced intestinal NPC1L1 protein levels in WT mice 
but not in PXR-/- mice (Fig. 3.7, B).  Consistent with a previous report [310], PXR 
activation did not affect expression levels of the cholesterol efflux transporters 
ABCG5 and ABCG8.  In addition, the known PXR ligand PCN was also able to 
induce NPC1L1 expression in intestine (Fig. 3.8), indicating that NPC1L1 is a 
downstream target of PXR.  
 To further investigate the effects of TBC on PXR activity and NPC1L1 
expression, we isolated primary enterocytes from WT and PXR-/- mice.  
Consistent with in vivo results, TBC treatment increased NPC1L1 mRNA and 
protein levels in WT enterocytes (Fig. 3.7, C and D).  TBC-mediated NPC1L1 
induction was abolished in PXR-deficient enterocytes.  Because NPC1L1 plays 
a key role in cholesterol uptake by intestinal cells, we then performed 
cholesterol uptake assays using primary enterocytes.  As expected, TBC 
treatment increased [H3]-cholesterol uptake by primary enterocytes of WT mice 
but did not affect cholesterol uptake by PXR-deficient enterocytes (Fig. 3.7, E).  
Taken together, these results indicate a previously unrecognized role of PXR in 
the regulation of intestinal cell cholesterol uptake. 
3.3.5 Activation of PXR by TBC Transcriptionally 
Regulates NPC1L1 Expression and Increases 
Cholesterol Uptake by Human Intestinal Cells 
 To determine the impact of TBC-mediated PXR activation on NPC1L1 
regulation and cholesterol uptake in human intestinal cells, we used small 
interfering RNA (siRNA) to successfully reduce PXR expression in human 
LS180 cells (Fig. 3.9, A).  As expected, TBC treatment induced NPC1L1 mRNA 
levels in control LS180 cells and siRNA-mediated PXR knockdown decreased 
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TBC-induced NPC1L1 induction (Fig. 3.9, B).  In addition, TBC was also able to 
significantly increase [H3]-cholesterol uptake by LS180 cells (Fig. 3.9, C).  
LS180 cells transfected with siRNA against PXR can still take up [H3]-
cholesterol, which may be due to incomplete inhibition of endogenous PXR 
expression by siRNA.  However, TBC-mediated cholesterol uptake was 
significantly reduced by siRNA-mediated PXR knockdown.  These results 
confirm that TBC-mediated PXR activation can increase NPC1L1 expression 
and cholesterol uptake in human intestinal cells.  
 We next analyzed the promoter of the human NPC1L1 gene and identified 
a DR-4-type (direct repeat spaced by 4 nucleotides) of nuclear receptor 
response element (AGATCACTTGAGGTCA), similar to DR-4 element found in 
other PXR target genes [95].  EMSA confirmed that PXR and RXR heterodimer 
was able to bind to this DR-4 element as well as the positive control, the ER-6 
(everted repeat spaced by 6 nucleotides) element in the CYP3A4 promoter (Fig. 
3.10, A).  The binding of NPC1L1/DR-4 or CYP3A4/ER-6 by PXR-RXR is 
specific as excess cold probe decreased PXR-RXR binding to those elements 
(Fig. 3.10, A).  In addition, 2 different anti-PXR antibodies disrupted the protein-
DNA complex (Fig. 3.10, B), suggesting that PXR is a component of the protein 
complex that binds to the NPC1L1/DR4 element.  Further, mutations of the DR-
4 elements were also able to abolish the binding of PXR-RXR dimers to both 
mutant DR-4 sites (Fig. 3.10, C). 
 Next, ChIP analysis demonstrated that TBC can promote the recruitment 
of PXR onto the NPC1L1 promoter region containing the DR-4 element (Fig. 
3.10, D).  ChIP on the CYP3A4 promoter region containing the ER-6 element 
was included as a positive control.  Last, 4 copies of the NPC1L1/DR-4 or 
mutated DR-4 elements were synthesized and inserted into a luciferase reporter 
vector.  Transfection assays were performed to determine whether the DR-4 
motif is necessary and sufficient for mediating PXR transactivation.  Indeed, 
both TBC and RIF can activate PXR and increase the NPC1L1/DR-4 reporter 
gene activity in a dose-dependent manner (Fig. 3.10, E).  In contrast, TBC and 
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RIF had no effect on activity of 2 mutated DR-4 reporters (Fig. 3.10, F and G).  
Collectively, activation of PXR by TBC transcriptionally regulates NPC1L1 
expression and increases cholesterol uptake by human intestinal cells.  
 
3.4 Discussion 
 Because of their variety and low costs, plastics are fundamental in modern 
life and plastic production exceeded 300 million tons in 2010 [293].  Plastic-
associated chemicals are produced in high volume for use in the production of 
plastics, including the base chemical BPA and numerous plasticizers.  The 
adverse effects of BPA and several phthalate plasticizers (e.g., DEHP) on 
human health have attracted considerable attention and engendered 
controversy in the past few decades, partly due to their endocrine-disrupting 
properties.  We and others have identified BPA, BPA analogs (e.g., bisphenol B 
and bisphenol AF), and the widely used phthalate plasticizer DEHP as potent 
PXR agonists [179, 298, 306].  In addition to these well-known EDCs, there are 
many phthalate substitute plasticizers that have not been tested for endocrine 
disruption.  For example, citrate esters, including TBC, ATBC, and TEC, 
represent a large group of plasticizers that have been approved by the FDA to 
be used in food packaging materials, vinyl toys, medical devices, cosmetics, 
and pharmaceutical drugs [311-314].  ATBC has recently been shown to 
activate PXR and induce PXR target gene expression [308].  However, it is 
unclear whether ATBC or other phthalate substitute plasticizers have any 
adverse effects on the development of complex diseases.  In the current study, 
we demonstrate that TBC is a more potent PXR agonist than ATBC in our 
assays.  Similar to ATBC, TBC activated intestinal PXR and induced PXR target 
gene expression but did not affect hepatic PXR activity.  Nevertheless, TBC-
mediated intestinal PXR activation was sufficient to increase plasma cholesterol 
levels, especially atherogenic LDL levels in WT mice.  We then identified a key 
intestinal cholesterol transporter, NPC1L1, as a direct transcriptional target of 
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PXR.  Activation of PXR stimulated NPC1L1 expression and promoted 
cholesterol uptake by intestinal cells, which may contribute to TBC-induced 
hyperlipidemia.  These findings demonstrate a previously unrecognized role of 
intestinal PXR in the regulation of lipid homeostasis. 
 Whereas the role of PXR in xenobiotic metabolism has been well 
established, recent studies have revealed a role of PXR in dyslipidemia and 
atherosclerosis.  We previously reported that chronic activation of PXR elicited 
by feeding mice the potent mouse PXR agonist PCN led to increased levels of 
plasma total cholesterol and VLDL and LDL in WT mice but not in PXR-/- mice 
[177].  PCN-mediated PXR activation affected several genes involved in hepatic 
lipid homeostasis.  Because TBC does not activate PXR in the liver, it is unlikely 
that hepatic PXR signaling contributes to TBC-elicited hypercholesterolemia.  
Cholesterol uptake from the intestinal lumen by the enterocytes is the rate-
limiting step in cholesterol absorption [309].  NPC1L1, a multitransmembrane 
protein containing a conserved N-terminal NPC1 domain and a putative sterol-
sensing domain, has been established as an essential transporter in mediating 
intestinal cholesterol uptake [20, 27, 309].  NPC1L1 expression is enriched in 
the small intestine and is in the brush border membrane of enterocytes [20].  
NPC1L1 takes up free cholesterol into cells through vesicular endocytosis and is 
required for intestinal cholesterol absorption [20, 27, 309].  Indeed, NPC1L1-
deficient mice had substantially reduced intestinal cholesterol absorption and 
plasma cholesterol (particularly LDL) levels and were completely resistant to 
diet-induced hypercholesterolemia [20, 27].  NPC1L1 is also the molecular 
target of the clinically used drug ezetimibe, a potent cholesterol absorption 
inhibitor widely used to treat hypercholesterolemia [20].  Very recently, 
inactivating mutations in NPC1L1 has been associated with reduced plasma 
LDL cholesterol levels and as reduced risk of CVD in a large-scale human study 
[315].  Despite the established function of NPC1L1 in intestinal cholesterol 
absorption, the transcriptional regulation of NPC1L1 has not been fully 
understood.  Our results suggest that PXR is an important regulator of NPC1L1 
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transcription.  PXR can directly bind to a DR-4 motif in human NPC1L1 
promoter and stimulate NPC1L1 expression upon ligand activation.  Thus, PXR-
mediated NPC1L1 up-regulation may contribute to the TBC and other ligand-
induced hypercholesterolemia.  
 Whereas NPC1L1 plays an essential role in intestinal cholesterol 
absorption, another PXR-regulated transporter, CD36, mediates enterocyte 
uptake of fatty acids, which are then converted to triglycerides for transport into 
chylomicrons [282, 309].  We and others previously reported that activation of 
PXR induces CD36 expression and increases lipid accumulation in the liver 
[114], intestine [265], and macrophage [177].  In addition, activation of intestinal 
PXR can also induce the expression levels of several enzymes involved in 
intestinal lipid transportation and chylomicron secretion including diacylglycerol 
acyltransferase 1 and 2 [265].  Therefore, the functions of PXR in intestinal lipid 
homeostasis are complex, and further studies are needed to define the precise 
mechanisms through which intestinal PXR modulates lipid homeostasis in 
animal models as well as in humans.  
 It is intriguing that TBC can only activate intestinal PXR but not hepatic 
PXR.  Several tissue-specific PXR ligands have been identified [265, 267, 316].  
For example, rifaximin, a nonsynsynthetic antibiotic, has been shown to be a 
potent intestine-specific PXR ligand [316].  The tissue-specific effect of rifaximin 
on intestinal PXR was probably related to its poor absorption as rifaximin 
accumulated in the intestine after oral treatment.  However, the reason that TBC 
cannot activate hepatic PXR is unlikely due to poor absorption by the intestine 
as TBC was unable to activate hepatic PXR even after ip delivery.  Further, TBC 
treatment did not affect PXR activity in HepaRG and HepG2 cells in vitro.  It is 
possible that hepatic cells can rapidly catalyze TBC.  Further studies, including 
development of appropriate HPLC-tandem mass spectrometry assays and 
examination of TBC metabolites in vivo and in vitro, will be required to elucidate 
the detailed mechanisms underlying the tissue-specific effects of TBC and 
similar chemicals.  In addition, we previously demonstrated that tocotrienols, 
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members of the vitamin E family, show tissue-specific induction of PXR target 
genes, particularly CYP3A4 [267]. Tocotrienols can up-regulate expression of 
CYP3A4 in human primary hepatocytes but not in LS180 cells.  Nuclear 
receptor co-regulators play critical roles in nuclear receptor activation and are 
also involved in the mechanisms underlying the divergent activities of selective 
estrogen receptor modulators [317, 318].  We found that NCoR is expressed at 
different levels in intestinal LS180 cells and primary hepatocytes and that 
tocotrienols can only partially disrupt the interaction of unliganded PXR and 
NCoR in LS180 cells [267].  Therefore, it is plausible the coregulator difference 
between liver and intestine may contribute to the tissue-specific effects of TBC. 
 A fundamental question about all EDC studies is whether low-dose 
exposure to EDCs can influence human endocrine functions and cause adverse 
effects.  Currently, there is little information about human exposure to TBC.  The 
dose of 10 mg/kg/d TBC used in the present study to treat animals was based 
on human exposure to other plasticizers such as DEHP, DnBP, and ATBC.  A 
retrospective human biomonitoring study of German adults aged 20 to 29 years 
showed median daily intakes for DnBP and DEHP of 7 and 4 mg/kg BW/day, 
respectively.  Fourteen percent of subjects showed DnBP intakes above the 
tolerable daily intake value of 10 mg/kg BW/d set by the European Food Safety 
Authority [319, 320].  Patients taking drugs containing another citrate ester 
plasticizer, ATBC, may be exposed to as much as 20 mg ATBC daily [308].  The 
10 mg/kg BW/d TBC dose used in our study was also significantly lower than 
concentrations experimentally used for DEHP (1000 mg/kg BW/d) and DnBP 
(2000 mg/kg BW/d) to treat mice in some studies [293, 321].  We have also 
examined whether lower TBC concentrations can activate PXR in vivo by testing 
2 lower doses, 2.5 and 5 mg/kg/d, but neither dose activated PXR.  Therefore, 
the 10 mg/kg/d dose used in this study is close to the lower limit of the TBC 
concentration that activates PXR in vivo.  Considering the wide use TBC in 
consumer products (e.g., plastic wrap, toys, and drugs), we believe that the 
dose, which was sufficient to activate PXR activity and cause adverse effects in 
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vivo, was reasonable.  It would be interesting to measure the internal TBC 
concentrations in human samples and correlate internal TBC concentrations to 
plasma lipid levels in the future.  Such information would provide important 
insights about the relationship of EDC exposure and disease outcomes in 
humans. 
 In addition to TBC, we and others have identified many other 
environmentally significant chemicals (e.g. BPA, bisphenol B, and DEHP) as 
PXR agonists.  Further, we recently demonstrated that certain EDCs can 
synergistically activate human PXR [179].  The synergism between different 
EDCs supports the need to include mixtures for future in vitro and in vivo 
studies, which may have important implications for environmental chemical risk 
assessment.  In addition to CVD, activation of PXR has been shown to induce 
tumor aggressiveness in humans and mice [322].  Further studies are needed to 
investigate whether TBC-mediated intestinal PXR activation can induce 
tumorigenesis in animal models.   
 In summary, we have demonstrated that the phthalate substitute 
plasticizer TBC is potent agonist of PXR.  Of particular interest is the finding that 
TBC activated intestinal PXR but did not affect hepatic PXR activity.  
Nevertheless, activation of intestinal PXR by TBC was sufficient to increase 
plasmas cholesterol levels in mice.  We then identified the intestinal cholesterol 
transporter NPC1L1 as a direct transcriptional target of PXR and found that 
activation of PXR increased cholesterol uptake by intestinal cells.  These 
findings demonstrate a previous unrecognized role of PXR in the regulation of 
intestine lipid homeostasis.  Findings from this study will hopefully stimulate 
further investigations of phthalate substitute plasticizers, in particular, the 
mechanisms by which TBC and other chemicals activate PXR, the tissue-
specific TBC activation of PXR, and PXR regulation of intestinal lipid 
homeostasis.  Activation of PXR should be taken into consideration for future 
risk assessment of phthalate substitute plasticizers and related environmental 
chemicals.
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Table 3.1 Primer sequences for QPCR and ChIP 
Genes Primer sequences Genes Primer sequences 
mCYP3A11 
 
5’-CAGCTTGGTGCTCCTCTACC-3’ 
5’-TCAAACAACCCCCATGTTTT-3’ 
hCYP3A4 
 
5’-GGCTTCATCCAATGGACTGCATAAAT-3’ 
5’-TCCCAAGTATAACACTCTACACAGACAA-3’ 
mGSTA1 
5’-CAGCCTGGCAGCCAGAGA-3’ 
5’-TCTGTGGCTCCATCAATGCA-3’ 
hUGT1A1 
5’-TGCTCATTGCCTTTTCACAG-3’ 
5’-GGGCCTAGGGTAATCCTTCA-3’ 
mMDR1a 
5’-CCCCCGAGATTGACAGCTAC-3’ 
5’-ACTCCACTAAATTGCACATTTCCTTC-3’ 
hMDR1a 
5’-CCCATCATTGCAATAGCAGG-3’ 
5’-GAGCATACATATGTTCAAACTTC-3’ 
mCD36 
5’-CAGTCGGAGACATGCT-3’ 
5’-CTCGGGGTCCTGAGTT-3’ 
hNPC1L1 
5’-CTGGTATCACTGGAAGCGAGT-3’ 
5’-CACGCGGGTCACATTGATGA-3’ 
mNPC1L1 
5’-TTGCCTTGACCTCTGGCTTAG-3’ 
5’-AGGGCGGATGAATCTGTGC-3’ 
hGAPDH 
5’-GGCCTCCAAGGAGTAAGACC-3’ 
5’-AGGGGAGATTCAGTGTGGTG-3’ 
mABCG5 
5’-TGCCCATTCCTTTAAAAATCC-3’ 
5’-GATGAACTGGACCCCTTGG-3’ 
hCYP3A4 
(ChIP) 
5’-TTGGACTCCCCAGTAACATTG-3’ 
5’-TGCATGGAGCTTTCCTGC-3’ 
mABCG8 
5’-GTAGCTGATGCCGATGACAA-3’ 
5’-GGGGCTGATGCAGATTCA-3’ 
hNPC1L1 
(ChIP) 
5’-TTGTGGTCAGGTGCAATGGCTCATG-3’ 
5’-GTGCCACAATCTTGGCTCACTGCA-3’ 
mGAPDH 
5’-AACTTTGGCATTGTGGAAGG-3’ 
5’-GGATGCAGGGATGATGTTCT-3’ 
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Figure 3.1 Activation of PXR by phthalates and phthalate substitute 
plasticizers. 
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Figure 3.1 Activation of PXR by phthalates and phthalate substitute 
plasticizers. 
(A)  LS180 cells were cotransfected with full-length human PXR and a 
CYP3A4-luciferase reporter. Cells were treated with DMSO vehicle, 
TBC, DEHP, ATBC, ATEC, DiNP, TEC, DnBP, DiBP, and DEP at the 
indicated concentrations for 24 hours. (B)  LS180 cells were 
cotransfected with a GAL4 reporter and a series of GAL4 DBD-nuclear 
receptor ligand- binding domain constructs. Cells were treated with 
DMSO vehicle or 10 µM TBC for 24 hours. CAR, constitutive androstane 
receptor; ERα, estrogen receptor α. (C and D)  LS180 cells were 
cotransfected with a GAL4 reporter, VP16-hPXR, and expression vector 
for GAL4 DBD or GAL4 DBD linked to the receptor interaction domains 
of PXR coactivators (GAL-SRC1 or GAL-PBP) (C) or PXR corepressors 
(GAL-SMRT or GAL-NCoR) (D).  Cells were treated with DMSO vehicle, 
TBC, or RIF at the indicated concentrations for 24 hours.  Data are 
shown as fold induction of normalized luciferase activity compared with 
that for DMSO treatment and represent the means from triplicate 
experiments.  Results are presented as mean ± SEM. 
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Figure 3.2  TBC activates intestinal PXR but does not affect hepatic 
PXR activity. 
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Figure 3.2 TBC activates intestinal PXR but does not affect hepatic 
PXR activity. 
(A)  Human HepaRG hepatoma cells and LS180 intestinal cells were 
treated with control medium or medium containing 10 μM TBC or RIF.  
Total RNA was isolated, and gene expression levels of human PXR 
target genes were analyzed by qPCR (n=3; **P<0.01, ***P<0.001; 
assessed by one-way ANOVA).  (B)  Primary hepatocytes and 
enterocytes were isolated from WT mice and were incubated with 
control medium or medium containing 10 µM TBC or PCN.  Total RNA 
was isolated, and gene expression levels of mouse PXR target genes 
were analyzed by qPCR (n=3; *P<0.05, **P<0.01, ***P <0.001; 
assessed by one-way ANOVA).  (C)  Eight-week-old WT mice were 
treated with vehicle or 10 mg/kg BW TBC or PCN daily by oral gavage 
for 1 week. Total RNA was isolated from liver and small intestine.  
Expression levels of PXR target genes, CYP3A11, GSTA1, and 
MDR1a, were measured by qPCR (n = 4-5; *P<0.05, **P<0.01, and 
***P<0.001 assessed by one-way ANOVA).  Results are presented as 
mean ± SEM. 
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Figure 3.3 TBC increases PXR reporter activity in human intestinal 
cells but not in hepatic cells. 
(A and B) Human hepatic HepG2 cells (A) or intestinal LS180 cells (B) were 
cotransfected with full-length hPXR and a CYP3A4-luc reporter.  Cells were 
treated with TBC or RIF at the indicated concentrations for 1, 3, or 6 h.  Data 
are shown as fold induction of normalized luciferase activity compared with 
DMSO treatment and represent the mean of triplicate experiments.  Results 
are presented as mean ± SEM. 
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Figure 3.4 TBC does not activate intestinal PXR at 2.5 or 5 mg/kg/day 
doses. 
Eight-week-old WT mice were treated with vehicle control, 2.5, or 5 mg/kg BW 
of TBC daily by oral gavage for 1 week.  Expression levels of PXR target 
genes, CYP3A11 (A), GSTA1 (B), and MDR1a (C) in the proximal intestine 
was measured by QPCR (n=5).  Results are presented as mean ± SEM. 
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Figure 3.5 Intraperitoneally delivered TBC does not alter hepatic PXR 
signaling. 
Eight-week-old WT mice were treated with vehicle control or 10 mg/kg BW of 
TBC daily via intraperitoneal (IP) deliver for 1 week.  Expression levels of PXR 
target genes, CYP3A11, GSTA1, and MDR1a in liver were measured by 
QPCR (n=5).  Results are presented as mean ± SEM. 
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Figure 3.6 Exposure to TBC induces hyperlipidemia in WT but not in 
PXR-/- mice.  
(A)  Eight-week-old male WT mice were treated with vehicle or 10 
mg/kg BW TBC or PCN daily by oral gavage for 1 week.  Plasma total 
cholesterol levels and lipoprotein levels (LDL, VLDL, and HDL) were 
measured (n = 6-10; *P<0.05 and ***P<0.001; assessed by one-way 
ANOVA). (B)  Eight-week-old male PXR-/- mice were treated with 
vehicle or 10 mg/kg BW TBC daily by oral gavage for 1 week.  Plasma 
total cholesterol levels and lipoprotein levels (LDL, VLDL, and HDL) 
were measured (n=4-5).  Results are presented as mean ± SEM. 
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Figure 3.7 Activation of PXR by TBC stimulates the expression of the 
intestinal cholesterol transporter NPC1L1 in mice and increases 
cholesterol uptake by murine intestinal cells. 
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Figure 3.7 Activation of PXR by TBC stimulates the expression of the 
intestinal cholesterol transporter NPC1L1 in mice and increases 
cholesterol uptake by murine intestinal cells. 
(A) WT and PXR-/- mice were treated with vehicle or 10 mg/kg BW TBC 
daily for 1 week.  Total RNA was isolated from small intestine, and the 
expression levels of indicated genes were measured by qPCR (n=5-6; 
*P<0.05; assessed by student’s t-test). (B)  Western blot analysis of 
intestinal NPC1L1 protein levels in control or TBC-treated WT and 
PXR-/- mice.  The top band indicates glycosylated NPC1L1. (C and D)  
Primary enterocytes isolated from WT and PXR-/- mice were treated 
with vehicle control or 10 µM TBC for 3 hours.  NPC1L1 mRNA levels 
were measured by qPCR (n=3; ***P<0.001; assessed by student’s t-
test), and protein levels were analyzed by Western blot (D). (E)  Primary 
enterocytes isolated from WT and PXR-/- mice were treated with vehicle 
control or 10 µM TBC for 2 hours, followed by incubation with [3H]-
cholesterol and TBC for 1 hour.  The cellular cholesterol uptake was 
then measured (n=3; *P<0.05, **P<0.01; assessed by two-way 
ANOVA).  Results are presented as mean ± SEM. 
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Figure 3.8 Both TBC and PCN can stimulate intestinal NPC1L1 
expression in vivo.  
Eight-week-old WT mice were treated with vehicle control, 10 mg/kg BW of 
TBC, or PCN daily by oral gavage for 1 week.  Expression levels of intestinal 
PXR were measured by QPCR (n=5, *P<0.05, ***P<0.001; assessed by one-
way ANOVA).  Results are presented as mean ± SEM. 
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Figure 3.9 TBC promotes cholesterol uptake by human intestinal 
cells. 
(A)  Western blot analysis of PXR levels in human intestinal LS180 
cells transfected with control siRNA or siRNA against PXR (siPXR). 
(B)  Control or siPXR LS180 cells were treated with 10 µM TBC for 3 
hours, and NPC1L1 expression was analyzed by qPCR (n=3; 
***P<0.001; assessed by student’s t-test). (C)  Control or siPXR 
LS180 cells were treated with 10 µM TBC for 2 hours followed by 
incubation with [3H]-cholesterol and TBC for an additional 1 hour. The 
cellular cholesterol uptake was then measured (n=3; *P<0.05, 
**P<0.01; assessed by two-way ANOVA).  Results are presented as 
mean ± SEM. 
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Figure 3.10 NPC1L1 is a direct transcriptional target of PXR 
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Figure 3.10 NPC1L1 is a direct transcriptional target of PXR. 
(A) In vitro translated human PXR and RXR, as indicated, were incubated 
with 32P-labeled NPC1L1/DR-4 or CYP3A4/ER-6 probes and analyzed by 
EMSA.  Ten- or 25-fold excess of unlabeled NPC1L1/DR-4 or 
CYP3A4/ER-6 probes were used for the competition experiments.  (B) 
PXR/RXR proteins were incubated with 2 different anti-PXR antibodies, 
goat anti-PXR (1) or rabbit anti-PXR antibodies (2) for 1 hour before the 
addition of the 32P-labeled NPC1L1/DR-4 probe. (C) PXR/RXR proteins 
were incubated with 32P-labeled WT NPC1L1/DR-4 or mutated DR-4 (DR-
4m1 and DR-4m2) probes and were analyzed by EMSA.  (D) LS180 cells 
were treated with 10 µM TBC for 3 hours, and ChIP analysis was 
performed to determine the recruitment of PXR onto the NPC1L1 or 
CYP3A4 promoter. (E–G) LS180 cells were cotransfected with full-length 
hPXR and RXR expression plasmids along with a synthetic reporter 
containing 4 copies of NPC1L1/DR-4 element (E) or mutated DR-4 
elements, DR-4m1 (F) and DR-4m2 (G). Cells were then treated with 
DMSO vehicle (control), TBC, or RIF at the indicated concentrations for 24 
hours. Data are shown as fold induction of normalized luciferase activity 
compared with that for DMSO treatment and represent the means for 
triplicate experiments.  Results are presented as mean ± SEM. 
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Chapter 4: Targeting IKKβ in Adipocyte Lineage Cells for Treatment of 
Obesity and Metabolic Dysfunctions 
4.1 Introduction 
 Obesity is a rapidly growing epidemic representing a serious threat to the 
health of populations in an increasing number of countries and the number of 
overweight and obese individuals are expected to increase to over half of the 
world’s population by 2030 [323].  There is an urgent need to understand the 
mechanisms underlying obesity and obesity-related metabolic diseases.  
Obesity is associated with both increased adipocyte size (hypertrophy) and 
adipocyte number (hyperplasia).  Adipocyte number is a major determinant of 
fat mass in adults [252, 324] and approximately 10% of the body’s adipocytes 
are re-generated annually at all adult ages [324].  Obese individuals also have a 
significantly greater number of adipocytes added per year than lean individuals 
[252, 324]; suggesting that regulation of new adipocyte production is a potential 
therapeutic target to treat obesity.  However, the mechanisms underlying 
nutritionally induced hyperplasia remain largely unknown.   
 It is generally accepted that obesity is associated with a state of chronic 
low-grade inflammation that is a major contributor to type 2 diabetes and 
atherosclerosis [325, 326].  Many inflammatory pathways that contribute to the 
pathogenesis of insulin resistance and atherosclerosis are regulated by the 
transcriptional factor NF-κB, a master regulator of the innate and adaptive 
immune responses [238].  IκB kinase (IKK) β is the predominant catalytic 
subunit of the IKK complex and is required for activation of NF-κB by 
inflammatory mediators in the canonical or classical activation pathway [238, 
239, 255, 271, 327].  It has been well established that overnutrition can lead to 
IKKβ activation in vitro and in vivo [327-329], and recent studies have implicated 
IKKβ as a key molecular link between obesity, inflammation and metabolic 
disorders [325, 330, 331].  For example, diet-induced insulin resistance has 
been associated with the activation of IKKβ/NF-κB in multiple tissues including 
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liver, adipose tissue, and brain [241, 244, 247-249, 327, 332].  Deletion of IKKβ 
in the liver improved diet-induced insulin resistance, and deficiency of IKKβ in 
myeloid cells rendered global insulin sensitivity upon high-fat (HF) feeding [244].  
By contrast, constitutive activation of IKKβ in the liver caused systemic insulin 
resistance [247].  Activation of IKKβ in the hypothalamus has also been linked 
to obesity and metabolic disease [249, 333].   
 We have recently demonstrated that IKKβ functions in smooth muscle 
cells (SMCs) to regulate vascular inflammatory responses and atherosclerosis 
development [255].  Of particular interest is that many adipocyte precursor cells 
express SMC markers and ablation of IKKβ blocked adipocyte differentiation in 
vitro and in vivo, suggesting that IKKβ functions in adipocyte precursor cells to 
regulate adipose tissue development [255].  In the present study, we explored a 
novel and more efficient pharmacological approach to inhibit IKKβ in vivo by 
using antisense oligonucleotides (ASOs) and found that ASO-mediated IKKβ 
knockdown ameliorated diet-induced obesity and metabolic disorders in mice.  
Interestingly, IKKβ ASO also inhibited high-fat diet (HFD)-elicited adipocyte 
differentiation and reduced adipose tissue growth.  As the functions of IKKβ in 
regulating adipogenesis and adipose tissue development has not been fully 
understood, we then selectively deleted IKKβ in the white adipose lineage in 
mice to further elucidate the role of adipose progenitor cell IKKβ signaling in 
obesity and metabolic function.  Deficiency of IKKβ decreased adipogenesis 
and systemic inflammation elicited by HF feeding, leading to resistance to diet-
induced obesity and insulin resistance.  Lastly, inhibition of IKKβ in human 
adipose stem cells also blocked adipogenesis in these cells.  Our results 
establish IKKβ as an important regulator of adipogenesis and adipose tissue 
development.  Overnutrition-mediated IKKβ activation may serve as an initial 
signal that triggers adipose progenitor cell differentiation in response to 
consumption of a HFD.  Inhibition of IKKβ with antisense therapy may present 
as a novel therapeutic approach to combat obesity and metabolic dysfunctions. 
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4.2 Materials and Methods 
4.2.1 Animals and Diet 
 For the IKKβ ASO studies, 8-week-old male C57BL/6 mice (Jackson 
Laboratory) were fed a normal chow diet (ND) or a Western-type HFD (21.2% 
fat, 0.2% cholesterol; Harlan Teklad) and received biweekly intraperitoneal 
injections of either a nontargeting control ASO (5’-
CCTTCCCTGAAGGTTCCTCC-3’) or an IKKβ targeted ASO (5’-
GCAGACTCTCATCCTCCGTC-3’) for 8 weeks at a dose of 25 mg/kg body 
weight/week. The 20-mer phosphorothioate ASOs were designed to contain 2’-
O-methoxyethyl groups at positions 1 to 5 and 15 to 20, and were generated 
and purified by Ionis Pharmaceuticals (Carlsbad, CA).  For cell lineage analysis, 
PDGFRβ-Cre mice [334] were crossed with Rosa26lacZ reporter mice [335] to 
generate PDGFRβ-Cre/Rosa26lacZ mice.  To delete IKKβ in adipocyte lineage 
cells, mice containing loxP-flanked IKKβ alleles (IKKβF/F) [255, 336] was 
crossed with PDGFRβ-Cre transgenic mice [334] to generate PDGFRβ-
Cre/IKKβF/F mice (termed as IKKβΔPDGFRβ).  For obesity studies, 4-week-old 
male IKKβF/F and IKKβΔPDGFRβ littermates were fed a normal chow diet (ND) or a 
HFD for 16 weeks until euthanization at 20 weeks of age.  For the BrdU studies, 
4-week-old male IKKβF/F and IKKβΔPDGFRβ littermates were intraperitoneal 
injected with 50 mg/kg body weight/day BrdU (TCI America) and mice were 
placed on a HFD for 7 days prior to euthanization.  All animals were housed in a 
specific pathogen-free environment with a light-dark cycle, under a protocol 
approved by the University of Kentucky Institutional Animal Care and Use 
Committee. 
4.2.2 Metabolic Analysis 
 Body weight was measured weekly and body composition was measured 
by NMR spectroscopy (Echo MRI).  Intraperitoneal glucose tolerance test (GTT) 
and insulin tolerance test (ITT) were performed, as previously described [255].  
Plasma insulin was measured using a Rat/Mouse Insulin ELISA kit (Millipore).  
Plasma TNFα levels were measured by a mouse TNFα ELISA kit (BioLegend). 
Plasma cytokine levels were measured by a mouse cytokine multiplex assay kit 
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and a BioPlex 200 system (Bio-Rad Laboratories).  For insulin stimulation 
studies, 20-week-old male IKKβF/F and IKKβΔPDGFRβ littermates or ASO-treated 
C57BL/6 mice were injected with insulin (0.35 U/kg body weight) into the inferior 
vena cava [337].  After 5 minutes, mice were euthanized and tissues were 
collected for protein isolation and Western blot analysis.  
4.2.3 Glucose Uptake in Adipose Tissue Explants 
 Glucose uptake in adipose tissue explants was achieved following a 
previously described protocol [337].  Briefly, HFD-fed IKKβF/F and IKKβΔPDGFRβ 
littermates were fasted at the beginning of the light cycle for 7 h and epiWAT 
was collected. The tissue explants were minced into small pieces and incubated 
for 2 h in 1% BSA-Krebs-Ringer Bicarbonate (KRB) buffer.  The tissues were 
washed and then incubated with saline or 17 nm insulin for 40 min at 37̊C.  After 
the insulin incubation, 1 μCi [3H]-2-deoxyglucose (Perkin Elmer) was added to 
the buffer and incubated for another 20 min at 37̊C and then the tissues were 
washed with cold 1% BSA-KRB and the weight of the tissues were measured 
and recorded.  The explants were then added to 1 ml 1N NaOH and incubated 
for 1 h at 65̊C. Half of the cell lysate was then used to measure the amount of 
radioactivity in a scintillation counter and a portion was used to measure the 
protein concentration.  
4.2.4 MRI Analysis and Data Segmentation 
 HFD-fed IKKβF/F and IKKβ∆PDGFRβ littermates were imaged on a 7T 
CliniScan MRI (Bruker, Ettlingen, Germany) using a 2 point Dixon technique and 
a 72 mm diameter circularly polarized transmit receive coil at the Magnetic 
Resonance Imaging and Spectroscopy Center at the University of Kentucky. 
Anesthesia was induced and maintained using 1-2 % isoflurane in oxygen at a 
rate of 1.0 L/min. Respiration and temperature were monitored. Temperature 
was maintained between 36-37 °C using a water bath and tubing. Image data 
sets including a fat only and water only image were obtained using a dual echo 
Flash sequence with TR 12ms, TE 2ms and 3.5ms; flip 15°, FOV 80mm x 
57.5mm x 31.7, and resolution 0.18mm x 0.18 mm x 0.18 mm. The fat and 
water images were generated from the in and out of phase images using 
Siemens Syngo software. FSL software was used for image analysis [338]. The 
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fat image was resampled to 1.8mm x 0.18mm x 0.18mm using FSL. The 
visceral cavity was segmented out manually. The total fat volume was 
calculated by taking a histogram from the fat only image of the visceral cavity 
and including voxels that were greater than 80% of the fat peak. 80% was 
chosen to include adipose tissue and exclude voxels from the liver [339]. 
4.2.5 Histological Analysis 
 For hematoxylin and eosin staining of liver, tissues were fixed in 4% 
neutral buffered formalin and embedded in paraffin. 5 μm tissue sections were 
stained with hematoxylin and eosin following standard protocols. Oil-Red O 
staining of hepatic neutral lipids was performed as previously described [255]. In 
brief, livers were embedded in OCT and sectioned at 10 μm. Liver sections 
were then dried, fixed in 4% PFA, incubated for 5 min in 60% isopropanol then 
incubation in 0.3% Oil-Red O (Sigma) for 20 min.  The livers were 
counterstained with hematoxylin and mounted with glycerol-gelatin (Sigma).   
4.2.6 Immunohistochemistry 
 Immunohistochemistry was performed on 5 μm adipose tissue sections 
embedded in paraffin. For F4/80 staining, rehydrated sections were subjected to 
antigen retrieval by heating in antigen unmasking solution (Vector Laboratories). 
Slides were cooled and treated with 5% BSA, 3% hydrogen peroxide, and 
avidin/biotin blocking kit (Vector Laboratories). Sections were incubated with 
anti-F4/80 (Serotec) or rat IgG (negative control; Jackson Immunoresearch) 
antibodies at 4̊C overnight. Sections were then incubated with biotinylated anti-
rat IgG (Vector) for 1 h, VECTASTAIN ABC reagent (Vector Laboratories) for 30 
min at room temperature and visualized by the avidin-biotin-complex method 
using the ImmPACT DAB Peroxidase Substrate Kit (Vector Laboratories). 
Sections were then mounted with glycerol-gelatin. For BrdU staining, sections 
were incubated with anti-BrdU (Life Sciences; B35130) antibodies for 30 min 
using a M.O.M. Immunodetection kit (Vector Laboratories) per manufacturer’s 
instructions. Sections were then counterstained with DAPI.  Percent BrdU-
positive cells were calculated by dividing BrdU-positive cells by DAPI-positive 
cells. Two view fields were randomly selected from each mouse for calculation 
of BrdU-positive cells.   
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4.2.7 3T3L1 Cell Differentiation and Transfection Assays 
 3T3-L1 cells were obtained from American Type Culture Collection.  For 
adipocyte differentiation assays, confluent 3T3-L1 cells were exposed to 
differentiation media (high-glucose DMEM supplemented with 10% FBS and 
differentiation cocktail including 1 ug/ml insulin, 1 μM dexamethasone, and 0.5 
mM isobutylmethylxanthine[255]. Forty eight hours post-induction, the cells were 
maintained in high-glucose DMEM containing insulin (1ug/ml) and 10% FBS 
until they were ready for analysis [255].  The Clustered regularly interspaced 
short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) 
method was used to delete IKKβ in 3T3-L1 cells [340].  Briefly, annealed oligos 
(5-CACCGGCAGCCGTTGGGGCCATACT-3’) were cloned using BsmBI 
digestion into the lentiCRISPRv2 plasmid (generously provided by Dr. Feng 
Zhang, Addgene plasmid #52961).  The lentivirus was prepared in 293T cells 
and the viral supernatant was then used to infect 3T3-L1 cells.  Cells were 
selected with puromycin and single clones were expanded and screened by 
western blot.  Further, the Transgenomic Surveyor Mutation Detection Kit 
(Fisher Scientific) was used to verify genomic mutations within the IKKβ locus.  
For transfection assays, 3T3-L1 cells were transfected with the TOP-flash 
reporter [341] and β-gal control plasmid [342] by electroporation using Amaxa 
Cell Line Nucleofector kit V (Lonza).  Two days post-transfection, cells were 
lysed and luciferase and β-gal values were measured as previously described 
[299, 342].  We would like to thank Dr. Brett Spear (University of Kentucky) for 
the TOP-flash reporter. 
4.2.8 Adipose SV Cell Isolation and Differentiation 
 Adipose SV cells and mature adipocytes were isolated as previously 
described [255].  The SV cells were used for RNA and protein isolation or 
cultured in 12-well plates for differentiation.  For differentiation assays, SV cells 
were induced by high-glucose DMEM containing dexamethasone (1 μM), 
isobutylmethylxanthine (0.5 mM), insulin (10 μg/ml), rosiglitazone (1 μM), and 
10% FBS until they were ready for analysis [255]. 
4.2.9 RNA Isolation and QPCR Analysis  
 Total RNA was isolated from mouse tissues or cells using TRIzol Reagent 
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(Life Technologies) and QPCR was performed using gene-specific primers and 
the SYBR Green PCR kit (Life Technologies) as previously described [179, 
299]. The sequences of primer sets used in this study are listed in Table 4.1. 
4.2.10 Western Blot Analysis 
 Western blot was performed as previously described [255, 271].  Briefly, 
protein was isolated from cells or tissues with homogenization in RIPA buffer 
containing complete mini protease inhibitor cocktail (Roche). Protein 
concentrations were determined by the Pierce BCA protein assay kit (Thermo 
Fisher Scientific). Anti-IKKβ, anti-IKKα, anti-Smurf2, and anti-TFIIB were 
purchased from Cell Signaling Technology; anti-β-catenin and anti-β-actin were 
purchased from Sigma-Aldrich.  For immunoprecipitation experiments [255], 
control or IKKβ knockdown cells, or adipose SV cells, were incubated with 100 
nM of PS-341 for 4 h. The whole-cell lysates were isolated, incubated with anti-
β-catenin antibody overnight at 4̊ C, and then incubated with Protein A Agarose 
beads (Roche) for another 5 h. The samples were washed and analyzed by 
Western blot using anti-ubiquitin monoclonal antibodies [255].  
4.2.11 Human Subjects and ADHASC Isolation 
 Human adipocytes were derived from the differentiation of adult derived 
human adipocyte stem cells (ADHASC) as described previously [343, 344].  The 
adipose tissue was from a collagenase digestion of the lipoaspirate of patients 
undergoing liposuction of subcutaneous fat.  These patients were generally 
young, healthy women undergoing cosmetic procedures, and this method of 
collection was approved by the University of Kentucky Institutional Review 
Board.  Differentiation was induced using differentiation media as previously 
described [343, 344].  At least 80 to 90% of the cells developed lipid droplets in 
7-10 days. 
4.2.12 Quantification of Mitochondrial DNA 
Genomic DNA was extracted from subcutaneous WAT by the DNAeasy Blood 
and Tissue kit (Qiagen).  QPCR was performed on COX1 mitochondrial DNA 
and normalized to a nuclear 28S sequence [345, 346].  The sequences of 
primer sets used in this study are listed in Supporting Information Table 4.1. 
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4.2.13 Statistical Analysis 
 All data are presented as the mean ± SEM. Individual pairwise 
comparisons were analyzed by two-sample, two-tailed Student’s t-test unless 
otherwise noted, with P<0.05 was regarded as significant. Two-way analysis of 
variance (ANOVA) was used when multiple comparisons were made followed 
by a Bonferroni multiple comparisons test.  N numbers and the statistical tests 
are listed in figure legends.  All statistics were done using SigmaPlot 13.0. 
 
4.3 Results 
4.3.1 ASO-Mediated IKKβ Knockdown Protects Mice 
from Diet-Induced Obesity 
 We recently demonstrated that IKKβ inhibitors can inhibit adipocyte 
differentiation in vitro and ameliorate diet-induced adiposity in mice [255].  To 
explore novel and more efficient pharmacological approaches for IKKβ 
inhibition, we utilized second-generation ASO targeting technology [347] and 
investigated the impact of IKKβ ASO treatment on diet-induced obesity and 
metabolic disorders.  Subcutaneous delivery of ASO has been shown to reach a 
variety of tissues including liver and adipose tissue [348, 349].  Indeed, we 
found that IKKβ ASO can efficiently decrease IKKβ gene expression in multiple 
tissues including liver, skeletal muscle, and white adipose tissue (WAT) at a 
relatively low dose, 25 mg/kg BW/week (Fig. 4.1, A).  Interestingly, IKKβ mRNA 
levels were not significantly altered in brown adipose tissue (BAT) by IKKβ ASO 
treatment at this dose.  Western blot analysis also confirmed the specific and 
efficient IKKβ knockdown in tissues including liver and WAT as IKKα protein 
levels were not affected by IKKβ ASO treatment (Fig. 4.1, B).   
 We next determined whether IKKβ ASO treatment can ameliorate diet-
induced obesity.  Groups of 8-week-old wild-type male mice were fed a ND or a 
HFD and were treated with control ASO or IKKβ ASO for 8 weeks (Fig. 4.1, C).  
HF-feeding increased body weight in mice treated with both control and IKKβ 
ASOs.  However, IKKβ ASO treatment significantly decreased HFD-induced 
body weight gain and adiposity.  While lean mass was slightly but significantly 
increased in IKKβ ASO-treated mice, fat mass was decreased by 45% in HFD-
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fed mice treated with IKKβ ASOs (Fig. 4.1, D).  IKKβ ASO was able to decrease 
both subcutaneous (sub) WAT and visceral WAT including epididymal (epi) and 
retroperitoneal (retro) fat pads in HFD-fed mice as compared with littermate 
controls (Fig. 4.1, E).   
4.3.2 IKKβ ASOs Improves Insulin Sensitivity and 
Reverses Hepatic Steatosis in Obese Mice 
 Obesity is frequently associated with metabolic disorders such as insulin 
resistance and hepatic steatosis.  We next investigated whether IKKβ ASO 
treatment can protect HFD-fed mice from these disorders.  IKKβ ASO-treated 
mice had decreased fasting plasma glucose and insulin concentrations as 
compared with control mice (Fig. 4.1, F), suggesting improved diabetic 
phenotype.  Upon glucose and insulin tolerance test, IKKβ ASO-treated mice 
had improved glucose tolerance and showed an increased hypoglycemic 
response to the injected insulin (Fig. 4.1, G).  To further assess the impact of 
IKKβ ASO treatment on insulin signaling, HFD-fed mice were injected with 
insulin prior to euthanization and phosphorylation of Akt was analyzed in 
multiple tissues.  IKKβ ASO was able to enhance phosphorylation of Akt in 
response to insulin in liver, skeletal muscle and WAT (Fig. 4.1, H).  While 
hepatic IKKβ signaling has been demonstrated to contribute to obesity-
associated insulin resistance [244, 247], the role of adipose IKKβ signaling in 
the regulation of insulin sensitivity has not been well-defined.  We then 
performed adipose glucose uptake assays. Interestingly, adipose tissue 
explants from IKKβ ASO-treated mice had elevated glucose uptake in the 
absence of insulin and insulin stimulation further enhanced glucose update by 
adipose tissues (Fig. 4.1, I).  Therefore, the enhanced Akt phosphorylation and 
increased glucose uptake in adipose tissue likely contribute to the improved 
insulin sensitivity in IKKβ ASO-treated mice.  Further, HF feeding also caused 
lipid accumulation and hepatic steatosis in control mice.  However, IKKβ ASO-
treated mice were protected from these detrimental effects (Fig. 4.1, J and K).  
Consistently, hepatic triglyceride and cholesterol contents were significantly 
reduced in IKKβ ASO-treated mice (Fig. 4.1, L).  Collectively, these results 
suggest that pharmacological inhibition of IKKβ by ASO ameliorates obesity-
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associated metabolic disorders in mice.  
4.3.3 IKKβ Regulates Murine Adipocyte Differentiation 
 We next investigated whether IKKβ ASO treatment can also affect IKKβ 
expression in adipocyte precursor cells and affect adipocyte differentiation. 
Indeed, we found that IKKβ expression was decreased in both adipose SV cells 
and mature adipocytes in IKKβ ASO-treated mice (Fig. 4.2, A).  Consistent with 
our previous study [255], ASO-mediated IKKβ knockdown diminished the ability 
of adipose SV cells to differentiate into adipocytes (Fig. 4.2, B).  As expected, 
the expression levels of adipogenic genes including PPARγ, Zfp423, and 
C/EBPs were significantly decreased in epiWAT from IKKβ ASO-treated mice 
(Fig. 4.2, C). Further, IKKβ ASO treatment also decreased the expression of a 
known NF-κB target, Smad ubiquitination regulatory factor 2 (Smurf 2) (Fig. 4.2, 
D).  Smurf2 is an ubiquitin E3 ligase that regulates proteasome-mediated 
degradation of several proteins including β-catenin [255, 350, 351].  
Consistently, ASO-mediated IKKβ knockdown increased nuclear β-catenin 
protein levels in epiWAT (Fig. 4.2, E).  Since Wnt/β-catenin signaling has been 
well defined to inhibit adipogenesis in vitro and in vivo [352, 353], the increased 
Wnt signaling likely contributes to the decreased adipogenesis in IKKβ ASO-
treated mice. 
 To further define the role of IKKβ in adipogenesis, we used the CRISPR-
Cas9 system to delete the IKKβ gene in murine 3T3-L1 preadipocytes (Fig. 4.2, 
F).  We found that deletion of IKKβ almost completely blocked 3T3-L1 cell 
differentiation (Fig. 4.2, G).  Gene expression analysis showed that mRNA 
levels of adipogenic genes and adipocyte markers including PPARγ and 
adiponectin were significantly decreased by IKKβ-deficiency (Fig. 4.2, H). 
Consistently, deletion of IKKβ decreased the expression of Smurf2 (Fig. 4.2, I) 
and increased nuclear β-catenin accumulation (Fig. 4.2, J), leading to increased 
β-catenin activity in these cells (Fig. 4.2, K).  We further confirmed that β-
catenin ubiquitination was inhibited by IKKβ deficiency in 3T3-L1 cells (Fig. 4.2, 
L), suggesting the impact of reduced Smurf2 expression. Taken together, these 
results confirm the important role of IKKβ in adipogenesis and indicate that 
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pharmacological inhibition of IKKβ by ASO can decrease adipogenesis and diet-
induced adiposity.  
4.3.4 Targeted Deletion of IKKβ in the White Adipose 
Lineage 
 Since ASO treatment affects many tissues and cell types, it is not clear 
how significantly the ASO-mediated IKKβ knockdown in adipose progenitor 
contributes to the beneficial effects on obesity and metabolic disorders in mice. 
Compared with other tissues or cell types, the role of IKKβ signaling in adipose 
progenitor cells has not been well-defined.  To investigate the function of IKKβ 
signaling in adipose progenitors, we sought to generate a mouse model that 
selectively lacks IKKβ in white adipose lineage.  Recent studies have identified 
a subset of perivascular cells as adipose progenitors which express multiple 
mural stem cell markers, including platelet-derived growth factor receptor 
(PDGFR) β, α smooth muscle actin (SMA), and NG2 [354].  For example, 
PDGFRβ, a human mesenchymal stem cell (MSC) marker [355], and another 
isoform of PDGFR, PDGFRα have been confirmed to be adipose progenitor 
markers by independent groups [356-359].  Consistently, we also found high 
expression levels of PDGFRβ in adipose SV cells as compared with mature 
adipocytes (Fig. 4.3, A).  We then crossed PDGFRβ promoter-drive Cre mice 
[334] with Rosa26lacZ reporter mice that express β-galactosidase (lacZ) in target 
tissues upon Cre-mediated excision of a “Stop” sequence to generate PDGFRβ-
Cre/Rosa26lacZ mice (Fig. 4.3, B).  While none of the adipose SV cells from 
control Rosa26lacZ mice were lacZ+ cells, many of the adipose SV cells from 
PDGFRβ-Cre/ Rosa26lacZ mice were lacZ+ cells (Fig. 4.3, C).  Staining of the 
white adipose depots and tissue sections also indicated that PDGFRβ-Cre is 
activated in adipose progenitors that give rise to white adipocytes as PDGFRβ 
generated strong lacZ expressed in adipocytes, in addition to the vasculature 
(Fig. 4.3, D and E). Taken together, our results are consistent with previous 
reports [354, 357] and confirm that PDGFRβ is a marker for adipose lineage 
cells. 
 We then deleted IKKβ in adipocyte lineage cells by intercrossing PDGFRβ-
Cre mice with mice containing loxP-flanked IKKβ alleles (IKKβF/F) [255, 336].  
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The resulting PDGFRβ-Cre/IKKβF/F (termed IKKβΔPDGFRβ) mice were viable and 
appeared indistinguishable from their control IKKβF/F littermates.  Western blot 
analysis confirmed the deletion of IKKβ in WAT including epiWAT and subWAT 
but not in BAT, liver, and skeletal muscle (Fig. 4.4, A). As expected, PDGFRβ-
Cre-mediated IKKβ deletion also caused reduced IKKβ expression in adipose 
SV cells of IKKβΔPDGFRβ mice (Fig. 4.4, B). Further, IKKβ deficiency reduced NF-
κB-mediated proinflammatory gene expression in response to LPS in adipose 
SV cells of IKKβΔPDGFRβ mice (Fig. 4.4, C-G), suggesting impaired NF-κB 
activation in these cells. 
4.3.5 Deficiency of IKKβ in Adipocyte Lineage Cells 
Renders Mice Resistant to Diet-Induced Obesity 
 To determine the role of adipose progenitor IKKβ signaling in obesity, 
IKKβF/F and IKKβΔPDGFRβ littermates were fed a normal chow diet (ND) or a HFD 
for 16 weeks.  There were no significant differences in body weight for ND-fed 
mice.  Body weight was significantly increased following HFD-feeding for both 
IKKβF/F and IKKβΔPDGFRβ mice; however, IKKβ deficiency significantly decreased 
diet-induced bodyweight gain in HFD-fed mice (Fig. 4.5, A).  While lean mass 
was not affected by IKKβ deficiency, HFD-fed IKKβΔPDGFRβ mice had 
significantly decreased fat mass as compared with control littermates (Fig. 4.5, 
B).  
 HFD-fed IKKβΔPDGFRβ mice also had decreased visceral adipose pads 
including epididymal and retroperitoneal fat pads.  However, deficiency of IKKβ 
did not affect the size or weight of subWAT and BAT (Fig. 4.5-4.6).  As subWAT 
often undergoes “browning” process which enhances oxidative metabolism and 
protects mice from metabolic dysfunctions [254, 345, 360, 361], we then 
examined whether deficiency of IKKβ affects “browning” of subWAT in these 
mice.  Interestingly, the expression levels of beige or brown adipocyte markers 
as well as mitochondrial function-related genes such as UCP-1 and PGC-1α 
[345, 360, 361] were not affected in subWAT of IKKβΔPDGFRβ mice (Fig. 4.7, A).  
Consistently, IKKβΔPDGFRβ mice also had comparable mitochondrial content in 
subWAT as that of control littermates (Fig. 4.7, B).  MRI analyses confirmed that 
IKKβΔPDGFRβ mice had a significantly decreased volume of visceral adipose 
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tissue but a similar subcutaneous adipose tissue volume as compared with 
IKKβF/F mice under HF feeding conditions (Fig. 4.5-4.6). We next analyzed the 
expression levels of IKKβ and adipose progenitor markers in SV cells isolated 
from subWAT and epiWAT of control mice. Interestingly, IKKβ expression levels 
were significantly higher in visceral SV cells than subcutaneous SV cells.  
Further, the expression levels of adipose progenitor markers such as PDGFRβ 
were much higher in visceral SV cells as compared with subcutaneous SV cells, 
indicating more abundant adipose progenitor cell population in visceral WAT 
(Fig. 4.8).  Collectively, these results demonstrate that PDGFRβ-Cre-driven 
IKKβ deficiency in the white adipose lineage decreases diet-induced obesity 
and visceral adiposity. 
4.3.6 IKKβ-Deficient Mice are Protected From Obesity-
Associated Metabolic Disorders 
 We next investigated whether deficiency of IKKβ also protected mice from 
obesity-associated insulin resistance.  IKKβΔPDGFRβ mice had comparable 
glucose and insulin levels and similar glucose tolerance and insulin tolerance as 
that of IKKβF/F when fed a ND (Fig. 4.9-4.10).  As expected, HF feeding 
increased plasma glucose and insulin levels in both IKKβF/F and IKKβΔPDGFRβ 
mice (Fig. 4.9, A).  Although glucose concentrations were not affected by IKKβ 
deficiency, HFD-fed IKKβΔPDGFRβ mice had significantly decreased insulin 
concentrations as compared with HFD-fed control littermates (Fig. 4.9, A).  
Consistently, IKKβΔPDGFRβ mice also had improved glucose tolerance and insulin 
tolerance as compared with IKKβF/F mice under HF feeding conditions (Fig. 4.9, 
B). PDGFRβ-Cre-mediated IKKβ deletion also enhanced phosphorylation of Akt 
in response to insulin in WAT but not in liver and skeletal muscle (Fig. 4.9, C).  
Further, adipose tissue explants from IKKβΔPDGFRβ mice had significantly 
increased insulin-stimulated glucose uptake compared with that of IKKβF/F mice 
(Fig. 4.9, D).   
 Obesity-associated macrophage infiltration contributes to the development 
of systemic insulin resistance [362]. Although IKKβ expression levels were not 
affected in macrophages of IKKβΔPDGFRβ mice (Fig. 4.9, E), macrophage 
infiltration was substantially decreased in WAT of IKKβΔPDGFRβ mice fed a HFD 
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(Fig. 4.9-4.10), suggesting that deficiency of IKKβ in adipose lineage blocks the 
increased inflammatory infiltrates in WAT under obese conditions.  Consistently, 
the mRNA levels of macrophage markers and several key pro-inflammatory 
cytokines including TNFα, MCP-1, and IL-1β were significantly decreased in 
WAT of IKKβΔPDGFRβ mice (Fig. 4.9, G).  Next, we measured plasma cytokine 
levels to determine whether IKKβ-deficient mice also had decreased systemic 
inflammation.  Indeed, deficiency of IKKβ significantly decreased HFD-induced 
plasma pro-inflammatory cytokines including TNFα, MCP-1 and IL-6 in 
IKKβΔPDGFRβ mice (Fig. 4.9, H).  Taken together, deficiency of IKKβ improved 
insulin signaling in adipose tissue and protected mice from obesity-associated 
metabolic disorders.  
4.3.7 Deficiency of IKKβ Inhibits Adipogenesis in Mice 
 We next investigated whether deficiency of IKKβ can decrease HF 
feeding-elicited adipogenesis in vivo.  For this experiment, IKKβF/F and 
IKKβΔPDGFRβ mice were treated with BrdU during the first week of HF feeding.  
We then used BrdU as a marker to track newly differentiated adipocytes in 
these mice after 7d of HFD.  Immunostaining of adipose tissue sections with 
BrdU antibodies revealed that IKKβΔPDGFRβ mice had significantly decreased 
BrdU positive adipocytes in WAT (Fig. 4.11, A and B), indicating decreased 
adipogenesis.  We also assessed the adipogenic potential of adipose SV cells 
isolated from visceral adipose tissue of IKKβF/F and IKKβΔPDGFRβ mice and 
confirmed that IKKβ deficiency impaired the adipogenic potential of SV cells 
from IKKβΔPDGFRβ mice (Fig. 4.11, C).  Further, the expression levels of 
adipocyte markers and key adipogenic genes including PPARγ, C/EBPα, and 
Zfp423, were significantly reduced by IKKβ deficiency (Fig. 4.11, D).  Consistent 
with results from IKKβ ASO treatment and 3T3-L1 experiments (Fig. 2), 
IKKβΔPDGFRβ mice had decreased Smurf2 levels and increased nuclear β-catenin 
levels in epiWAT (Fig. 4.11, E and F) as well as in primary adipose SV cells 
(Fig. 4.11, G and H).  Further, deficiency of IKKβ substantially decreased β-
catenin ubiquitination in adipose SV cells (Fig. 4.11, I), which likely contributes 
to the accumulation of nuclear β-catenin in IKKβΔPDGFRβ mice.   
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4.3.8 Inhibition of IKKβ Decreases Adipogenesis in 
Human Adipose Stem Cells 
 In addition to murine 3T3-L1 preadipocytes and primary SV cells, we also 
determined whether IKKβ regulates the differentiation of human adipose stem 
cells. Human adipose stem cells, also known as adult-derived human adipose 
stem cells (ADHASCs) [343, 344, 363], were isolated from healthy subjects. 
Consistent with previous reports [343, 344, 363], human adipose stem cells 
were able to efficiently differentiate into mature adipocytes in vitro and at least 
80 to 90% of the cells developed lipid droplets in 7-10 days (Fig. 4.12, A).  
Pharmacological inhibition of IKKβ by BMS-345541 strongly inhibited human 
adipose stem cell differentiation and repressed human adipogenic gene 
expression (Fig. 4.12, B).  BMS-345541 treatment also led to reduced Smurf2 
expression and decreased β-catenin ubiquitination, leading to increased nuclear 
β-catenin levels (Fig. 4.12, C-E), which likely contribute to the decreased 
adipogenesis in human adipose stem cells.  Collectively, these results 
demonstrated IKKβ as an important regulator of both human and murine 
adipocyte differentiation. 
 
4.4 Discussion  
 As a central coordinator of inflammatory responses, IKKβ signaling in 
multiple tissues including liver, pancreas, and brain have been associated with 
obesity and obesity-related metabolic dysfunctions [241, 244, 247, 249, 333, 
364].  High doses of IKKβ inhibitors such as salicylates have been used to treat 
inflammatory conditions including diabetes in humans for more than a century 
[365, 366].  Moreover, inhibition of IKKβ activity by salicylates also protected 
mice against insulin resistance triggered by HFD or obesity [241, 248].  
Interestingly, long-term anti-inflammatory therapy has also been associated with 
weight loss in human studies [367].  We recently demonstrated that salicylates 
and the potent IKKβ inhibitor, BMS-345541, can also inhibit adipocyte 
differentiation in a dose-dependent manner [255].  In the current study, we 
demonstrated that IKKβ ASO can efficiently decrease IKKβ expression in 
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various tissues including liver and WAT, and ameliorate diet-induced obesity 
and metabolic disorders in mice.  To our knowledge, our study is the first to use 
ASOs targeting IKKβ in vivo and investigate its metabolic impact.  Consistent 
with previous reports demonstrating that hepatic IKKβ signaling contribute to 
insulin resistance [244, 247], IKKβ ASO-treated mice had improved insulin 
signaling in the liver.  Nevertheless, knockdown of IKKβ in WAT also resulted in 
enhanced Akt phosphorylation and increased glucose uptake.  Therefore, the 
improved diabetic phenotype in IKKβ ASO-treated mice was likely due to the 
repressed IKKβ signaling in multiple tissues including liver and WAT.  In 
addition to improved insulin signaling, IKKβ ASO treatment also repressed IKKβ 
expression in SV cells, leading to decreased adipogenesis in WAT.  Collectively, 
our studies demonstrate IKKβ as a potential target for future anti-obesity drugs 
and provide evidence for the use of appropriate IKKβ ASOs as a potential 
therapeutic strategy to treat obesity and metabolic disease (Fig.4.12, A-C). 
 Despite substantial progress in defining transcription factors such as 
PPARγ and C/EBPs in the regulation of committed preadipocyte differentiation, 
the initial signals that trigger adipose progenitor cell commitment to adipocyte 
lineage in response to overnutrition remained unknown.  In addition to its well-
established role as a central mediator of inflammation and immune responses, 
IKKβ/NF-κB signaling plays key roles in the regulation of hematopoietic cell 
development and stem cell differentiation [350, 368-370].  It has also been 
reported that NF-κB activity increases during adipocyte differentiation [371] and 
IKKβ/NF-κB activation is associated with increased adipogenesis and insulin 
resistance in maternal obesity [372].  Further, pro-inflammatory signals have 
been demonstrated to be important for adipogenesis in vivo and many IKKβ/NF-
κB activators including LPS, IL-1β, and MCP-1 can stimulate adipogenesis and 
promote adipocyte differentiation [373-375].  While the role of IKKβ signaling in 
regulating HFD-elicited tissue inflammation and insulin resistance is well 
recognized [327, 330, 331], it remained elusive if activation of IKKβ also 
mediates adipogenesis and adipose tissue growth in response to overnutrition.  
Since ASOs affects many cell types, we then selectively deleted IKKβ in white 
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adipose lineage in mice and confirmed that deficiency of IKKβ in adipocyte 
lineage cells decreased adipogenesis and systemic inflammation elicited by HF 
feeding, leading to resistance to diet-induced obesity and insulin resistance. 
 Intriguingly, IKKβΔPDGFRβ mice displayed no significant phenotype under 
standard laboratory conditions but were resistant to obesity when challenged 
with a HFD, indicating that HFD-induced IKKβ activation in adipose progenitors 
is essential for HFD-induced adipose tissue growth.  Consistent with our 
previous report [255], deficiency of IKKβ significantly decreased Smurf2 
expression and substantially inhibited β-catenin ubiquitination in adipose SV 
cells, leading to accumulation of nuclear β-catenin and increased β-catenin 
activity.  Wnt/β-catenin signaling plays an important role in the regulation of 
MSC lineage and has been well defined to inhibit adipogenesis in vitro and in 
vivo [352, 353, 376].  Consistently, Cre-mediated IKKβ deletion or ASO-
mediated IKKβ knockdown impaired the adipogenic potential of adipose SV 
cells in mice.  We also demonstrated, for the first time, that inhibition of IKKβ 
activity can also block human adipose stem cells differentiation, suggesting that 
IKKβ plays an important role in regulation of both murine and human adipocyte 
differentiation.  
 It is worth noting that IKKβΔPDGFRβ mice had decreased visceral adipose 
tissue but comparable subcutaneous adipose tissue as control mice when fed a 
HFD.  There is a major ontogenetic difference between visceral and 
subcutaneous fat as they have different developmental origins [377].  Wang et 
al. [254] demonstrated that different fat depots have extensive differences in 
adipogenic potential.  Visceral adipose tissue has a high capacity for 
adipogenesis in vivo but subcutaneous adipogenesis is limited [254].  A recent 
study also confirmed that HF feeding rapidly and specifically activates 
adipogenesis in visceral but not subcutaneous depots in mice [378].  Further, 
subcutaneous fat depot can also undergo extensive “browning” process after 
cold exposure and the appearance brown-like cells or beige cells are mainly 
found in subcutaneous fat but not in visceral fat [254].  It has been recently 
demonstrated that the PDGFRβ-positive adipocyte lineage cells contribute to 
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beige adipogenesis after prolonged cold exposure [253].  While deficiency of 
IKKβ did not affect the beige or brown adipocyte marker expression or 
mitochondrial content in subWAT of IKKβΔPDGFRβ mice under HF-feed conditions, 
it would be of interest to investigate whether IKKβΔPDGFRβ mice have affected 
beige adipocyte formation or mitochondrial function after chronic cold exposure 
in the future.  Consistent with previous studies demonstrating that human 
visceral adipose tissue expresses high levels of IKKβ as compared with 
subcutaneous adipose tissue [379], we also found that IKKβ expression levels 
were significantly higher in murine visceral SV cells than in murine 
subcutaneous SV cells.  Moreover, the expression levels of adipose progenitor 
markers including PDGFRβ were much higher in visceral SV cells than in 
subcutaneous SV cells.  It is plausible that visceral adipose tissue has more 
abundant adipose progenitor population and activation of IKKβ signaling is 
required for these cells differentiating into adipocytes in response to HF feeding.  
Deletion of IKKβ in adipocyte lineage cells therefore has more impact on 
visceral adipose tissue growth than that of subcutaneous adipose tissue when 
challenged with a HFD.  Further studies will be required to determine the 
detailed mechanisms that account for the different effects of IKKβ deficiency on 
visceral vs. subcutaneous fat.  While both subcutaneous and visceral fat are 
increased in obese mice and human, accumulation of visceral but not 
subcutaneous adipose tissue contributes to the increased risk of obesity-
associated metabolic dysfunctions [380].  Our data suggest that targeting IKKβ 
in adipocyte lineage cells may represent a novel therapeutic approach to reduce 
visceral adipose tissue mass in obesity.  
 In summary, we have revealed a pivotal role of IKKβ in the regulation of 
adipocyte differentiation and adipose tissue growth in obesity.  ASO-mediated 
IKKβ knockdown protected mice from diet-induced obesity and metabolic 
dysfunctions.  Deficiency of IKKβ in adipocyte lineage cells also inhibited HF 
feeding-elicited adipocyte differentiation and adipose tissue growth, leading to 
resistance to obesity and insulin resistance.  Our findings suggest that 
overnutrition-induced IKKβ activation in adipose progenitors is an important 
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trigger for adipocyte differentiation and inhibition of IKKβ with antisense therapy 
may represent as a novel therapeutic approach to combat obesity and related 
metabolic dysfunctions. 
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Table 4.1 Primer sequences for QPCR. 
Gene                 Primer sequence Genes                           Primer sequence 
IKKβ 
5’-GAGCTCAGCCCAAAGAACAG-3’ 
5’-AGGTTCTGCATCCCCTCTGG-3’ 
PDGFRα 
5’-AGCAGGCAGGGCTTCAACGG-3’ 
5’-ACACAGTCTGGCGTGCGTCC-3’ 
MCP-1 
5’-TTAAAAACCTGGATCGGAACCAA-3’ 
5’-GCATTAGCTTCAGATTTACGGGT-3’ 
CD137 
5’-CGTGCAGAACTCCTGTGATAAC-3’ 
5’-GTCCACCTATGCTGGAGAAGG-3’ 
IL-1α 
5’-GCACCTTACACCTACCAGAGT-3’ 
5’-TGCAGGTCATTTAACCAAGTGG-3’ 
HOXC9 
5’-GCAGCAAGCACAAAGAGGAGAAG-3’ 
5’-GCGTCTGGTACTTGGTGTAGGG-3’ 
IL-1β 
5’-GCAACTGTTCCTGAACTCAACT-3’ 
5’-ATCTTTTGGGGTCCGTCAACT-3’ 
SHOX2 
5’-TGGAACAACTCAACGAGCTGGAGA-3’ 
5’-TTCAAACTGGCTAGCGGCTCCTAT-3’ 
IL-6 
5’-TAGTCCTTCCTACCCCAATTTCC-3’ 
5’-TTGGTCCTTAGCCACTCCTTC-3’ 
TBX1 
5’-GGCAGGCAGACGAATGTTC-3’ 
5’-TTGTCATCTACGGGCACAAAG-3’ 
IL-10 
5’-GCTCTTACTGACTGGCATGAG-3’ 
5’-CGCAGCTCTAGGAGCATGTG-3’ 
UCP1 
5’-ACTGCCACACCTCCAGTCATT-3’ 
5’-CTTTGCCTCACTCAGGATTGG-3’ 
TNFα 
5’-CCCATATACCTGGGAGGAGTCTTC-3’ 
5’-CATTCCCTTCACAGAGCAATGAC-3’ 
PGC1α 
5’-AACCACACCCACAGGATCAGA-3’ 
5’-TCTTCGCTTTATTGCTCCATGA-3’ 
F4/80 
5’-CTTTGGCTATGGGCTTCCAGTC-3’ 
5’-GCAAGGAGGACAGAGTTTATCGTG-3’ 
MEOX2 
5’-CTTTGACCCGCTTCCACTT-3’ 
5’-AATCTAGACCTCACTGAAAGACAGG-3’ 
CD68 
5’-CTTCCCACAGGCAGCACAG-3’ 
5’-AATGATGAGAGGCAGCAAGAGG-3’ 
EVA1 
5’-CCACTTCTCCTGAGTTTACAGC-3’ 
5’-GCATTTTAACCGAACATCTGTCC-3’ 
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Table 4.1 (continued) 
Gene                 Primer sequence Genes                           Primer sequence 
PDGFRβ 
5’-AGACACTGGGGAATACTTTTGTG-3’ 
5’-CGGCCCTAGTGAGTTGTTGT-3’ 
LHX8 
5’-GAGCTCGGACCAGCTTCA-3’ 
5’-TTGTTGTCCTGAGCGAACTG-3’ 
PPARγ 
5’-GTGCCAGTTTCGATCCGTAGA-3’ 
5’-GGCCAGCATCGTGTAGATGA-3’ 
MYOGENIN 
5’-CTACAGGCCTTGCTCAGCTC-3’ 
5’-TGGGAGTTGCATTCACTGG-3’ 
C/EBPα 
5’-GACATCAGCGCCTACATCGA-3’ 
5’-TCGGCTGTGCTGGAAGAG-3’ 
Human 
PPARγ 
5’-CCAGGAAGGCCTTGACCTTT-3’ 
5’-CTGATCATCCAGCAGGTGTT-3’ 
C/EBPβ 
5’-ATTTCTATGAGAAAAGAGGCGTATGT-3’ 
5’-AAATGTCTTCACTTTAATGCTCGAA-3’ 
Human 
Zfp423 
5’-GGCATCAACCACGAGTGTAAGC-3’ 
5’-CTTCTGCGGAGAGGTGTCCTGT-3’ 
Zfp423 
5’-TGGCCTGGGATTCCTCTGT-3’ 
5’-CTCTTGACTTGTCACGCTGTT-3’ 
Human 
C/EBPα 
5’-CGGTGGACAAGAACAGCAAC-3’ 
5’-CGGAATCTCCTAGTCCTGGC-3’ 
SM22 
5’-CCACAAACGACCAAGCCTTCT-3’ 
5’-CGGCTCATGCCGTAGGAT-3’ 
Human aP2 
5’-ACCAGGAAAGTGGCTGGCAT-3’ 
5’-CAGGTCAACGTCCCTTGGCT-3’ 
NG2 
5’-AGGCGTCTACCGATGTGATGT-3’ 
5’-TGGCTGCCCTGTAGTGAAAC-3’ 
Human 
Adiponectin 
5’-AGCCTCCTTCTCCTGGGTCC-3’ 
5’-GTTGCCTCTAGCCTGGTGGG-3’ 
aP2 
5’-AAGGTGAAGAGCATCATAACCCT-3’ 
5’-TCACGCCTTTCATAACACATTCC-3’ 
Human 
GAPDH 
5’-GGCCTCCAAGGAGTAAGACC-3’ 
5’-AGGGGAGATTCAGTGTGGTG-3’ 
Adiponectin 
5’-GCACTGGCAAGTTCTACTGCAA-3’ 
5’-GTAGGTGAAGAGAACGGCCTTGT-3’ 
mtDNA 
(COX1) 
5’-CCGCAAGGGAAAGATGAAAGAC-3’ 
5’-TCGTTTGGTTTCGGGGTTTC-3’ 
36B4 
5’-CCAGGAAGGCCTTGACCTTT-3’ 
5’-CTGATCATCCAGCAGGTGTT-3’ 
nDNA (28S) 
5’-GCCAGCCTCTCCTGATTTTAGTGT-3’ 
5’-GGGAACACAAAAGACCTCTTCTGG-3’ 
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Figure 4.1 Pharmacological inhibition of IKKβ with ASOs protects 
mice from diet-induced obesity, improves insulin sensitivity, and 
reverses hepatic steatosis in obese mice. 
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Figure 4.1 Pharmacological inhibition of IKKβ with ASOs protects 
mice from diet-induced obesity, improves insulin sensitivity, and 
reverses hepatic steatosis in obese mice. 
 (A)  IKKβ mRNA expression in liver, kidney, spleen, skeletal muscle (Sk.M.), 
brown adipose tissue (BAT), subcutaneous white adipose tissue (subWAT), 
retroperitoneal WAT (retroWAT), and epididymal WAT (epiWAT) from mice 
treated with control ASO or IKKβ ASO for 8 weeks (n=6-10; *P<0.05, 
***P<0.001, assessed by Student’s t-test).  (B) Western blot analysis of IKKβ 
and IKKα expression in liver and epiWAT from mice treated with control or 
IKKβ ASO for 4 weeks.  (C and D) Growth curves (C), and fat mass and lean 
mass (D) of ND and HFD-fed mice treated with control ASO or IKKβ ASO 
(n=10 for ND and 30 for HFD; *P<0.05, **P<0.01, and ***P<0.001, assessed 
by two-way ANOVA).  (E) Representative images of adipose depots (top) and 
weight of adipose depots (bottom) from mice treated with control or IKKβ ASO 
for 8 weeks (n=20; ***P<0.001, assessed by Student’s t-test).  (F) Fasting 
plasma glucose and insulin levels of HFD-fed mice treated with control or IKKβ 
ASO (n=29-30; ***P<0.001, assessed by Student’s t-test).  (G) Intraperitoneal 
glucose tolerance test (IPGTT), intraperitoneal insulin tolerance tests (IPITT), 
and area of curve (AUC) of IPGTT and IPITT of HFD-fed mice treated with 
control or IKKβ ASO (n=8-10; **P<0.01, ***P<0.001, assessed by Student’s t-
test).  (H) Western blot analysis of phosphorylated Akt and total Akt levels in 
liver, epiWAT, and skeletal muscle of control or IKKβ ASO-treated mice 
injected with saline or 0.35U/kg body weight.  (I) Glucose uptake was 
measured in primary adipose tissues from mice treated with control or IKKβ 
ASO (n=9; **P<0.01, ***P<0.001, assessed by two-way ANOVA).  (J and K): 
Representative appearance (J) and hematoxylin and eosin (top) and Oil-red-O 
(bottom) stained sections (K) of livers from mice treated with control or IKKβ 
ASO (scale bar=100μm).  (L) Hepatic cholesterol and triglyceride levels of 
mice treated with control or IKKβ ASO (n=10; ***P<0.001, assessed by 
Student’s t-test).  Results are presented as mean ± SEM.  
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Figure 4.2 IKKβ regulates murine adipocyte differentiation. 
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Figure 4.2 IKKβ regulates murine adipocyte differentiation. 
(A) IKKβ mRNA expression in adipose SVF and mature adipocytes isolated 
from epiWAT of mice treated with control or IKKβ ASO (n=6; **P<0.01, 
assessed by Student’s t-test).  (B) Oil-red-O staining of adipose SV cells 
isolated from epiWAT of mice treated with control and IKKβ ASO induced by 
differentiation media (scale bar=100 μm, bottom panels).  (C) Expression of 
adipogenic genes in epiWAT of control and IKKβ ASO treated mice was 
measure by QPCR (n=6; **P<0.01, ***P<0.001, assessed by Student’s t-test).  
(D) Western blot analysis of Smurf2 protein levels in epiWAT.  (E) Western 
blot analysis of nuclear β-catenin levels in epiWAT. (F) Western blot analysis 
of IKKβ and IKKα protein levels in control 3T3-L1 cells or CRISPR-mediated 
IKKβ-deficient 3T3-L1 cells.  (G) Oil-red-O staining of control and IKKβ-
deficient 3T3-L1 cells induced by differentiation media (scale bar=100μm, 
bottom panels).  (H) Expression of adipogenic genes and adipocyte markers in 
control or IKKβ-deficient 3T3-L1 cells (n=6; **P<0.01, ***P<0.001, assessed by 
Student’s t-test).  (I) Western blot analysis of Smurf2 protein levels in control or 
IKKβ-deficient 3T3-L1 cells.  (J) Western blot analysis of nuclear β-catenin 
protein levels in control or IKKβ-deficient 3T3-L1 cells.  (K) β-catenin reporter 
(TOP-flash reporter) activity in control or IKKβ-deficient 3T3-L1 cells (n=6; 
***P<0.001, assessed by Student’s t-test).  (L) Control or IKKβ-deficient 3T3-
L1 cells were treated with vehicle control or 100 nM PS-341, as indicated, for 4 
h. β-catenin was immunoprecipitated with anti-β-catenin antibodies and then 
probed with anti-ubiquitin monoclonal antibodies.  The whole cell lysates were 
probed with anti-β-catenin antibodies as an internal control.  Results are 
presented as mean ± SEM. 
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Figure 4.3 PDGFRβ labels adipose progenitor cells in vivo. 
(A) The expression levels of endogenous PDGFRβ in adipose SV cells and 
adipocytes isolated from epiWAT of mice were measured by QPCR (n=4; 
***P<0.001, assessed by Student’s t-test).  (B) Schematic of the 
PDGFRβCre+lacZF/F mouse model.  (C) Primary adipose SV cells isolated from 
lacZF/F and PDGFRβCre+lacZF/F mice were stained with X-Gal (blue) and 
nuclear fast red (red) (scale bar=100μm).  (D) EpiWAT of lacZF/F and 
PDGFRβCre+lacZF/F mice were stained for β-galactosidase expression (blue) 
(top). White arrows indicate the vasculature in stained epiWAT of 
PDGFRβCre+lacZF/F mice (bottom).  (E) Cross-sections of epiWAT from lacZF/F 
and PDGFRβCre+lacZF/F mice were stained for β-galactosidase expression 
(scale bar=100μm).  Results are presented as mean ± SEM. 
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Figure 4.4 Generation of mice lacking IKKβ in the white adipose 
lineage. 
(A) Western blot analysis of IKKβ and IKKα protein levels in epiWAT, subWAT, 
liver, BAT, and skeletal muscle (Sk.M.) of IKKβF/F and IKKβΔPDGFRβ mice.  (B) 
Western blot analysis of IKKβ and IKKα protein levels in adipose SV cells 
isolated from IKKβF/F and IKKβΔPDGFRβ mice.  (C-G) Adipose SV cells isolated 
from IKKβF/F and IKKβΔPDGFRβ mice were treated with LPS for 3 h. The 
expression levels for proinflammatory cytokines including TNFα (C), MCP-1 
(D), IL-1α (E), IL-1β (F), and IL-6 (G) were examined by QPCR (n=5; 
**P<0.01, ***P<0.001, assessed by two-way ANOVA).  Results are presented 
as mean ± SEM. 
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Figure 4.5 Deficiency of IKKβ in adipocyte lineage cells renders mice 
resistant to diet-induced obesity. 
(A) Growth curves of ND or HFD-fed IKKβF/F and IKKβΔPDGFRβ mice (n=9-18, 
***P <0.001 when comparing HFD-fed IKKβF/F mice to HFD-fed IKKβΔPDGFRβ 
mice, assessed by Student’s t-test).  (B) Body weight, fat mass, percentage of 
fat, and lean mass of 10-week-old IKKβF/F and IKKβΔPDGFRβ mice fed a ND or 
HFD for 16 weeks (n=7-19; **P<0.01, ***P<0.001, assessed by two-way 
ANOVA).  (C) Representative photographs of epiWAT, retroWAT, subWAT, 
and BAT from ND or HFD-fed IKKβF/F and IKKβΔPDGFRβ mice.  (D and E) 
Representative coronal section MRI images (D) and visceral and 
subcutaneous adipose tissue volume (E) of HFD-fed IKKβF/F and IKKβΔPDGFRβ 
(n=3; ***P<0.001, assessed by Student’s t-test).  Results are presented as 
mean ± SEM.   
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Figure 4.6 Loss of adipocyte progenitor IKKβ decreases visceral 
adiposity in mice fed a HFD. 
(A) Representative images of IKKβF/F and IKKβΔPDGFRβ mice fed a ND and 
HFD.  (B) Tissue weight of liver, epiWAT, subWAT, retroWAT and BAT of ND 
or HDF-fed IKKβF/F and IKKβΔPDGFRβ mice (top panels), and percentage of 
body weight of indicated tissues (bottom panels) (n=6-12, **P<0.01, 
***P<0.001, assessed by Student’s t-test).  Results are presented as mean ± 
SEM. 
 
 
 
 
 
 
 
133 
 
 
Figure 4.7 Deficiency of IKKβ in adipocyte lineage cells does not 
affect beige and brown adipocyte markers or mitochondrial DNA 
content in subWAT.  
(A) The expression levels of beige or brown adipocyte markers and 
mitochondrial function-related genes in subWAT of HFD-fed IKKβF/F and 
IKKβΔPDGFRβ mice were analyzed by QPCR (n=6).  (B) Quantification of 
mitochondrial DNA in subWAT of HFD-fed IKKβF/F and IKKβΔPDGFRβ mice 
(n=5).  Results are presented as mean ± SEM. 
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Figure 4.8 Adipose progenitor cell markers are highly enriched in 
visceral fat. 
The expression levels of IKKβ and adipose progenitor cell markers in adipose 
SV cells isolated from subWAT or epiWAT of WT mice were analyzed by 
QPCR (n=4; **P<0.01, ***P<0.001, assessed by Student’s t-test).  Results are 
presented as mean ± SEM. 
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Figure 4.9 IKKβ-deficient mice are protected from obesity-associated 
metabolic disorders. 
(A) Fasting plasma glucose and insulin levels in ND or HFD-fed IKKβF/F and 
IKKβΔPDGFRβ mice (n=5-11; **P<0.01, ***P<0.001, assessed by two-way 
ANOVA).  (B) IPGTT, IPITT, and area under the curve (AUC) of IPGTT and 
IPITT of HFD-fed IKKβF/F and IKKβΔPDGFRβ mice (n=6-11; *P<0.05, **P<0.01, 
***P<0.001, assessed by Student’s t-test).  (C) Western blot analysis of 
phosphorylated Akt and total Akt levels in epiWAT, liver, and skeletal muscle 
of IKKβF/F and IKKβΔPDGFRβ mice injected with saline or 0.35U/kg body weight.  
(D) Glucose uptake was measured in primary adipose tissues from HFD-fed 
IKKβF/F and IKKβΔPDGFRβ mice (n=9; ***P<0.001, assessed by two-way 
ANOVA).  (E) Western blot analysis of IKKβ protein levels in peritoneal 
macrophages of IKKβF/F and IKKβΔPDGFRβ mice.  (F) Representative 
immunohistochemistry for the macrophage marker, F4/80, in epiWAT from 
HFD-fed IKKβF/F and IKKβΔPDGFRβ mice (scale bar=100μm).  (G) The 
expression levels of pro-inflammatory genes and macrophage markers in 
epiWAT of HFD-fed IKKβF/F and IKKβΔPDGFRβ mice were measured by QPCR 
(n=5; *P<0.05, **P<0.01, ***P<0.001, assessed by Student’s t-test).  (H) 
Plasma cytokine levels of ND or HFD-fed IKKβF/F and IKKβΔPDGFRβ mice (n=5-
7; **P<0.01, ***P<0.001, assessed by two-way ANOVA).  Results are 
presented as mean ± SEM. 
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Figure 4.10 Deficiency of IKKβ in adipocyte lineage cells has no 
impact of adipose tissue inflammation or glucose and insulin 
tolerance in mice fed a normal chow. 
(A) Representative immunohistochemistry for the macrophage marker, F4/80 
in epiWAT from ND-fed IKKβF/F and IKKβΔPDGFRβ mice (scale bar=100μm). (B) 
IPGTT, IPITT and area under the curve (AUC) of IPGTT and IPITT of ND-fed 
IKKβF/F and IKKβΔPDGFRβ mice (n=5-11).  Results are presented as mean ± 
SEM. 
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Figure 4.11 Deficiency of IKKβ inhibits adipogenesis in mice. 
(A and B) Representative images (A) and quantification (B) of immunostaining 
for BrdU in epiWAT from BrdU-treated IKKβF/F and IKKβΔPDGFRβ mice fed a 
HFD for 7 days (n=4-5; **P<0.01, significance assessed by Student’s t-test). 
The nuclei were stained with DAPI (blue) and the BrdU-positive cells are 
indicated by arrows.  (C) Oil-red-O staining of adipose SV cells isolated from 
epiWAT of IKKβF/F and IKKβΔPDGFRβ mice induced by differentiation media. 
(Scale bar=100μm, bottom panels).  (D) The expression levels of adipogenic 
genes and adipocyte markers in adipose SV cells of IKKβF/F and IKKβΔPDGFRβ 
mice were measured by QPCR (n=5-8; *P<0.05, **P<0.01, ***P<0.001, 
assessed by Student’s t-test).  (E and F) Western blot analysis of Smurf2 
protein levels (E) and nuclear β-catenin protein levels (F) in epiWAT of IKKβF/F 
and IKKβΔPDGFRβ mice.  (G and H) Western blot analysis of Smurf2 protein 
levels (G) and nuclear β-catenin protein levels (H) of adipose SV cells isolated 
from IKKβF/F and IKKβΔPDGFRβ mice.  (I) Adipose SV cells isolated from IKKβF/F 
and IKKβΔPDGFRβ mice were treated with vehicle control or 100 nM PS-341, as 
indicated, for 4 h. β-catenin was immunoprecipitated with anti-β-catenin 
antibodies and then probed with anti-ubiquitin monoclonal antibodies.  The 
whole cell lysates were probed with anti-β-catenin antibodies as an internal 
control.  Results are presented as mean ± SEM. 
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Figure 4.12 Inhibition of IKKβ decreases adipogenesis in human 
adipose stem cells. 
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Figure 4.12 Inhibition of IKKβ decreases adipogenesis in human 
adipose stem cells. 
(A) Oil-red-O staining of adult-derived human adipose stem cells induced by 
differentiation media or media containing 5 μM IKKβ inhibitor BMS-345541 
(scale bar=100μm, bottom panels).  (B) The expression levels of adipogenic 
genes and adipocyte markers of  human adipose stem cells treated with 
vehicle control or 5μM BMS-345541 were measured by QPCR (n=4; *P<0.05, 
**P<0.01, ***P<0.001, assessed by Student’s t-test).  (C and D) Western blot 
analysis of Smurf2 protein levels (C) and nuclear β-catenin protein levels (D) in 
control or BMS-345541-treated human adipose stem cells.  (E) Control or 
BMS-345541-treated human adipose stem cells were treated with vehicle 
control or 100 nM PS-341, as indicated, for 4 h.  β-catenin was 
immunoprecipitated with anti-β-catenin antibodies and then probed with anti-
ubiquitin monoclonal antibodies. The whole cell lysates were probed with anti-
β-catenin antibodies as an internal control. **p<0.01, ***p<0.001. Results are 
presented as mean ± SEM. 
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Figure 4.13 Working model of the role of IKKβ signaling in adipocyte 
lineage cells in obesity. 
(A) Under normal feeding conditions, the IKKβ/NF-κB signaling is maintained 
at basal activity.  (B) Under HFD feeding conditions, overnutrition (e.g. excess 
FFA) activates IKKβ, leading to increased adipogenesis and inflammation. (C) 
In our current study, pharmacological inhibition or genetic deletion of IKKβ in 
adipocyte lineage cells impairs adipogenesis and protects mice from HFD-
induced obesity and metabolic dysfunctions.   
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Chapter 5: Future Directions 
5.1 Investigate the Consequences Associated with the SNPs Located 
Within the 3’ UTR of PXR 
 The SNPs found within PXR that correlate with alterations in cholesterol 
metabolism are intriguing.  Interestingly, many of these SNPs are located within 
the 3’ UTR of PXR, indicative of extensive post-transcriptional regulation.  
Whether or not these SNPs are the causal variant in altering cholesterol balance 
remains to be determined; however, the idea that SNPs elicit changes in host 
gene expression by altering binding sites of transcription factors and/or 
microRNAs is well accepted.  For instance, Musunuru and colleagues recently 
demonstrated that a SNP linked to myocardial infarction and high LDL-
cholesterol levels disrupts a binding site for the transcription factor 
CCAAT/enhancer binding protein (C/EBP) in the sortilin 1 (Sort1) gene [381, 
382].  Subsequently, the risk allele generates reduced expression of Sort1, 
ultimately increasing VLDL and LDL cholesterol levels in the blood and 
increased risk for CAD [381, 382].  It is possible that the SNPs within PXR 
generate gain-of-function and/or loss-of-function miRNA binding sites that 
subsequently elicit changes in RNA stability.  For example, miR-148a has been 
recently implicated as a significant modulator of plasma cholesterol by 
regulating many genes involved in cholesterol homeostasis, including LDLR and 
ABCA1 [383].  Micro-RNA 148a has also been demonstrated to regulate PXR 
[117], but whether these SNPs are altering miR148a-binding, or other microRNA 
binding, remains to be ascertained.  
 
5.2 Determine the Involvement of PXR in Currently Recommended 
ARV Drug-Associated Dyslipidemia 
 We recently reported that amprenavir and ritonavir, HIV PIs, are potent 
PXR agonists and that acute amprenavir exposure induced pro-atherogenic 
LDL cholesterol levels in WT but not in PXR-deficient mice [299].  Both PIs have 
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been associated with dyslipidemia and increased risk for CVD in HIV infected 
individuals [65, 67].  Currently, amprenavir is not widely prescribed, partially due 
to its deleterious effects on lipid levels, and ritonavir is most commonly used as 
a booster drug at relatively low doses (e.g. 100 mg/day).  In addition to these 
well-studied PIs, several currently recommended first-line antiretroviral (ARV) 
drugs including efavirenz, darunavir, and lopinavir also have dyslipidemic effects 
in HIV patients [61, 67].  Recently, we tested currently recommended first-line 
HIV drugs from three commonly used drug classes (NNRTIs, NRTIs, and PIs) 
and found that several widely-prescribed ARV drugs including efavirenz and 
rilpivirine (NNRTIs), etravirine and darunavir (PIs) can also activate human PXR 
(Fig A.1).  Many of these drugs have been associated with dyslipidemia in HIV 
patients [67].  For example, efavirenz has profound effects on elevating total 
and LDL-cholesterol levels in patients [61, 67].  By contrast, the widely used 
NRTIs, emtricitabine (FTC) and tenofovir, which do not activate PXR, have low 
risk of dyslipidemia [384-386].  These results suggest the involvement of PXR in 
ARV drug-associated dyslipidemia.   
 To further investigate the role of these widely used ARV drugs on PXR 
activity, we utilized a mammalian two-hybrid system to determine if these drugs 
can permit association of two well-known coactivators, SRC-1 and PBP.  
Binding of these ARV drugs to human PXR allowed co-activator/PXR interaction 
in a dose-dependent manner (Fig. A.2).  Similarly, these drugs dose-
dependently promoted co-repressor/PXR disassociation (Fig. A.2).  To 
determine whether these ARV drugs act specifically through PXR, we tested 
their ability to activate a panel of other nuclear receptors, including RXR, FXR, 
LXRα, PPARα/γ, VDR, and ERα/β.  Efavirenz, darunavir, and rilpivirine were 
unable to activate any of these other nuclear receptors (Fig. A.3), indicating the 
importance of investigating the effects of these ARV drugs on PXR activity in 
vivo.  These results indicate that these ARV drugs specifically activate PXR and 
promote coactivator association leading to transcriptional activation.   
 We are currently investigating the role of these ARV drugs on PXR activity 
and plasma lipid levels in vivo.  We plan to choose ARV drugs from three 
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commonly used classes: emtricitabine (NRTI), efavirenz (NNRTI), and darunavir 
(PI).  Based on previous pharmacokinetic studies, steady state plasma levels of 
these compounds reach approximately 10-20 μM, which is sufficient to activate 
PXR in cell culture systems [387].  Since emtricitabine does not affect PXR 
activity, we do not anticipate that it will alter plasma lipid levels in vivo.  Based 
on the observation that both efavirenz and darunavir are agonists for both 
mouse and human PXR, we do not feel it is necessary to include another cohort 
of mice expressing the huPXR transgene on a mouse PXR-deficient 
background.  Since we previously demonstrated that PXR transcriptionally 
regulates NPC1L1 [342], we also may consider incorporating ezetimibe into the 
diet to determine if cholesterol absorption is a major determinant in PXR-elicited 
hypercholesterolemia.  It will be interesting to see if these widely-used drugs 
can promote hypercholesterolemia in vivo in a PXR-dependent manner.  All 
drugs should be assessed for their ability to activate PXR considering the 
adverse side effects of PXR activation in sterol and energy metabolism. 
 
5.3 Investigate the PXR/HNF4α Axis in Regulating MTP  
 Mechanisms governing transcriptional regulation of MTP have been 
investigated by a few groups; however, identification of novel regulators is 
warranted.  A comparative alignment of promoter sequences from different 
species revealed an evolutionarily conserved 204 bp element upstream from the 
MTP transcriptional start site that contains several cis elements [7, 44, 388, 
389].  For example, three HNF-1 family members synergistically enhance the 
HNF-4α mediated transactivation of the proximal MTP promoter [388].  
Moreover, MTP was identified as a possible PXR-target gene in Chromatin 
Immunoprecipitation-sequencing (ChIP-seq) assays [390].  Furthermore, PXR 
has been demonstrated to bind to HNF4α and ligand treatment enhanced this 
interaction [187].  HNF4α also mediates PXR transactivation of CYP3A4 [391].  
ChIP-seq of HNF4α and several nuclear receptors revealed PXR binds within 
close proximity to all HNF4α binding sites within the genome [392]; whether 
PXR is directly binding to cis elements in MTP or binding is mediated through 
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HNF4α remains to be determined.   
 To gain insight into whether PXR directly regulates MTP expression, we 
first isolated primary enterocytes, treated with a wide array of PXR agonists and 
measured expression of genes involved in lipid metabolism.  As expected, PXR 
activation stimulated NPC1L1 mRNA expression with all ligands tested (Fig. 
A.4).  Furthermore, PXR activation also stimulated MTP expression with all 
ligands tested in a PXR-dependent manner (Fig A.4).  These results suggest 
that PXR is absolutely essential for the xenobiotic-elicited MTP response.  In the 
immediate future, we plan to use ChIP and gel-shift assays to determine if PXR 
is directly binding to the MTP promoter or if activation is mediated through 
HNF4α or other factors.  These experiments are pivotal in understanding why 
PXR activation promotes hyperlipidemia. 
 If PXR does indeed transcriptionally regulate MTP, we plan to examine the 
role of PXR activation on chylomicron secretion.  Since MTP is a major regulator 
of secretion of apoB-containing lipoproteins, we hypothesize that PXR activation 
may elicit increases in chylomicron secretion.  Once the intestinal-specific PXR-
knockout mice are available, we will gavage mice with [H3]-triolein and inject a 
LPL inhibitor to examine the amount of tritium in the plasma over time, as 
previously described [276, 393].  Moreover, with our colleagues at the University 
of Cincinnati, we plan to measure the intestinal uptake, absorption and 
lymphatic transport of dietary lipid in the conscious mouse [394].  Taken 
together, the overall contribution of intestinal PXR on whole body metabolism 
will be investigated in the near future. 
 
5.4 Determine the Role of IKKβ in Hepatic Gluconeogenesis 
 The regulation of hepatic glucose production (HGP) is a critical step in 
maintaining blood glucose levels, and pathological changes in gluconeogenesis 
in the liver are a central characteristic in type-2 diabetes.  Arkan and colleagues 
first demonstrated that mice with hepatocyte-specific deletion of IKKβ had 
improved glucose tolerance in aged and HFD-fed mice [244].  Utilizing a 
euglycemic-hyperinsulinemic clamp, the same group demonstrated that these 
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hepatocyte IKKβ deficient mice had approximately 50% suppression of HGP 
during insulin clamp, compared to only a 15% reduction in floxed mice fed a 
HFD [244].  Furthermore, an independent group demonstrated that mice with 
hepatocyte IKKβ-overexpression were resistant to the suppression of HGP 
during the insulin clamp [247].  These data demonstrate that the effect of IKKβ 
in HGP may result from enhanced insulin sensitivity in mice fed a HFD.     
 In Chapter 4 of this dissertation, we observed a significant decrease in 
fasting glucose levels and improved glucose tolerance in mice fed a HFD with 
IKKβ ASO treatment (Fig. 4.1, F and G).  Further, mice treated with the IKKβ 
ASOs had significantly enhanced Akt signaling in the liver, adipose tissue, and 
skeletal muscle with and without exogenous insulin (Fig. 4.1, H).  To examine 
whether the benefit of reducing IKKβ expression with ASOs on adiposity was 
HFD-elicited, we treated another cohort of mice fed chow for 8 weeks.  Chow-
fed mice had no changes in body weight or fat mass, but still had small, albeit 
significant, increases in lean mass (Fig. 4.1, C and D).  Interestingly, however, 
fasting glucose was decreased and these mice were considerably more glucose 
tolerant (Fig. A.5, A and B).  It would be of interest to examine plasma insulin 
levels in these mice.  Since IKKβ is a negative regulator of insulin signaling by 
direct phosphorylation of IRS-1 [250], these mice most likely have enhanced 
hepatic insulin signaling and more suppressed HGP, which would explain the 
decrease in plasma glucose levels.  The IKKβΔPDGFRβ mice did not exhibit 
changes in plasma blood glucose levels, but that is most likely due to intact 
IKKβ signaling in the liver in these mice (Fig. 4.4, A).  Further, the improvement 
of glucose tolerance in both models may also be due to enhanced glucose 
uptake in other tissues, such as skeletal muscle.  IKKβΔPDGFRβ mice fed a HFD 
had increased expression of genes involved in skeletal muscle mitochondrial 
biogenesis and oxidative metabolism (data not shown).  Moreover, IKKβΔPDGFRβ 
mice exhibited increases in mitochondrial content in skeletal muscle (data not 
shown).  Taken together, these results demonstrate that the improved metabolic 
parameters associated with IKKβ deletion in adipose progenitor cells is likely 
attributed to enhanced oxidative metabolism in skeletal muscle.   
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5.5 Does IKKβ Act as a “Switch” Modulating Stem Cell Commitment? 
 The IKKβ/NFκB signaling pathway has been demonstrated to play a role in 
stem cell commitment.  Mesenchymal stem cells (MSCs) are multipotent stem 
cells that differentiate into mesoderm-type cells, including osteoblasts and 
adipocytes.  There has been a lot of work trying to identify the modulators that 
link MSC commitment between bone and adipose tissue, such as β-catenin.  
For example, disruption of a negative regulator of Wnt, axin-2, in mice leads to 
enhanced osteoblast differentiation and matrix mineralization [395].  Mutations 
in the Wnt antagonist SFRP1 results in high bone mass in mice, suggesting the 
involvement of canonical Wnt signaling on osteoblast differentiation and bone 
formation [396].  It was later identified that β-catenin transcriptionally regulates 
Runx2, a transcription factor that is absolutely essential for osteoblast 
differentiation [397].  Aside from bone formation, Wnt signaling is a potent 
suppressor of adipogenesis and fat formation [353].  Thus, signaling pathways 
converging on Wnt signaling may alter bone and fat formation.   
 Interestingly, the IKKβ/NFκB signaling pathway exerts opposite effects on 
mesenchymal stem cell differentiation into bone and adipose tissue.  Ligands for 
IKKβ/NF-κB have been shown to promote adipocyte differentiation and 
suppress osteoblast formation [253, 254, 350, 374, 378].  Moreover, NFκB 
inhibits MSC differentiation into bone by promoting β-catenin degradation via the 
E3 ligases Smurf1 and Smurf2 [350].  The major questions is, are all these 
effects mediated primarily through NF-κB or does IKKβ mediate NF-κB-
independent changes that play a role in the commitment of MSCs?  
Interestingly, IKKβ has been demonstrated to directly phosphorylate β-catenin 
[398].  It was initially thought that phosphorylation of β-catenin by IKKβ may 
stimulate its degradation by the proteasome by enhancing the ubiquitination by 
β-TrCP; however, no evidence was presented to support this mechanism.  
Thus, further work identifying the specific amino acids that are phosphorylated 
by IKKβ and the physiological consequence of the initial phosphorylation is 
warranted.  Taken together, these data demonstrate that IKKβ may sense its 
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environment (e.g. FFA) and propagate a signaling cascade that initiates stem 
cell commitment into bone or fat. 
 
5.6 Investigate the Role of PXR and IKKβ in Inflammation 
 It is evident that reciprocal crosstalk exists between the PXR and NF-κB 
signaling pathways.  What remains to be determined is the precise mechanism.  
As mentioned above, PXR can suppress NF-κB signaling by a variety of 
mechanisms, including the physical interaction between PXR and the NF-κB 
subunit, p65.  Furthermore, activation of NF-κB signaling may also suppress 
PXR signaling by binding to RXR, which may interfere with RXR binding to PXR 
and ultimately suppress PXR transactivation.  Recent work by Ito and 
colleagues revealed a mechanism linking LXRs to inflammation through its 
target gene ABCA1 [220].  ABCA1 was demonstrated to alter the lipid 
membrane composition and disrupt binding of adaptor proteins to the TLRs 
[220].  Since PXR has also been implicated to regulate ABCA1 [168, 399], it is 
worth investigating if activation of PXR works in a similar manner by disrupting 
TLR signaling.   
 Since IKKβ clearly has NF-κB independent substrates that play a role in 
many different processes, it is plausible that upon stimulation, IKKβ directly 
phosphorylates many different nuclear receptors leading to their 
degradation/suppression in activity.  Moreover, IKKβ has the potential to also 
phosphorylate and regulate the activity of several cofactors needed for proper 
nuclear receptor signaling.  It would be interesting to do phosphoproteomics in 
cells with and without IKKβ stimulation.  This would provide an unbiased 
approach to identify several signaling pathways that crosstalk and explore novel 
areas of research.  Taken together, there is a lot of room for discovery in this 
area of research that could lead to druggable targets for the cure of certain 
inflammatory conditions. 
Copyright © Robert Nathaniel Helsley, 2016 
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Appendices 
 
Figure 5.1 Currently recommended HIV drugs activate PXR. 
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Figure A.1 Currently recommended HIV drugs activate PXR. 
(A-D) LS180 cells were transfected with full-length hPXR or full-length 
mPXR together with a hPXR reporter (CYP3A4-luc) or a mPXR reporter 
((CYP3A2)3-luc) and a CMX-β-galactosidase control plasmid.  Cells were 
then treated with HIV protease inhibitors (A, C), non-nucleoside and 
nucleoside reverse transcriptase inhibitors (B, D), RIF (a hPXR ligand; A, 
B), or PCN (a mPXR ligand; C, D) at the indicated concentrations for 24 
h.  Data are shown as fold induction of normalized luciferase activity 
compared with that for DMSO treatment and represent the means from 
triplicate experiments.  Results are presented as mean ± SEM. 
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Figure A.2 Currently used HIV drugs promote PXR coactivator 
association and corepressor disassociation. 
(A and B)  LS180 cells were cotransfected with a GAL4 reporter, VP16-hPXR, 
and expression vector for GAL4 DBD or GAL4 DBD linked to the receptor 
interaction domains of PXR coactivators (GAL-SRC1 or GAL-PBP) (A) or PXR 
corepressors (GAL-SMRT or GAL-NCoR) (B).  Cells were treated with DMSO 
control, efavirenz, darunavir, rilpivirine, or RIF at the indicated concentrations 
for 24 hours.  Data are shown as fold induction of normalized luciferase activity 
compared with that for DMSO treatment and represent the means from 
triplicate experiments.  Results are presented as mean ± SEM. 
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Figure A.3 Widely used HIV drugs are PXR-selective agonists. 
LS180 cells were co-transfected with a GAL4 reporter and a series of GAL4 
constructs in which the GAL4 DBD is linked to the indicated nuclear receptor 
LBD.  Cells were treated with DMSO control, 10μM efavirenz, 10μM darunavir, 
or 10μM rilpivirine for 24 h.  Data are shown as fold induction of normalized 
luciferase activity compared with DMSO treatment and represent the mean of 
triplicate experiments.  Results are presented as mean ± SEM. 
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Figure A.4 PXR activation increases mRNA expression of NPC1L1 
and MTP in primary enterocytes isolated from WT but not PXR-
deficient mice. 
Primary enterocytes were isolated from WT and PXR-deficient mice and 
were incubated with control medium or medium containing 10 µM 
amprenavir, TBC, or PCN.  Total RNA was isolated and expression of 
genes involved in lipid metabolism were analyzed by qPCR (n=3; **P<0.01 
and ***P <0.001; assessed by one-way ANOVA).  Results are presented as 
mean ± SEM. 
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Figure A.5 Glucose metabolism is improved in IKKβ ASO mice fed 
chow. 
(A and B) Fasting plasma glucose levels (A) and intraperitoneal glucose 
tolerance test (B) in chow-fed mice treated with control ASO or IKKβ ASO 
(n=10; *P<0.05, **P<0.01, ***P<0.001, assessed by Student’s t-test 
compared to control).  Results are presented as mean ± SEM. 
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